0000950170-21-004466.txt : 20211115 0000950170-21-004466.hdr.sgml : 20211115 20211115074218 ACCESSION NUMBER: 0000950170-21-004466 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Frequency Therapeutics, Inc. CENTRAL INDEX KEY: 0001703647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472324450 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39062 FILM NUMBER: 211406372 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE STREET 2: SUITE 300 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-315-4600 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE STREET 2: SUITE 300 CITY: LEXINGTON STATE: MA ZIP: 02421 10-Q 1 freq-20210930.htm 10-Q 10-Q
truefalsetrueNovember 30, 2014Q30001703647true--12-31true00017036472019-12-310001703647freq:UnvestedRestrictedStockUnitsMember2021-07-012021-09-300001703647freq:LicenseAndCollaborationAgreementMemberfreq:AstellasPharmaLimitedLiabilityCompanyMember2019-07-012019-07-310001703647us-gaap:EquipmentMember2021-09-300001703647freq:AstellasPharmaLimitedLiabilityCompanyMemberus-gaap:RoyaltyMemberfreq:MassachusettsInstituteOfTechnologyMember2016-12-012016-12-3100017036472021-11-080001703647us-gaap:RestrictedStockMember2021-09-300001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001703647us-gaap:RestrictedStockMember2020-12-310001703647freq:LicenseAndCollaborationAgreementMemberfreq:AstellasPharmaLimitedLiabilityCompanyMember2021-01-012021-09-300001703647freq:LoanAndSecurityAgreementMember2020-12-110001703647us-gaap:CommonStockMember2021-06-300001703647freq:TermLoanMember2021-01-012021-09-300001703647us-gaap:EmployeeStockMember2021-01-012021-06-300001703647freq:LexingtonMassachusettsFacilityMember2021-09-3000017036472021-07-012021-09-300001703647us-gaap:FairValueMeasurementsRecurringMember2020-12-310001703647us-gaap:LeaseholdImprovementsMember2020-12-310001703647us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001703647freq:OutstandingStockOptionsMember2021-07-012021-09-300001703647us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001703647us-gaap:CommonStockMember2020-07-012020-09-300001703647freq:LicenseAndCollaborationAgreementMemberfreq:AstellasPharmaLimitedLiabilityCompanyMember2019-07-012019-09-300001703647us-gaap:RetainedEarningsMember2021-06-300001703647us-gaap:RestrictedStockMember2020-01-012020-09-300001703647freq:UnvestedRestrictedCommonStockMember2020-07-012020-09-300001703647srt:MaximumMemberfreq:MassachusettsInstituteOfTechnologyMember2016-12-012016-12-310001703647freq:LicenseAndCollaborationAgreementMemberfreq:Phase3ClinicalTrailMemberfreq:AstellasPharmaLimitedLiabilityCompanyMembersrt:EuropeMember2019-07-012019-07-310001703647freq:MassachusettsInstituteOfTechnologyMemberfreq:PatentLicenseAgreementMember2016-12-012016-12-310001703647srt:DirectorMemberfreq:MassachusettsInstituteOfTechnologyMember2020-01-012020-12-310001703647freq:OutstandingStockOptionsMember2020-07-012020-09-300001703647us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001703647us-gaap:AdditionalPaidInCapitalMember2020-06-3000017036472014-01-012021-09-300001703647us-gaap:FurnitureAndFixturesMember2021-09-300001703647us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001703647us-gaap:FurnitureAndFixturesMember2020-12-310001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001703647us-gaap:EmployeeStockOptionMember2020-12-3100017036472021-01-012021-09-300001703647freq:TwoThousandAndNineteenIncentiveAwardPlanMember2021-01-012021-09-300001703647us-gaap:FairValueInputsLevel2Memberfreq:LongTermMarketableSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-3000017036472020-01-012020-12-310001703647us-gaap:ConstructionInProgressMember2020-12-310001703647freq:LoanAndSecurityAgreementMemberfreq:TermLoanMember2020-12-112020-12-110001703647freq:LoanAndSecurityAgreementMemberfreq:TermLoanMember2020-12-110001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001703647freq:LicenseAndCollaborationAgreementMembersrt:AsiaMemberfreq:AstellasPharmaLimitedLiabilityCompanyMemberfreq:Phase2bClinicalTrialMember2019-07-012019-07-310001703647us-gaap:CommonStockMember2021-09-300001703647freq:OutstandingStockOptionsMember2020-01-012020-09-300001703647us-gaap:AdditionalPaidInCapitalMember2021-06-3000017036472020-12-310001703647freq:MassachusettsInstituteOfTechnologyMember2016-12-012016-12-310001703647freq:OutstandingStockOptionsMember2021-01-012021-09-300001703647us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001703647us-gaap:CommonStockMember2021-01-012021-09-300001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001703647us-gaap:CommonStockMember2020-06-300001703647us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001703647us-gaap:RestrictedStockMember2021-01-012021-09-300001703647us-gaap:CommonStockMember2019-12-310001703647us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001703647us-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2020-07-200001703647freq:TwoThousandAndFourteenStockIncentivePlanMember2021-01-012021-09-3000017036472021-09-300001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001703647us-gaap:RetainedEarningsMember2021-09-300001703647us-gaap:CommonStockMember2020-12-310001703647us-gaap:CommonStockMember2021-07-012021-09-300001703647us-gaap:EmployeeStockMember2019-09-192019-09-200001703647us-gaap:FairValueInputsLevel2Memberfreq:ShortTermMarketableSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001703647us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001703647freq:TwoThousandAndNineteenIncentiveAwardPlanMember2021-09-300001703647srt:DirectorMemberfreq:MassachusettsInstituteOfTechnologyMember2021-07-012021-09-300001703647us-gaap:StockCompensationPlanMember2020-12-310001703647us-gaap:StockCompensationPlanMember2021-09-300001703647freq:MassachusettsInstituteOfTechnologyMember2021-01-012021-09-300001703647freq:LicenseAndCollaborationAgreementMembersrt:AsiaMemberfreq:Phase3ClinicalTrailMemberfreq:AstellasPharmaLimitedLiabilityCompanyMember2019-07-012019-07-310001703647freq:LicenseAndCollaborationAgreementMemberfreq:AstellasPharmaLimitedLiabilityCompanyMember2021-09-300001703647us-gaap:CommonStockMember2020-01-012020-09-300001703647us-gaap:AccountingStandardsUpdate201912Member2021-09-300001703647freq:LoanAndSecurityAgreementMemberfreq:PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMemberfreq:TermLoanMember2020-12-112020-12-110001703647us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-12-310001703647us-gaap:FairValueMeasurementsRecurringMember2021-09-300001703647us-gaap:RestrictedStockMember2020-07-012020-09-300001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001703647freq:LicenseAndCollaborationAgreementMemberfreq:AstellasPharmaLimitedLiabilityCompanyMember2019-07-012021-06-3000017036472021-06-300001703647us-gaap:RestrictedStockMember2021-07-012021-09-300001703647us-gaap:RetainedEarningsMember2020-12-310001703647freq:UnvestedRestrictedStockUnitsMember2021-01-012021-09-300001703647us-gaap:CommonStockMember2020-09-300001703647us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001703647us-gaap:EmployeeStockMember2021-09-300001703647freq:LoanAndSecurityAgreementMemberfreq:PrepaymentOccursAfterSecondAnniversaryOfClosingDateMemberfreq:TermLoanMember2020-12-112020-12-110001703647us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001703647us-gaap:AdditionalPaidInCapitalMember2019-12-310001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100017036472020-01-012020-09-300001703647us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-09-300001703647freq:LoanAndSecurityAgreementMemberus-gaap:PrimeRateMemberfreq:TermLoanMember2020-12-112020-12-110001703647us-gaap:RetainedEarningsMember2020-09-300001703647us-gaap:RetainedEarningsMember2019-12-310001703647us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001703647us-gaap:RetainedEarningsMember2021-01-012021-09-300001703647freq:UnvestedRestrictedCommonStockMember2020-01-012020-09-300001703647us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001703647freq:TwoThousandAndFourteenStockIncentivePlanMember2020-12-310001703647us-gaap:AccountingStandardsUpdate201815Member2021-09-300001703647us-gaap:RestrictedStockUnitsRSUMember2021-09-300001703647us-gaap:RetainedEarningsMember2020-07-012020-09-300001703647us-gaap:EquipmentMember2020-12-310001703647freq:LicenseAndCollaborationAgreementMemberfreq:AstellasPharmaLimitedLiabilityCompanyMemberfreq:Phase2bClinicalTrialMembersrt:EuropeMember2019-07-012019-07-310001703647freq:TwoThousandAndNineteenIncentiveAwardPlanMember2020-01-012020-12-310001703647us-gaap:RetainedEarningsMember2021-07-012021-09-300001703647us-gaap:RestrictedStockUnitsRSUMember2020-12-310001703647freq:LicenseAndCollaborationAgreementMembersrt:MaximumMemberfreq:AstellasPharmaLimitedLiabilityCompanyMember2019-07-012019-07-310001703647us-gaap:AdditionalPaidInCapitalMember2020-12-3100017036472020-06-300001703647us-gaap:ConstructionInProgressMember2021-09-300001703647freq:TwoThousandAndNineteenIncentiveAwardPlanMember2020-12-310001703647us-gaap:AdditionalPaidInCapitalMember2020-09-300001703647us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001703647us-gaap:RetainedEarningsMember2020-01-012020-09-300001703647srt:DirectorMemberfreq:MassachusettsInstituteOfTechnologyMember2021-01-012021-09-300001703647us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001703647us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001703647us-gaap:AdditionalPaidInCapitalMember2021-09-300001703647freq:MassachusettsInstituteOfTechnologyMember2016-12-310001703647us-gaap:EmployeeStockOptionMember2021-09-300001703647freq:LoanAndSecurityAgreementMemberfreq:PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMemberfreq:TermLoanMember2020-12-112020-12-110001703647us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001703647freq:LicenseAndCollaborationAgreementMemberfreq:AstellasPharmaLimitedLiabilityCompanyMember2021-07-012021-09-300001703647us-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2020-07-202020-07-2000017036472020-07-012020-09-3000017036472020-09-300001703647freq:TermLoanMember2021-07-012021-09-300001703647us-gaap:RetainedEarningsMember2020-06-300001703647freq:TwoThousandAndFourteenStockIncentivePlanMember2021-09-30xbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

Commission File Number: 001-39062

 

FREQUENCY THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

47-2324450

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

75 Hayden Avenue, Suite 300

Lexington, MA

02421

(Address of principal executive offices)

(Zip Code)

 

(781) 315-4600

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

FREQ

 

The Nasdaq Stock Market LLC (The Nasdaq Global Select Market)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

As of November 8, 2021, the registrant had 34,602,285 shares of common stock, $0.001 par value per share, outstanding.

 

 


 

 

 

 


 

Table of Contents

 

 

 

Page

 

 

 

 

Forward-Looking Statements

2

 

Risk Factors Summary

4

PART I.

FINANCIAL INFORMATION

5

Item 1.

Consolidated Financial Statements (Unaudited)

5

 

Consolidated Balance Sheets

5

 

Consolidated Statements of Operations

6

 

Consolidated Statements of Comprehensive Loss

7

 

Consolidated Statements of Stockholders’ Equity (Deficit)

8

 

Consolidated Statements of Cash Flows

9

 

Notes to Unaudited Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

22

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

37

Item 4.

Controls and Procedures

37

PART II.

OTHER INFORMATION

38

Item 1.

Legal Proceedings

38

Item 1A.

Risk Factors

38

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

82

Item 3.

Defaults Upon Senior Securities

82

Item 4.

Mine Safety Disclosures

82

Item 5.

Other Information

82

Item 6.

Exhibits

83

Signatures

84

 

 

 

 


 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, clinical development plans and expectations, including, without limitation, planned commencements of clinical studies, patient enrollment expectations, expected release of clinical trial results and data, and expected completion dates, potential regulatory submissions, prospective products, product approvals, research and development costs, timing and likelihood of success, and plans and objectives of management for future operations and results, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the risks, uncertainties and assumptions described under the sections in this Quarterly Report titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These forward-looking statements are subject to numerous risks, including, without limitation, the following:

the initiation, timing, progress and results of our preclinical and clinical trials and research and development of programs, including our ongoing Phase 1b clinical trial (FX-322-113), Phase 2b clinical trial of FX-322 (FX-322-208), extension trials of FX-322-111 and FX-322-112, and any future clinical trials for our product candidates;
the continued impact of the novel coronavirus, COVID-19, on our ongoing and planned clinical trials, our research and development activities and our business and financial markets;
our ability to continue to develop our progenitor cell activation, or PCA, platform and identify additional product candidates;
our ability to successfully complete clinical trials of any product candidate and obtain regulatory approval for it;
the timing or likelihood of regulatory filings and approvals;
the commercialization, marketing and manufacture of any product candidate, if approved;
the pricing and reimbursement of any product candidate, if approved;
the rate and degree of market acceptance and clinical utility of any products for which we receive regulatory approval;
the implementation of our strategic plans for our business, product candidates, and technology;
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, PCA platform, and technology;
estimates of our expenses, future revenues, capital requirements, and our need for additional financing;
our ability to maintain and establish collaborations, including our License and Collaboration Agreement with Astellas Pharma Inc.;
our ability to protect our network from cybersecurity threats;
our financial performance and the sufficiency of our financial resources; and
developments relating to our competitors and our industry, including the impact of government regulation.

2


 

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.

You should read this Quarterly Report and the documents that we reference in this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

 

3


 

RISK FACTORS SUMMARY

 

Our business is subject to numerous risks and uncertainties, including those described in Part II Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:

 

We are heavily dependent on the success of FX-322, our lead product candidate for the treatment of hearing loss, which is still under clinical development. If FX-322 does not receive regulatory approval or is not successfully commercialized, our business will be materially adversely harmed;

 

We utilize our PCA platform to develop product candidates that are designed to activate progenitor cells, which is a new approach to therapeutic intervention and, as a result, successful development, approval, and commercialization of our product candidates, including FX-322, is uncertain;

 

Clinical trials are expensive, time consuming, and difficult to design and implement, and involve an uncertain outcome. The results of preclinical studies and early clinical trials are not always predictive of future results. Our Phase 2a results (FX-322-202), for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval;

 

The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for FX-322 or our other product candidates, our business will be substantially harmed;

 

We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business;

 

If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business;

 

We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of FX-322 and additional product candidates;

 

We face significant competition from biotechnology, pharmaceutical, and medical device companies and our operating results will suffer if we fail to compete effectively;

 

If we are unable to establish sales and marketing capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidate we develop, if approved;

 

The COVID-19 pandemic has caused and could continue to cause disruptions to our business, including our preclinical studies, clinical trials and operations and could adversely impact our financial condition and results of operations; and

 

We are currently subject to securities class action litigation and could be subject to similar or other litigation in the future.

4


 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Frequency Therapeutics, Inc.

 

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

112,034

 

 

$

220,341

 

Short-term marketable securities

 

 

36,040

 

 

 

 

Prepaid expenses and other current assets

 

 

1,835

 

 

 

4,723

 

Total current assets

 

 

149,909

 

 

 

225,064

 

Long-term marketable securities

 

 

12,397

 

 

 

 

Property and equipment, net

 

 

6,232

 

 

 

7,287

 

Right of use assets

 

 

31,921

 

 

 

30,551

 

Restricted cash

 

 

1,726

 

 

 

1,820

 

Total assets

 

$

202,185

 

 

$

264,722

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,607

 

 

$

5,506

 

Accrued expenses

 

 

5,197

 

 

 

6,663

 

Deferred revenue

 

 

 

 

 

14,068

 

Lease liabilities

 

 

1,681

 

 

 

397

 

Total current liabilities

 

 

10,485

 

 

 

26,634

 

Lease liabilities, net of current portion

 

 

29,306

 

 

 

30,597

 

Term loan

 

 

15,000

 

 

 

15,000

 

Other long-term liabilities

 

 

278

 

 

 

 

Total liabilities

 

 

55,069

 

 

 

72,231

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2021 and December 31, 2020, respectively

 

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares authorized,
   
34,551,875 and 33,964,000 shares issued and outstanding at September 30, 2021
   and December 31, 2020, respectively

 

 

35

 

 

 

34

 

Additional paid-in capital

 

 

305,663

 

 

 

287,829

 

Accumulated other comprehensive income

 

 

3

 

 

 

27

 

Accumulated deficit

 

 

(158,585

)

 

 

(95,399

)

Total stockholders’ equity

 

 

147,116

 

 

 

192,491

 

Total liabilities and stockholders’ equity

 

$

202,185

 

 

$

264,722

 

 

 

 

 

 

 

 

 

See accompanying notes.

 

5


 

Frequency Therapeutics, Inc.

 

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue

 

$

 

 

$

11,247

 

 

$

14,068

 

 

$

27,034

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

15,662

 

 

 

10,153

 

 

 

48,169

 

 

 

25,587

 

General and administrative

 

 

9,328

 

 

 

6,512

 

 

 

28,571

 

 

 

18,720

 

Total operating expenses

 

 

24,990

 

 

 

16,665

 

 

 

76,740

 

 

 

44,307

 

Loss from operations

 

 

(24,990

)

 

 

(5,418

)

 

 

(62,672

)

 

 

(17,273

)

Interest income

 

 

172

 

 

 

74

 

 

 

315

 

 

 

962

 

Interest (expense)

 

 

(182

)

 

 

 

 

 

(582

)

 

 

 

Realized (loss) gain on investments

 

 

(9

)

 

 

 

 

 

(23

)

 

 

65

 

Foreign exchange (loss) gain

 

 

(4

)

 

 

18

 

 

 

16

 

 

 

27

 

Other (expense), net

 

 

(139

)

 

 

 

 

 

(227

)

 

 

 

Loss before income taxes

 

 

(25,152

)

 

 

(5,326

)

 

 

(63,173

)

 

 

(16,219

)

Income taxes

 

 

(3

)

 

 

(15

)

 

 

(13

)

 

 

(60

)

Net loss

 

$

(25,155

)

 

$

(5,341

)

 

$

(63,186

)

 

$

(16,279

)

Net loss per share attributable to common stockholders-basic and diluted

 

$

(0.73

)

 

$

(0.16

)

 

$

(1.84

)

 

$

(0.51

)

Weighted-average shares of common stock outstanding-basic and diluted

 

 

34,448,746

 

 

 

33,073,889

 

 

 

34,268,736

 

 

 

31,729,702

 

 

See accompanying notes.

6


 

Frequency Therapeutics, Inc.

 

Consolidated Statements of Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net loss

 

$

(25,155

)

 

$

(5,341

)

 

$

(63,186

)

 

$

(16,279

)

Other comprehensive (loss) gain:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (loss) on marketable securities

 

 

(4

)

 

 

(16

)

 

 

(24

)

 

 

(10

)

Total other comprehensive (loss) gain

 

 

(4

)

 

 

(16

)

 

 

(24

)

 

 

(10

)

Comprehensive loss

 

$

(25,159

)

 

$

(5,357

)

 

$

(63,210

)

 

$

(16,289

)

 

See accompanying notes.

7


 

Frequency Therapeutics, Inc.

 

Consolidated Statements Stockholders’ Equity (Deficit)

(in thousands, except share and per share amounts)

 

 

 

 

 

Common
shares issued

 

 

Common
par value

 

 

Additional
paid-in capital

 

 

Accumulated other
comprehensive income

 

 

Accumulated
deficit

 

 

Total stockholders’
equity (deficit)

 

Balance, December 31, 2019

 

 

30,844,507

 

 

$

31

 

 

$

236,161

 

 

$

54

 

 

$

(68,888

)

 

$

167,358

 

Stock-based compensation expense
  

 

 -

 

 

 

-

 

 

 

7,218

 

 

 

-

 

 

 

-

 

 

 

7,218

 

Issuance of common stock upon exercise of stock options

 

 

537,675

 

 

 

1

 

 

 

1,161

 

 

 

-

 

 

 

-

 

 

 

1,162

 

Issuance of common stock in Private Placement, net

 

 

2,350,108

 

 

 

2

 

 

 

40,141

 

 

 

-

 

 

 

-

 

 

 

40,143

 

Other comprehensive (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(10

)

 

 

-

 

 

 

(10

)

Net loss

 

 -

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(16,279

)

 

 

(16,279

)

Balance, September 30, 2020

 

 

33,732,290

 

 

 

34

 

 

 

284,681

 

 

 

44

 

 

 

(85,167

)

 

 

199,592

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2020

 

 

33,964,000

 

 

$

34

 

 

$

287,829

 

 

$

27

 

 

$

(95,399

)

 

$

192,491

 

Stock-based compensation expense
  

 

 

-

 

 

 

-

 

 

 

16,586

 

 

 

-

 

 

 

-

 

 

 

16,586

 

Purchase under Employee Stock Purchase Plan

 

 

7,064

 

 

 

1

 

 

 

60

 

 

 

-

 

 

 

-

 

 

 

61

 

Issuance of common stock upon exercise of stock options

 

 

582,976

 

 

 

-

 

 

 

1,188

 

 

 

-

 

 

 

-

 

 

 

1,188

 

Forfeiture of restricted stock

 

 

(2,165

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Other comprehensive (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(24

)

 

 

-

 

 

 

(24

)

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(63,186

)

 

 

(63,186

)

Balance, September 30, 2021

 

 

34,551,875

 

 

$

35

 

 

$

305,663

 

 

$

3

 

 

$

(158,585

)

 

$

147,116

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common
shares issued

 

 

Common
par value

 

 

Additional
paid-in capital

 

 

Accumulated other
comprehensive income

 

 

Accumulated
deficit

 

 

Total stockholders’
equity (deficit)

 

Balance, June 30, 2020

 

 

31,249,499

 

 

$

31

 

 

$

241,436

 

 

$

60

 

 

$

(79,826

)

 

$

161,701

 

Stock-based compensation expense
  

 

 -

 

 

 

-

 

 

 

2,643

 

 

 

-

 

 

 

-

 

 

 

2,643

 

Issuance of common stock upon exercise of stock options

 

 

132,683

 

 

 

1

 

 

 

461

 

 

 

-

 

 

 

-

 

 

 

462

 

Issuance of common stock in Private Placement, net

 

 

2,350,108

 

 

 

2

 

 

 

40,141

 

 

 

-

 

 

 

-

 

 

 

40,143

 

Other comprehensive (loss)

 

 -

 

 

 

-

 

 

 

-

 

 

 

(16

)

 

 

-

 

 

 

(16

)

Net loss

 

 -

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(5,341

)

 

 

(5,341

)

Balance, September 30, 2020

 

 

33,732,290

 

 

$

34

 

 

$

284,681

 

 

$

44

 

 

$

(85,167

)

 

$

199,592

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2021

 

 

34,385,916

 

 

$

34

 

 

$

299,429

 

 

$

7

 

 

$

(133,430

)

 

$

166,040

 

Stock-based compensation expense
  

 

 

-

 

 

 

-

 

 

 

5,886

 

 

 

-

 

 

 

-

 

 

 

5,886

 

Purchase under Employee Stock Purchase Plan

 

 

7,064

 

 

 

1

 

 

 

60

 

 

 

-

 

 

 

-

 

 

 

61

 

Issuance of common stock upon exercise of stock options

 

 

161,060

 

 

 

-

 

 

 

288

 

 

 

-

 

 

 

-

 

 

 

288

 

Forfeiture of restricted stock

 

 

(2,165

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Other comprehensive (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(4

)

 

 

-

 

 

 

(4

)

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(25,155

)

 

 

(25,155

)

Balance, September 30, 2021

 

 

34,551,875

 

 

$

35

 

 

$

305,663

 

 

$

3

 

 

$

(158,585

)

 

$

147,116

 

 

See accompanying notes.

8


 

Frequency Therapeutics, Inc.

 

Consolidated Statements of Cash Flows

(in thousands)

 

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(63,186

)

 

$

(16,279

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

 

 

Stock-based compensation

 

 

16,586

 

 

 

7,218

 

Depreciation expense

 

 

2,038

 

 

 

760

 

Non-cash lease expense

 

 

495

 

 

 

256

 

Non-cash interest expense

 

 

179

 

 

 

 

Loss on disposal of assets

 

 

16

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

2,888

 

 

 

985

 

Accounts payable

 

 

(1,910

)

 

 

2,870

 

Deferred revenue

 

 

(14,068

)

 

 

(27,034

)

Lease liabilities

 

 

(7

)

 

 

 

Accrued expenses

 

 

(1,202

)

 

 

869

 

Net cash (used in) operating activities

 

 

(58,171

)

 

 

(30,355

)

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(2,853

)

 

 

(2,253

)

Purchase of marketable securities

 

 

(66,226

)

 

 

 

Redemption of marketable securities

 

 

17,600

 

 

 

17,090

 

Net cash (used in) provided by investing activities

 

 

(51,479

)

 

 

14,837

 

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from issuance of common stock upon exercise of stock options

 

 

1,188

 

 

 

1,162

 

Proceeds from Employee Stock Purchase Plan

 

 

61

 

 

 

 

Proceeds from Private Placement, net of issuance costs

 

 

 

 

 

40,143

 

Net cash provided by financing activities

 

 

1,249

 

 

 

41,305

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

 

(108,401

)

 

 

25,787

 

Cash, cash equivalents, and restricted cash at beginning of period

 

 

222,161

 

 

 

200,259

 

Cash, cash equivalents, and restricted cash at end of period

 

$

113,760

 

 

$

226,046

 

Non-cash items:

 

 

 

 

 

 

Right-of-use assets in exchange for lease liabilities

 

$

 

 

$

2,163

 

Purchases of property and equipment in accounts payable and accrued expenses

 

$

34

 

 

$

24

 

 

See accompanying notes

 

 

9


 

Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements

(Amounts in thousands, except share and per share amounts)

 

1. Organization and basis of presentation

 

Organization

Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, and Frequency Therapeutics Securities Corporation, (the Company), headquartered in Lexington, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function.

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC).

Principles of consolidation

The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements on Form 10-Q are consistent with those discussed in Note 2, “Summary of significant accounting policies,” in the Company’s Form 10-K.

Unaudited interim financial information

The accompanying consolidated balance sheet as of September 30, 2021 and the consolidated statements of operations, the consolidated statements of comprehensive loss and the consolidated statements of stockholders’ equity (deficit) for the three and nine months ended September 30, 2021 and 2020, and the consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2021, the results of its operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2020 are also unaudited. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. The consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date. These unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Form 10-K. 

2. Recently adopted and issued accounting standards

 

Recently adopted accounting standards

In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. The Company adopted the standard on January 1, 2021 and it did not have a significant impact on its consolidated financial statements.

10


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

Recently issued accounting standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This new guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. ASU 2018-15 generally aligns the guidance on recognizing implementation costs incurred to develop or obtain internal use software, which includes hosting arrangements that include an internal-use software license. This standard will become effective for the Company for the 2021 annual financial statements. The Company is still evaluating the impact of this standard on its consolidated financial statements.  

3. Fair value measurements

Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:

Level 1 Quoted prices in active markets for identical assets or liabilities.

Level 2 Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3 Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

11


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy at September 30, 2021 and December 31, 2020 are summarized as follows:

 

 

 

 

 

September 30, 2021

 

 

 

Fair Value

 

Amortization

 

 

Unrealized

 

 

Fair Market

 

 

 

Hierarchy

 

Cost

 

 

Loss

 

 

Value

 

Money market funds

 

Level 1

 

 

65,939

 

 

 

 

 

 

65,939

 

Short-term marketable securities

 

Level 2

 

 

36,060

 

 

 

(20

)

 

 

36,040

 

Long-term marketable securities

 

Level 2

 

 

12,401

 

 

 

(4

)

 

 

12,397

 

 

 

 

 

$

114,400

 

 

$

(24

)

 

$

114,376

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2020

 

 

 

Fair Value

 

Amortization

 

 

Unrealized

 

 

Fair Market

 

 

 

Hierarchy

 

Cost

 

 

Gain

 

 

Value

 

Money market funds

 

Level 1

 

 

214,522

 

 

 

27

 

 

 

214,549

 

 

 

 

 

$

214,522

 

 

$

27

 

 

$

214,549

 

 

The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values.

4. Property and equipment

Property and equipment include the following:

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Lab equipment

 

$

6,107

 

 

$

4,166

 

Furniture and office equipment

 

 

3,220

 

 

 

283

 

Software

 

 

291

 

 

 

291

 

Leasehold improvements

 

 

 

 

 

1,419

 

Construction in progress

 

 

61

 

 

 

4,340

 

Total

 

 

9,679

 

 

 

10,499

 

Accumulated depreciation

 

 

(3,447

)

 

 

(3,212

)

Property and equipment, net

 

$

6,232

 

 

$

7,287

 

 

The Company recognized $735 and $2,038, and $301 and $760 of depreciation expense for the three and nine months ended September 30, 2021 and 2020, respectively.

5. Accrued expenses

Accrued expenses consist of the following:

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Payroll and employee related expenses

 

$

3,522

 

 

$

5,062

 

Professional fees

 

 

666

 

 

 

647

 

Third-party research and development expenses

 

 

766

 

 

 

874

 

Taxes and other

 

 

243

 

 

 

80

 

Total

 

$

5,197

 

 

$

6,663

 

 

12


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

6. Debt

On December 11, 2020 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with a commercial bank for a term loan with a principal balance of $15,000. The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”). Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in The Wall Street Journal, subject to an interest rate floor of zero) or (ii) 4.75%. The interest rate at September 30, 2021 was 4.75%, resulting in interest expense of $182 and $582 for the three and nine months ended September 30, 2021.

The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the borrowings under the Loan Agreement are refinanced by the bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date.

The Company will pay a final payment of $150, which will occur on the earliest of: (i) the Loan Maturity Date; (ii) the date that the Company prepays all of the outstanding principal in full; (iii) the date the loan payments are accelerated due to an event of default; or (iv) the termination of the Loan Agreement. The Company is accruing the final payment as interest expense over the term of the loan. The term loan is secured by substantially all of the Company’s assets, excluding intellectual property.

 

7. Net loss per share

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the three and nine months ended September 30, 2021 and 2020 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods.

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$

(25,155

)

 

$

(5,341

)

 

$

(63,186

)

 

$

(16,279

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares of common stock outstanding-
   basic and diluted

 

 

34,448,746

 

 

 

33,073,889

 

 

 

34,268,736

 

 

 

31,729,702

 

Net loss per share attributable to common stockholders-
   basic and diluted

 

$

(0.73

)

 

$

(0.16

)

 

$

(1.84

)

 

$

(0.51

)

 

The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.

 

 

 

Three and Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

Unvested restricted common stock

 

 

-

 

 

 

3,557

 

Unvested restricted stock units

 

 

698,300

 

 

 

-

 

Outstanding stock options

 

 

7,279,399

 

 

 

6,753,568

 

Total

 

 

7,977,699

 

 

 

6,757,125

 

 

 

 

 

 

 

 

 

13


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

 

8. Stockholders’ equity

Capital stock

The Company has authorized 10,000,000 shares of $0.001 par value preferred stock and 200,000,000 shares of $0.001 par value common stock. There were no shares of preferred stock outstanding as of September 30, 2021. There were 34,551,875 and 33,964,000 shares of common stock issued and outstanding as of September 30, 2021 and December 31, 2020, respectively. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.

The Company has reserved the following shares of common stock for future issuance as of September 30, 2021 and December 31, 2020:

 

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Stock options outstanding

 

 

7,279,399

 

 

 

6,816,798

 

Shares available for future grant under incentive plans

 

 

1,090,606

 

 

 

1,475,923

 

 

 

 

8,370,005

 

 

 

8,292,721

 

 

Private placement

On July 20, 2020, the Company issued and sold an aggregate of 2,350,108 shares of its common stock, par value $0.001 per share (the “Shares”), at a purchase price of $18.00 per share to new and existing investors in a private placement for net proceeds of $40,100 after deducting placement agent fees and offering expenses (the “Private Placement”). In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within 60 days after the closing of the Private Placement (the “Initial Filing Date”) for purposes of registering the resale of the Shares. The Company filed a registration statement (the “Registration Statement”) to register the Shares, which was declared effective by the SEC on September 3, 2020.

9. Stock-based compensation

Stock options

The below summary includes stock option activity within the Company’s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the nine months ended September 30, 2021:

 

 

Number of
shares

 

 

Weighted
average
exercise

 

 

Weighted average
remaining contractual
term

 

 

Aggregate
intrinsic

 

 

 

in Plans

 

 

price

 

 

(in years)

 

 

value

 

Outstanding as of December 31, 2020

 

 

6,816,798

 

 

$

10.11

 

 

 

8.45

 

 

$

171,415

 

Granted

 

 

1,343,376

 

 

 

33.04

 

 

 

8.65

 

 

 

 

Exercised

 

 

(582,976

)

 

 

2.04

 

 

 

 

 

$

11,369

 

Forfeited

 

 

(297,799

)

 

 

20.85

 

 

 

 

 

 

 

Outstanding as of September 30, 2021

 

 

7,279,399

 

 

$

14.55

 

 

 

7.71

 

 

$

13,138

 

Options exercisable as of September 30, 2021

 

 

3,702,862

 

 

$

9.13

 

 

 

7.36

 

 

$

10,197

 

Options unvested as of September 30, 2021

 

 

3,576,537

 

 

$

20.16

 

 

 

8.07

 

 

$

2,942

 

 

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock.

14


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

Stock option valuation

The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:

 

 

September 30,

 

 

 

2021

 

Risk-free interest rate

 

 

0.5

%

Expected term (in years)

 

 

6.0

 

Expected volatility

 

 

79.8

%

Expected dividend yield

 

 

0.0

%

 

The weighted-average grant date fair value of options granted during the three and nine months ended September 30, 2021 and 2020 was $5.64 and $22.57, and $14.02 and $15.73, respectively.

The total grant date fair value of options vested during the three and nine months ended September 30, 2021 and 2020 was $3,418 and $12,231, and $2,406 and $5,751, respectively.

Restricted common stock

The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder.

A summary of the status of restricted common stock as of September 30, 2021 is presented below:

 

 

 

Number of
shares

 

 

Weighted
average fair
value

 

Unvested, December 31, 2020

 

 

3,093

 

 

$

1.75

 

Awarded

 

 

 

 

 

 

Vested

 

 

(928

)

 

 

1.75

 

Forfeited

 

 

(2,165

)

 

 

1.75

 

Unvested as of September 30, 2021

 

 

 

 

$

-

 

 

 

 

 

 

 

 

 

The total value of restricted stock awards that vested during the three and nine months ended September 30, 2021 and 2020, based on estimated fair values of the stock underlying the restricted stock awards was $0 and $2, and $1 and $19, respectively.

Restricted stock units

In April 2021, the Company issued restricted stock units to employees which will vest in equal installments in the first quarter of 2022 and the third quarter of 2022.

 

A summary of the status of restricted stock units as of September 30, 2021 is presented below:

 

 

Number of
shares

 

 

Weighted
average fair
value

 

Unvested, December 31, 2020

 

 

 

 

$

-

 

Awarded

 

 

800,000

 

 

 

9.54

 

Vested

 

 

 

 

 

 

Forfeited

 

 

(101,700

)

 

 

9.54

 

Unvested as of September 30, 2021

 

 

698,300

 

 

$

9.54

 

 

15


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

Stock-based compensation

The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows:

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

2,774

 

 

$

1,036

 

 

$

7,393

 

 

$

3,039

 

General and administrative

 

 

3,112

 

 

 

1,607

 

 

 

9,193

 

 

 

4,179

 

Total

 

$

5,886

 

 

$

2,643

 

 

$

16,586

 

 

$

7,218

 

 

As of September 30, 2021, total unrecognized stock-based compensation expense relating to unvested stock options, restricted stock awards, and restricted stock units was $46,901. This amount is expected to be recognized over a weighted-average period of 2.64 years.

10. Employee stock purchase plan

On September 20, 2019, the Company’s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the “ESPP”) which became effective on the date of the Company’s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company’s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. The Company’s first offering period of 2021 concluded on June 30, 2021 with the purchase of 7,064 shares in July 2021 related to this offering period. A total of 956,021 shares remain for future offering periods.

11. Income taxes

The Company’s total provision is based on the United States statutory rate of 21%, increased by state taxes and reduced by a full valuation allowance on the Company’s deferred tax assets. The income tax expense for the three and nine months ended September 30, 2021 and 2020 represents state taxes on interest income earned by the Company’s subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation.

ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at September 30, 2021 and December 31, 2020 because the Company’s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position.

Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which no net tax benefit has been recorded due to uncertainty around utilizing these tax attributes within the respective carryforward periods.

12. Collaboration agreement

In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the “Astellas Agreement”), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the “Astellas Licensed Products”), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States.

16


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

These parties have agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries.

The collaboration is governed by a joint steering committee (“JSC”) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party’s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC.

As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80,000 in July 2019 and has agreed to pay potential development milestone payments up to $230,000 and commercialization milestones of up to $315,000. Specifically, the Company would receive development milestone payments of $65,000 and $25,000 upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100,000 and $40,000 upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315,000 in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan.

The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days’ written notice. Each party has the right to terminate the Astellas Agreement due to the other party’s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt.

The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808.

The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation.

17


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The Company determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and continued until the completion of the Phase 2a clinical trial of FX-322 (FX-322-202). The transaction price of $80,000 was allocated to the single combined performance obligation and recognized over such period. At commencement and throughout the trial, management analyzed the progress of the Phase 2a clinical trial (FX-322-202) and estimated the completion date of such trial and the total research and development costs it expects to incur in performing the trial to be June 30, 2021. As such, the Company recognized the $80,000 upfront fee as revenue over the period from July 2019 until June 30, 2021, the completion date of the Phase 2a clinical trial (FX-322-202), using the input method. The Company was required to pay MIT a royalty of $16,000 on the $80,000 of sublicense revenues. The $16,000 royalty was expensed in the third quarter of 2019. For a description of the MIT License Agreement, refer to Note 13.

The $80,000 upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and was recognized as revenue according to the policy described above. As of June 30, 2021, the Company completed its performance obligation with respect to the upfront payment and, accordingly, recognized all remaining revenue related to the Astellas Agreement.

The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee’s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statements of operations during the development period. In the three and nine months ended September 30, 2021, the Company invoiced Astellas $229 and $741 for joint costs.

 

13. License Agreement

 

Massachusetts Institute of Technology

In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement) with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement.

The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on

18


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company’s future development obligations are: (i) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product, (ii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii) to make a first commercial sale of such Product within 11 years of the IND filing for such Product. The Company also has certain development obligations for a second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fails to cure such breach within ninety (90) days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations.

Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 12.

The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents, including filed patent applications licensed thereunder, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.

In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product.

 

The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Pursuant to MIT’s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer received $1,980 from MIT under the MIT Policy during the year ended December 31, 2020. Dr. Langer received $6 from MIT under the MIT Policy during the three and nine months ended September 30, 2021.

14. Commitments and contingencies

Contract commitments

The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $600 through December 2021.

19


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

The Company also enters into contracts in the normal course of business with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run.

Guarantees

The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees.

As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid.

The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.

The Company leases office space in Lexington, Massachusetts under a ten-year noncancelable operating lease. The $1,726 security deposit for this lease is classified as restricted cash as of September 30, 2021. The Company exited its Woburn, Massachusetts facility in the second quarter of 2021. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease.

As of September 30, 2021, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established.

 

Legal Contingencies

 

The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company’s accrued liabilities would be recorded in the period in which such determination is made.

 

In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred.

 

On June 3, 2021 and June 22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company entitled Evans v. Frequency Therapeutics, Inc. et al. and Hingston v. Frequency Therapeutics, Inc. et al., respectively. The lawsuits allege violations of Section 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended, due to allegedly false and misleading statements and

20


Frequency Therapeutics, Inc.

Notes to Unaudited Consolidated Financial Statements –(continued)

(Amounts in thousands, except share and per share amounts)

 

omissions about the Company’s Phase 2a clinical trial (FX-322-202) for its product candidate FX-322 in the Company’s public disclosures between November 16, 2020 and March 22, 2021. The lawsuits seek, among other things, damages in connection with the Company’s allegedly artificially inflated stock price between November 16, 2020 and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys’ fees and costs. These matters are at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company is vigorously defending against all claims asserted in both lawsuits. The Company has not yet filed a responsive pleading. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of September 30, 2021.

 

On June 23, 2021, two purported stockholders of the Company filed a lawsuit in the Court of Chancery of the State of Delaware against (i) the Company, (ii) the Company’s Chief Executive Officer, President, and Director, David Lucchino, (iii) Computershare Inc., and (iv) Computershare Trust Company, N.A., entitled The Gregory J. Parseghian Revocable Trust, et al. v. Frequency Therapeutics, Inc., et al. The lawsuit alleges causes of action against the Company of conversion and unjust enrichment, and against Mr. Lucchino for breach of the fiduciary duty of loyalty, due to allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The lawsuit seeks monetary damages, as well as interest, attorneys’ fees and costs, against all defendants. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. We are vigorously defending against all claims asserted and have filed a motion to dismiss the complaint. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of September 30, 2021.

 

 

 

21


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and with our Annual Report on Form 10-K for the year ended December 31, 2020, or the 2020 Annual Report, including the audited consolidated financial statements and notes thereto contained in our 2020 Annual Report. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the section titled “Risk factors” in this Quarterly Report on Form 10-Q for a discussion of important factors that could cause actual results to differ materially from the results described below.

Overview

We are a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function. Our focus is on advancing our lead product candidate, FX-322, through clinical studies with the goal of developing and commercializing a medicine to help millions of patients with the most common form of hearing loss while continuing to build upon the potential of regenerative therapeutics in other applications.

 

Our initial therapeutic focus is sensorineural hearing loss, or SNHL, which is the most prevalent type of hearing loss. We are developing FX-322 to treat a major underlying cause of SNHL, which is the loss of hair cells. FX-322 is designed to regenerate hair cells through the activation of progenitor cells already present in the ear. In our Phase 1/2 clinical trial (FX-322-201) evaluating FX-322 in 23 patients with stable SNHL, we observed a statistically significant and clinically meaningful improvement in key measures of hearing loss, including word recognition, or WR, and clarity of sounds, and FX-322 was observed to be well-tolerated.

 

We commenced dosing of a Phase 2a clinical trial of FX-322 (FX-322-202) in patients with SNHL in October 2019. In September 2020, we completed enrollment of 95 patients across 16 sites in the Phase 2a clinical trial (FX-322-202). In March 2021, we announced topline, day-90 interim data from the Phase 2a clinical trial (FX-322-202), and in June 2021, we announced final results from the Phase 2a clinical trial (FX-322-202). Consistent with the topline, day-90 interim data, the end-of-study results (as of day 210) showed that four weekly injections of FX-322 did not demonstrate improvements in any hearing measures versus placebo. We also observed an unexpected increase in WR scores in the placebo group that did not occur in previous FX-322 trials and exceeded well-established published standards, potentially suggesting bias due to trial design. Given this lack of reliability of baseline WR scores of the placebo group, we were unable to evaluate hearing improvements in WR scores for FX-322 dosing regimens versus placebo. Consistent with the interim data, the end-of-study results showed a favorable safety and tolerability profile for FX-322 in the Phase 2a clinical trial.

In March 2021, we announced data from a Phase 1b clinical trial of FX-322 designed to evaluate the impact of injection conditions on tolerability (FX-322-111). The data showed hearing improvement from a single injection of FX-322. In the multi-center, randomized study, subjects with mild to severe SNHL (n=33) were injected in one ear with FX-322 with the untreated ear as the control. Hearing function was tested over the course of 90 days following dosing. Thirty-two subjects completed the 90-day clinical assessment period and, at day 90 following dosing, 34% of these subjects achieved a 10% or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear (p <0.05). This included a subset of subjects that more than doubled their WR scores. Twenty-five subjects were subsequently evaluated during the 8 to 12 months following FX-322 dosing and, as of September 22, 2021, nine subjects had shown statistically significant hearing improvements when evaluated during this time period. Of the five subjects that showed a statistically significant response and doubled their WR scores at day 90, four of these returned for evaluation and had scores that remained above their baseline word recognition measures, though were below the threshold for statistical significance. In this trial, FX-322 showed a favorable safety profile and was well tolerated.

In May 2021, we announced data from a Phase 1b clinical trial of FX-322 in presbycusis (age-related hearing loss) (FX-322-112). The double-blind, placebo-controlled, randomized, multicenter safety study enrolled 30 individuals aged 66-85 with age-related hearing loss. Study participants were randomized 4:1 to receive either FX-322 or placebo in one ear. Validated hearing measures, as well as safety, otologic and audiologic assessments were also evaluated in the study. By design, the study recruited subjects with no medical history of noise-induced or sudden sensorineural hearing loss (SSNHL), etiologies where FX-322 associated hearing benefits were observed in prior studies, as we continue to separately evaluate subjects with specific forms of hearing loss to better refine cohorts for future studies. While the treatment effect was not significant compared to placebo, results from the study showed a favorable safety and tolerability profile with no reported treatment-related serious adverse events.

22


 

In November 2020 we commenced a Phase 1b clinical trial of FX-322 in patients aged 18-65 with severe SNHL (FX-322-113). The trial was fully enrolled with 31 subjects. Severe SNHL is defined as a pure tone average deficit between 71-90 dB and many patients with this clinical profile typically would be candidates for cochlear implants. The primary objectives of the study are to assess the local and systemic safety of a single dose of FX-322 and evaluate hearing responses in a more severe adult cohort. Study participants are randomized 4:1 to receive either FX-322 or placebo in one ear. Validated measures of hearing including WR, sentences in noise, and pure tone audiometry are utilized in the study. Safety, otologic and audiologic assessments are being conducted at days 30 and 90 following administration of FX-322 or placebo. We expect topline results from this study in the fourth quarter of 2021.

In October 2021, we commenced dosing of a Phase 2b clinical trial of FX-322 (FX-322-208) in patients with SNHL. FX-322-208 is a randomized, placebo-controlled, multi-center study designed to evaluate the impact of a single administration of FX-322 on speech perception in approximately 124 subjects with either noise-induced or sudden SNHL. The study’s primary endpoint is speech perception, a measure of sound clarity and understanding speech. In a Type-C meeting with the U.S. Food and Drug Administration, or the FDA, the FDA agreed that speech perception is an acceptable primary efficacy endpoint. The Phase 2b study’s inclusion criteria are designed to enroll subjects with the same hearing loss severities and etiologies as those subjects in which statistically significant improvements in speech perception were observed in prior FX-322 clinical studies.

In November 2021, we introduced our new SNHL investigational therapeutic program, FX-345, designed to achieve broader exposure through the cochlea. Preclinical pharmacokinetic measures and human modeling data indicate that FX-345 achieves greater exposure through a larger portion of the cochlea for longer periods of time. This increased exposure corresponds to a wider range of hearing frequencies, creating the potential to benefit an expanded SNHL patient population. We anticipate filing an IND for FX-345 in the second quarter of 2022.

We believe our PCA approach can impact a wide range of degenerative diseases. As such, we continue to advance our preclinical research efforts designed to repair neurological damage in individuals with multiple sclerosis, or MS. This program focuses on inducing remyelination, activating oligodendrocyte progenitor cells in the central nervous system to regenerate the myelin sheath that supports nerve signaling and protects axons, potentially repairing the damage caused by MS. In November 2021, we introduced FREQ-162, a preclinical stage lead compound that induces substantially more remyelination than published comparator approaches based on in vivo models. Our efforts are focused on advancing FREQ-162 in preclinical safety studies in preparation for the initiation of clinical development.

Separately, we have worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this additional approach at Cambridge University.

In July 2020, we completed a private placement of our common stock to new and existing investors, or the Private Placement. In the Private Placement, we issued and sold 2,350,108 shares of our common stock at a purchase price of $18.00 per share. We received approximately $40.1 million in net proceeds, after deducting placement agent fees and other offering expenses. In connection with the Private Placement, we entered into a Registration Rights Agreement, or the Registration Rights Agreement, with the investors purchasing shares in the Private Placement. Pursuant to the Registration Rights Agreement, we filed a registration statement with the Securities and Exchange Commission, or the SEC, which was declared effective on September 3, 2020, registering the resale of the shares sold in the Private Placement.

 

Since our formation in 2014, we have devoted substantially all our resources to developing our PCA platform, conducting research and development activities, including product candidate development, recruiting skilled personnel, establishing our intellectual property portfolio, and providing general and administrative support for these operations. We have financed our operations primarily through proceeds from the sale of convertible notes, convertible preferred stock, and common stock, payments under the Astellas Agreement and loan financing.

Since our formation, we have incurred significant operating losses and have not generated any revenue from the sale of products. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $63.2 million and $26.5 million for the nine months ended September 30, 2021 and year ended December 31, 2020, respectively. As of September 30, 2021, we had an accumulated deficit of $158.6 million.

We expect our operating expenses to increase substantially in connection with the expansion of our product development programs and capabilities. In addition, we expect to continue to incur significant additional costs associated

23


 

with operating as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval for, and successfully commercialize our product candidates, or until our collaborators do so, which could result in milestone payments or royalties to us. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing and distribution.

As a result of these anticipated expenditures, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We cannot be sure that we will ever generate sufficient revenue to achieve profitability.

Because of the numerous risks and uncertainties associated with the development of therapeutics, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we can generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be required to raise additional capital on terms that are unfavorable to us or we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

Our offices are located in states that have lifted most COVID-19 restrictions. As of the date of the filing of this Quarterly Report, the majority of our non-laboratory based employees continue to work from home two to three days per week, while our laboratory personnel have resumed a full in-person schedule in our Lexington, MA facility. We have also taken steps consistent with the FDA’s updated industry guidance for conducting clinical trials. The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, COVID-19 may cause disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue.

License and collaboration agreements

Astellas Pharma Inc.

In July 2019, we entered into the Astellas Agreement with Astellas, under which we granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek, and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, or the Astellas licensed products, including our product candidate FX-322, outside of the United States. We and Astellas have agreed to jointly develop the Astellas licensed products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in SNHL and in age-related hearing loss, in each case in one major Asian country and one major European country. We have agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in the United States. Astellas has the sole right to commercialize the Astellas licensed products outside of the United States and we have the sole right to commercialize the Astellas licensed products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas licensed products in a major Asian country and a major European country following receipt of regulatory approval in such countries.

As a consideration for the licensed rights under the Astellas Agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestones up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively, and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments and tiered royalties at rates ranging from low to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint

24


 

manufacturing plan. Pursuant to our Exclusive Patent License Agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, we are required to pay MIT a royalty on sublicense revenues. A royalty of $16.0 million related to the $80.0 million upfront payment received from Astellas was expensed in the quarter ended September 30, 2019 and paid in November 2019. The $80.0 million upfront payment received from Astellas in July 2019 was recorded as deferred revenue. In accordance with ASC 606, we recognized the $80.0 million as revenue over the period that research and development services for the Phase 2a clinical study for FX-322 (FX-322-202) were being provided using the input method. These research and development services concluded in June 2021.

Massachusetts Institute of Technology

In December 2016, we entered into the MIT License with MIT, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, or the MIT Licensed Products, and to develop and perform processes, or the MIT licensed processes, which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. We are required to use diligent efforts to develop and commercialize the MIT licensed products or processes, and to make such products or processes reasonably available to the public. We are also subject to certain development obligations with regards to a first MIT Licensed Product. We have satisfied certain obligations related to preclinical studies and the filing of an IND for a first MIT Licensed Product with our development activities related to FX-322. Our future development obligations are: (i) to commence a Phase III clinical trial for such product within five years of the IND filing for such product, (ii) to file a New Drug Application, or NDA, or equivalent with the FDA or comparable European regulatory agency for such product within nine years of the IND filing for such Product, and (iii) to make a first commercial sale of such Product within 11 years of the IND filing for such product. We also have certain development obligations with regards to a second MIT licensed product.

Upon entering into the MIT License, we paid a $50 thousand license fee payment and issued shares of our common stock equal to 5% of our then-outstanding capital stock to MIT. We are required to pay certain annual license maintenance fees ranging from $30 thousand to $0.1 million per year prior to first commercial sale of a MIT licensed product and an annual license maintenance fee of $0.2 million every year afterwards, which may be credited to running royalties during the same calendar year, if any. We are also required to make potential milestone payments in an aggregate amount of up to $2.9 million on each MIT licensed product or process. In addition, we agreed to pay a low single-digit royalty on the MIT licensed products and processes and a low-twenties royalty on sub-license revenues. In the year ended December 31, 2019, we paid MIT a $16.0 million royalty on the upfront license fee received from Astellas.

Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary)

In February 2019, we entered into a Non-Exclusive Patent License Agreement, or the MEE License, with the Massachusetts Eye and Ear, or MEE, under which we received a non-exclusive, non-sub-licensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, and to develop and perform processes that incorporate the licensed technology for the treatment or prevention of hearing loss, or the MEE licensed products. We are obligated to use diligent efforts to develop and commercialize the MEE licensed products. We are also subject to milestone timeline obligations to dose a first patient in a Phase III trial by December 31, 2024.

Upon entering into the MEE License, we made a $20 thousand license fee payment. We are obligated to pay certain annual license maintenance fees between $5 thousand and $7.5 thousand per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. We are also obligated to pay a minimum annual royalty payment of $15 thousand per each MEE patent family case number included in the licensed MEE patent rights after first commercial sale of an MEE licensed product. We are also obligated to make milestone payments up to $350 thousand on each product or process that incorporates the licensed patent rights. In addition, we have agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights.

The Scripps Research Institute (California Institute for Biomedical Research)

In September 2018, we entered into a license agreement, or the CALIBR License, with the California Institute for Biomedical Research, or CALIBR, a division of Scripps, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the CALIBR licensed products, which incorporate licensed technology for the treatment of MS. We have agreed to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR licensed product. We are also subject to certain milestone timeline obligations, which may be extended in certain circumstances as described in the CALIBR License, to: (i) submit an

25


 

IND (or equivalent) for a CALIBR licensed product by the 30th month after the effective date of the CALIBR License, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR licensed product by the fourth anniversary of the effective date of the CALIBR License, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR licensed product by the sixth anniversary of the effective date of the CALIBR License.

Upon entering into the CALIBR License, we made a $1.0 million license fee payment, and are required to make milestone payments in an aggregate amount of up to $26.0 million for each category of CALIBR licensed products. Category 1 is any CALIBR licensed products containing a compound that modulates any muscarinic receptor, and Category 2 is any CALIBR licensed products not included in Category 1 that could differentiate oligodendrocyte precursor cells from in vitro studies and/or are active in animal models relevant to MS. We are also required to pay a mid-single-digit royalty on CALIBR licensed products and a royalty on sub-license revenues ranging from a low-teen percentage to 50%.

 

The Scripps Research Institute

In September 2018, we entered into a Research Funding and Option Agreement with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Research Funding and Option Agreement, we are required to make funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Research Funding and Option Agreement.

The Research Funding and Option Agreement had a one-year term and was renewed for a second year by mutual written agreement. We have the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt.

In September 2020, we extended the term of the Research Funding and Option Agreement through the end of December 2021 related to research activities. As consideration for this extension, we are required to make additional funding payments of $0.6 million to Scripps through December 2021.

We have the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt.

Cambridge Enterprise Limited

In December 2019, we entered into an Exclusive Patent License Agreement, or the Cambridge License, with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge), or Cambridge, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the Cambridge licensed products, which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant sublicenses under the Cambridge License. Cambridge reserves the right to use for itself (as well as the investors and the funder) and the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.

We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge licensed product. Upon entering into the Cambridge License, we made a $50 thousand license fee payment. We are obligated to pay an annual license fee of $50 thousand. We are also obligated to make milestone payments up to $10.5 million on each Cambridge licensed product. In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.

The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon 90 days’ prior written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge licensed product or we or our affiliates or sub-licensees commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.

Components of our results of operations

26


 

Revenue

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, we recognized the $80.0 million as revenue over the period that research and development services for the Phase 2a clinical study for FX-322 (FX-322-202) were being provided using the input method. These research and development services concluded in June 2021.

Research and development expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and for the development of our product candidate, FX-322. These include the following:

salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;
expenses incurred under agreements with third parties, including CROs and other third parties that conduct preclinical research and development activities and clinical trials on our behalf;
costs to manufacture our clinical trial material for use in our preclinical studies and clinical trials;
costs of outside consultants, including their fees and related travel expenses;
costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;
option and license payments made to third parties, including MIT, Scripps, MEEI and Cambridge, for intellectual property used in research and development activities; and
facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically, identifiable to research activities.

We expense research and development costs as incurred.

We track external research and development costs, including the cost of services, outsourced research and development, clinical trials, contract manufacturing, laboratory equipment and maintenance, and certain other development costs, by product candidate when the costs are specifically identifiable to a product candidate. Internal and external costs associated with infrastructure resources, other research and development costs, facility-related costs, and depreciation and amortization that are not identifiable to a specific product candidate are included in the platform development, early-stage research, and unallocated expenses category.

 

We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we conduct our Phase 2b trial of FX-322 (FX-322-208), continue ongoing activities, initiate additional clinical trials for FX-322, and continue to discover and develop additional product candidates. These activities may require us to continue to engage additional third parties and CROs in response to the COVID-19 pandemic to advance certain projects. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to increased scale, duration and the higher costs associated with later stage clinical trials.

We cannot determine with certainty the duration and costs of future clinical trials of FX-322 or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. The duration, costs, and timing of clinical trials and development of FX-322 and any other product candidate we may develop will depend on a variety of factors, including:

the scope, rate of progress, expense and results of clinical trials of FX-322, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct, including any unforeseen costs we may incur as a result of clinical trial delays due to the COVID-19 pandemic;
the actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability, and commercial viability;
significant and changing government regulation and regulatory guidance;
the timing and receipt of any marketing approvals;
the progress of the development efforts of parties with whom we may enter into collaboration agreements;

27


 

our ability to secure manufacturing supply through relationships with third parties;
the commercialization of our product candidates, if and when approved
the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and
the impact of COVID-19 on our Phase 2b clinical trial of FX-322 (FX-322-208), extension trials of FX-322-111 and FX-322-112, and completion of our Phase 1b clinical trial of FX-322 in severe SNHL (FX-322-113).

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate.

General and administrative expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities, and other operating costs that are not specifically attributable to research and development activities.

We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued research activities and development of product candidates. In addition, we expect to continue to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with the requirements of The Nasdaq Stock Market LLC and the SEC; director and officer insurance costs; and investor and public relations costs.

Interest income

Interest income consists of interest earned on cash equivalents and short-term investments.

Interest (expense)

Interest expense consists of interest paid on the term loan.

Realized (loss) gain on investments

Realized loss on investments represents the loss realized on our marketable securities.

Foreign exchange (loss) gain

Foreign exchange loss represents the loss recorded as a result of remeasuring the financial statements of our foreign subsidiaries.

Other (expense), net

Other expense, net consists of amortization expense and accretion income on investments.

Income taxes

Our total provision is based on the United States statutory rate of 21%, increased by state taxes and reduced by a full valuation allowance on our deferred tax assets. The income tax expense for the three and nine months ended September 30, 2021 and 2020 represents state taxes on interest income earned by our subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation.

ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration

28


 

of all the evidence, both positive and negative, we have recorded a valuation allowance against our deferred tax assets at December 31, 2020 because we have determined that it is more likely than not that we will not recognize the benefits of our federal and state deferred tax assets primarily due to our cumulative loss position and, as a result, a valuation allowance has been established.

Since our inception in 2014, we have generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within their respective carryforward periods.

Results of operations

Comparison of three months ended September 30, 2021 and 2020

The following table summarizes our results of operations for the three months ended September 30, 2021 and 2020:

 

 

 

Three Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

Increase
(Decrease)

 

 

 

(in thousands)

 

Revenue

 

$

 

 

$

11,247

 

 

$

(11,247

)

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

15,662

 

 

 

10,153

 

 

 

5,509

 

General and administrative

 

 

9,328

 

 

 

6,512

 

 

 

2,816

 

Total operating expenses

 

 

24,990

 

 

 

16,665

 

 

 

8,325

 

Loss from operations

 

 

(24,990

)

 

 

(5,418

)

 

 

(19,572

)

Interest income

 

 

172

 

 

 

74

 

 

 

98

 

Interest (expense)

 

 

(182

)

 

 

 

 

 

(182

)

Realized (loss) on investments

 

 

(9

)

 

 

 

 

 

(9

)

Foreign exchange (loss) gain

 

 

(4

)

 

 

18

 

 

 

(22

)

Other (expense), net

 

 

(139

)

 

 

 

 

 

(139

)

Loss before income taxes

 

 

(25,152

)

 

 

(5,326

)

 

 

(19,826

)

Income taxes

 

 

(3

)

 

 

(15

)

 

 

12

 

Net loss

 

$

(25,155

)

 

$

(5,341

)

 

$

(19,814

)

Revenue

No revenue was recognized for the three months ended September 30, 2021 while $11.2 million was recognized for the three months ended September 30, 2020, which consists of the revenue recognized from the upfront fee we received under the Astellas Agreement. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, we recognized the $80.0 million as revenue over the period that research and development services for the Phase 2a clinical study for FX-322 (FX-322-202) were being provided using the input method. These research and development services concluded in June 2021.

29


 

Research and development expenses

 

 

 

Three Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

Increase
(Decrease)

 

 

 

(in thousands)

 

Direct research and development expenses by
   product candidate:

 

 

 

 

 

 

 

 

 

FX-322 external development costs

 

$

3,914

 

 

$

2,792

 

 

$

1,122

 

Platform development, early-stage research
   and unallocated expenses:

 

 

 

 

 

 

 

 

 

Employee-related costs

 

 

6,356

 

 

 

4,467

 

 

 

1,889

 

Laboratory supplies

 

 

141

 

 

 

138

 

 

 

3

 

Outsourced research and development

 

 

2,811

 

 

 

1,800

 

 

 

1,011

 

Facility-related costs

 

 

1,703

 

 

 

365

 

 

 

1,338

 

Depreciation and amortization

 

 

448

 

 

 

205

 

 

 

243

 

Other research and development costs

 

 

289

 

 

 

386

 

 

 

(97

)

Platform development, early-stage research and unallocated expenses total

 

 

11,748

 

 

 

7,361

 

 

 

4,387

 

Total research and development expenses

 

$

15,662

 

 

$

10,153

 

 

$

5,509

 

 

Research and development expenses for the three months ended September 30, 2021 were $15.7 million, compared to $10.2 million for the three months ended September 30, 2020. The increase of $5.5 million was primarily due to an increase of $4.4 million in platform development, early-stage research and unallocated expenses and an increase of $1.1 million in FX-322 external research and development expenses.

The $3.9 million of FX-322 external development costs incurred for the three months ended September 30, 2021 consisted primarily of $3.8 million of clinical and development costs for current and future studies, including $1.0 million related to drug manufacturing and development. The $2.8 million of FX-322 external development costs incurred in the three months ended September 30, 2020 consisted primarily of clinical development costs including manufacturing costs for FX-322 to be used in clinical trials.

The $11.7 million of platform development, early-stage research and unallocated expenses incurred for the three months ended September 30, 2021, consisted primarily of $6.4 million of employee-related costs, including $2.8 million of stock compensation expense, and $2.8 million of outsourced research and development expense. The increase in platform development, early-stage research and unallocated expenses of $4.4 million during the three months ended September 30, 2021, compared to the three months ended September 30, 2020, is primarily attributable to an increase of $1.9 million in employee-related expenses associated with increased headcount to support pre-clinical and clinical development of FX-322 and research on our PCA platform development, a $1.0 million increase in rent and utilities expense related to our relocation to Lexington, MA, and a $1.0 million increase in outsourced research and development spending on development programs, excluding FX-322.

 

General and administrative expenses

General and administrative expenses were $9.3 million for the three months ended September 30, 2021, compared to $6.5 million for the three months ended September 30, 2020. General and administrative expenses increased by $2.8 million due primarily to an increase of $2.1 million in employee-related costs, including $1.5 million in stock compensation expense, as we increased our general and administrative headcount to manage our growth and maintain operations, as well as an increase of $0.3 million in rent and utilities related to our relocation to Lexington, MA and an increase of $0.2 million in depreciation expense.

Interest income

Interest income was $0.2 million for the three months ended September 30, 2021 compared to interest income of $0.1 million for the three months ended September 30, 2020. This change is due to changes in interest rates from the previous year.

30


 

Interest (expense)

Interest expense was $0.2 million for the three months ended September 30, 2021. There was no interest expense for the three months ended September 30, 2020. This change is due to interest expense on the term loan which commenced in December 2020.

 

Realized (loss) on investments

Realized loss on investments was $9 thousand for the three months ended September 30, 2021. There was no realized loss on investments for the three months ended September 30, 2020 .

Foreign exchange (loss) gain

Foreign exchange loss was $4 thousand for the three months ended September 30, 2021 as compared to an $18 thousand gain for the three months ended September 30, 2020. The decrease of $22 thousand was due to differences in foreign exchange remeasurement of the financial statements of our foreign subsidiaries.

Other (expense), net

Other expense, net was $139 thousand for the three months ended September 30, 2021. This expense represents amortization expense on investments, partially offset by accretion income on investments. There was no comparable expense for the three months ended September 30, 2020.

Income taxes

Income tax expense, which represents taxes on interest income earned by our subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation, was $3 thousand for the three months ended September 30, 2021.

Results of operations

Comparison of nine months ended September 30, 2021 and 2020

The following table summarizes our results of operations for the nine months ended September 30, 2021 and 2020:

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

Increase
(Decrease)

 

 

 

(in thousands)

 

Revenue

 

$

14,068

 

 

$

27,034

 

 

$

(12,966

)

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

48,169

 

 

 

25,587

 

 

 

22,582

 

General and administrative

 

 

28,571

 

 

 

18,720

 

 

 

9,851

 

Total operating expenses

 

 

76,740

 

 

 

44,307

 

 

 

32,433

 

Loss from operations

 

 

(62,672

)

 

 

(17,273

)

 

 

(45,399

)

Interest income

 

 

315

 

 

 

962

 

 

 

(647

)

Interest (expense)

 

 

(582

)

 

 

 

 

 

(582

)

Realized (loss) gain on investments

 

 

(23

)

 

 

65

 

 

 

(88

)

Foreign exchange gain

 

 

16

 

 

 

27

 

 

 

(11

)

Other (expense), net

 

 

(227

)

 

 

 

 

 

(227

)

Loss before income taxes

 

 

(63,173

)

 

 

(16,219

)

 

 

(46,954

)

Income taxes

 

 

(13

)

 

 

(60

)

 

 

47

 

Net loss

 

$

(63,186

)

 

$

(16,279

)

 

$

(46,907

)

Revenue

Revenue was $14.1 million for the nine months ended September 30, 2021 and $27.0 million for the nine months ended September 30, 2020, which consists of the revenue recognized from the upfront fee we received under the Astellas Agreement. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, we recognized the $80.0 million as revenue over the period that research and

31


 

development services for the Phase 2a clinical study for FX-322 (FX-322-202) were being provided using the input method. These research and development services concluded in June 2021.

Research and development expenses

 

 

 

Nine Months Ended
September 30,

 

 

Increase

 

 

 

2021

 

 

2020

 

 

(Decrease)

 

 

 

(in thousands)

 

Direct research and development expenses by product candidate:

 

 

 

 

 

 

 

 

 

FX-322 external development costs

 

$

10,136

 

 

$

6,151

 

 

$

3,985

 

Platform development, early-stage research and
   unallocated expenses:

 

 

 

 

 

 

 

 

 

Employee-related costs

 

 

20,167

 

 

 

12,343

 

 

 

7,824

 

Laboratory supplies

 

 

564

 

 

 

256

 

 

 

308

 

Outsourced research and development

 

 

9,619

 

 

 

4,089

 

 

 

5,530

 

Facility-related costs

 

 

5,383

 

 

 

1,079

 

 

 

4,304

 

Depreciation and amortization

 

 

1,148

 

 

 

473

 

 

 

675

 

Other research and development costs

 

 

1,152

 

 

 

1,196

 

 

 

(44

)

Platform development, early-stage research and unallocated expenses total

 

 

38,033

 

 

 

19,436

 

 

 

18,597

 

Total research and development expenses

 

$

48,169

 

 

$

25,587

 

 

$

22,582

 

 

Research and development expenses for the nine months ended September 30, 2021 were $48.2 million, compared to $25.6 million for the nine months ended September 30, 2020. The increase of $22.6 million was primarily due to an increase of $18.6 million in platform development, early-stage research and unallocated expenses and an increase of $4.0 million in FX-322 external research and development expenses.

The $10.1 million of FX-322 external development costs incurred for the nine months ended September 30, 2021 consisted primarily of $9.7 million of clinical and development costs for current and future studies, including $3.0 million related to drug manufacturing and development. The $6.2 million of FX-322 external development costs incurred in the nine months ended September 30, 2020 consisted primarily of clinical development costs including manufacturing costs for FX-322 to be used in clinical trials.

The $38.0 million of platform development, early-stage research and unallocated expenses incurred for the nine months ended September 30, 2021, consisted primarily of $20.2 million of employee-related costs, including $7.4 million of stock compensation expense, and $9.6 million of outsourced research and development expense. The increase in platform development, early-stage research and unallocated expenses of $18.6 million during the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, is primarily attributable to an increase of $7.8 million in employee-related expenses associated with increased headcount to support pre-clinical and clinical development of FX-322 and research on our PCA platform development, a $3.3 million increase in rent and utilities expense related to our relocation to Lexington, MA, and a $5.5 million increase in outsourced research and development spending on development programs, excluding FX-322.

 

General and administrative expenses

General and administrative expenses were $28.6 million for the nine months ended September 30, 2021, compared to $18.7 million for the nine months ended September 30, 2020. General and administrative expenses increased by $9.9 million due primarily to an increase of $7.6 million in employee-related costs, including $5.0 million in stock compensation expense, as we increased our general and administrative headcount to manage our growth and maintain operations, as well as an increase of $1.0 million in rent and utilities related to our relocation to Lexington, MA and an increase of $0.6 million in depreciation expense.

Interest income

Interest income was $0.3 million for the nine months ended September 30, 2021 compared to interest income of $1.0 million for the nine months ended September 30, 2020. This change is due to changes in interest rates from the previous year.

32


 

Interest (expense)

Interest expense was $0.6 million for the nine months ended September 30, 2021. There was no interest expense for the nine months ended September 30, 2020. This change is due to interest expense on the term loan which commenced in December 2020.

 

Realized (loss) gain on investments

Realized loss on investments was $23 thousand for the nine months ended September 30, 2021 as compared to a realized gain of $65 thousand for the nine months ended September 30, 2020 due to changes in the market value of marketable securities.

Foreign exchange gain

Foreign exchange gain was $16 thousand for the nine months ended September 30, 2021 as compared to $27 thousand for the nine months ended September 30, 2020. The decrease of $11 thousand was due to differences in foreign exchange remeasurement of the financial statements of our foreign subsidiaries.

Other (expense), net

Other expense, net was $227 thousand for the nine months ended September 30, 2021. This expense represents amortization expense on investments, partially offset by accretion income on investments. There was no comparable expense for the nine months ended September 30, 2020.

Income taxes

Income tax expense, which represents taxes on interest income earned by our subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation, was $13 thousand for the nine months ended September 30, 2021.

Liquidity and capital resources

Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will continue to increase, including in connection with conducting preclinical studies and clinical trials for our product candidates, contracting with CROs or contracting with CMOs to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations particularly as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources.

We do not currently have any approved products and have never generated any revenue from product sales. We have financed our operations primarily through proceeds from the sale of our convertible notes, convertible preferred stock, the upfront payment under the Astellas Agreement, grants, our IPO, our Private Placement, option exercises, and the term loan. Our cash, cash equivalents and marketable securities totaled $160.5 million as of September 30, 2021.

Cash flows

The following table summarizes our sources and uses of cash for the periods presented:

 

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Net cash (used in) operating activities

 

$

(58,171

)

 

$

(30,355

)

Net cash (used in) provided by investing activities

 

 

(51,479

)

 

 

14,837

 

Net cash provided by financing activities

 

 

1,249

 

 

 

41,305

 

(Decrease) increase in cash and cash equivalents

 

$

(108,401

)

 

$

25,787

 

 

33


 

 

Cash flows for the nine months ended September 30, 2021

Operating activities

Net cash used in operating activities for the nine months ended September 30, 2021 was $58.2 million, consisting of a net loss of $63.2 million as we incurred expenses associated with our FX-322 program, platform development and early-stage research, and general and administrative expenses. In addition, we had non-cash charges of $19.3 million for depreciation, stock-based compensation expense, non-cash lease expense, non-cash interest expense and loss on disposal of assets. Net cash used in operating activities was also impacted by a net $14.3 million decrease in operating assets and liabilities, including a decrease of $14.1 million in deferred revenues from the upfront payment under the Astellas Agreement, a decrease in accrued expenses of $1.2 million, a $1.9 million decrease in accounts payable, and a $2.9 million decrease in prepaid expenses and other current assets.

Investing activities

Net cash used in investing activities for the nine months ended September 30, 2021 was $51.5 million, which was attributable to $66.2 million of purchases of marketable securities and $2.9 million of purchases of property and equipment, partially offset by $17.6 million in redemptions of marketable securities.

Financing activities

Net cash provided by financing activities for the nine months ended September 30, 2021 was primarily attributable to $1.2 million in proceeds from the exercise of stock options.

Cash flows for the nine months ended September 30, 2020

Operating activities

Net cash used in operating activities for the nine months ended September 30, 2020 was $30.4 million, consisting of a net loss of $16.3 million as we incurred expenses associated with our FX-322 program, platform development and early-stage research, and general and administrative expenses. In addition, we had non-cash charges of $8.2 million for depreciation, stock-based compensation expense, and non-cash lease expense. Net cash used in operating activities was also impacted by a net $22.3 million change in operating assets and liabilities, including a decrease of $27.0 million in deferred revenues from the upfront payment under the Astellas Agreement, a $2.9 million increase in accounts payable, $1.0 million decrease in accounts receivable, prepaid expenses and other current assets, and a $0.9 million increase in accrued expenses.

 

Investing activities

 

Net cash provided by investing activities for the nine months ended September 30, 2020 was $14.8 million, which was attributable to $17.1 million of net redemptions of marketable securities, partially offset by $2.3 million of purchases of property and equipment.

Financing activities

Net cash provided by financing activities for the nine months ended September 30, 2020 was $41.3 million, attributable to $40.1 million in net proceeds from the Private Placement and $1.2 million in proceeds from the exercise of stock options.

Funding requirements

34


 

We expect our operating expenses to continue to increase substantially in connection with our ongoing activities, particularly as we advance FX-322 through clinical trials and as we research and develop additional product candidates including preclinical activities, studies for INDs, and initiation of human clinical trials. In addition, we expect to incur additional general and administrative costs to build the infrastructure necessary to manage the growth of our research and development efforts and the increased costs associated with operating as a public company.

Specifically, our costs and expenses will increase as we:

advance the clinical development of FX-322;
pursue the preclinical and clinical development of other product candidates using our PCA platform, including our program for the treatment of MS;
in-license or acquire the rights to other products, product candidates or technologies;
maintain, expand, and protect our intellectual property portfolio;
hire additional personnel in research, manufacturing, and regulatory and clinical development, as well as management personnel; and
expand our operational, financial, investor relations, and management systems and increase personnel, including personnel to support our operations as a public company.

We believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into late 2023. We have based this estimate on assumptions that may prove to be incorrect, and we could utilize our available capital resources sooner than we expect.

Because of the numerous risks and uncertainties associated with the research, development, and commercialization of therapeutics, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including:

the progress, costs, and results of our clinical development and clinical trials for FX-322;
the progress, costs, and results of our additional research and preclinical development programs, including our program for the treatment of MS;
the outcome, timing and cost of meeting regulatory requirements established by the FDA and comparable foreign regulatory authorities, if applicable, for our product candidates;
business and operations interruptions resulting from the COVID-19 global pandemic;
the costs and timing of internal process development, manufacturing activities, and clinical trial management associated with FX-322 and other product candidates we advance through preclinical and clinical development;
our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements;
the scope, progress, results, and costs of any product candidates that we may derive from our PCA platform or any other product candidates we may develop alone or with collaborators;
the extent to which we in-license or acquire rights to other products, product candidates, or technologies;
additions or departures of key scientific or management personnel;
the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and protecting our intellectual property rights, and defending against any intellectual property-related claims; and
the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution for any product candidates for which we or our collaborators obtain marketing approval.

Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. Due to market volatility resulting from the COVID-19 global pandemic, our ability to raise additional capital as and when needed may be impacted. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interests of our stockholders will be diluted, and the terms of these securities

35


 

may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other sources, such as collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, product development, and research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.

Critical accounting policies and use of estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our unaudited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are described in more detail in the notes to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. During the three and nine months ended September 30, 2021, there were no material changes to our critical accounting policies from those described in our Annual Report on Form 10-K filed with the SEC on March 29, 2021.

Recent accounting pronouncements

A description of recent accounting pronouncements that may potentially impact our financial position, results of operations, or cash flows is disclosed in Note 2 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Emerging growth company status

The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company,” such as us, to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to take advantage of this extended transition period.

36


 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

This item is not required as we are currently considered a small reporting company.

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls and Procedures

Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2021. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

37


 

PART II—OTHER INFORMATION

On June 3, 2021 and June 22, 2021, purported stockholders of our company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against us entitled Evans v. Frequency Therapeutics, Inc. et al. and Hingston v. Frequency Therapeutics, Inc. et al., respectively. The lawsuits allege violations of Section 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended, due to allegedly false and misleading statements and omissions about our Phase 2a clinical trial (FX-322-202) for our product candidate FX-322 in our public disclosures between November 16, 2020 and March 22, 2021. The lawsuits seek, among other things, damages in connection with our allegedly artificially inflated stock price between November 16, 2020, and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys’ fees and costs. We can make no assurances as to the time or resources that will need to be devoted to these lawsuits or their final outcomes, or the impact, if any, of these lawsuits or any proceedings on our business, financial condition, results of operations and cash flows. We are vigorously defending against all claims asserted in both lawsuits.

 

On June 23, 2021, two purported stockholders of our company filed a lawsuit in the Court of Chancery of the State of Delaware against (i) us, (ii) our Chief Executive Officer, President, and Director, David Lucchino, (iii) Computershare Inc., and (iv) Computershare Trust Company, N.A., entitled The Gregory J. Parseghian Revocable Trust, et al. v. Frequency Therapeutics, Inc., et al. The lawsuit alleges causes of action against us of conversion and unjust enrichment, and against Mr. Lucchino for breach of the fiduciary duty of loyalty, due to allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The lawsuit seeks monetary damages, as well as interest, attorneys’ fees and costs, against all defendants. This matter is at the very early stages of the legal process, and as a result, we are not able to estimate a range of possible loss. We are vigorously defending against all claims asserted and have filed a motion to dismiss the complaint.

Item 1A. Risk Factors.

Our future operating results could differ materially from the results described in this Quarterly Report on Form 10-Q due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. In these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See “Forward Looking Statements” for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.

Risks related to our financial position and need for additional capital

We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability. If we are unable to achieve or sustain profitability, the market value of our common stock will likely decline.

We are a clinical-stage biotechnology company with a limited operating history. As a result, we are not profitable and have incurred significant losses since our formation. We had net losses of $63.2 million, $26.5 million and $19.8 million for the nine months ended September 30, 2021 and the years ended December 31, 2020 and 2019, respectively. As of September 30, 2021, we had an accumulated deficit of $158.6 million. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to licensing technologies and research and development, including our preclinical platform development activities and clinical trials.

We expect to incur significant additional operating losses for the next several years, at least, as we advance FX-322 and our other product candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize FX-322 or our other product candidates, if approved. The costs of advancing product candidates into each

38


 

clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any product candidate to marketing approval in even a single jurisdiction are substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any product candidates or achieve or maintain profitability. Our expenses will also increase substantially if and as we:

continue to conduct our Phase 2b trial of FX-322 (FX-322-208), complete our Phase 1b trial of FX-322 in severe SNHL (FX-322-113), continue extension trials of FX-322-111 and FX-322-112, commence additional clinical studies relating to our product candidates;
continue to develop and commence clinical trials of FX-345 and our remyelination program;
expand our development programs based on our progenitor cell activation, or PCA, platform;
continue to develop our PCA platform;
seek regulatory approvals for FX-322 and our other product candidates;
expand the target indications and patient population for FX-322;
secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any product candidate for which we obtain regulatory approval;
establish a sales, marketing and distribution infrastructure to commercialize FX-322 for the treatment of SNHL, if approved, and for any of our other product candidates for which we may obtain marketing approval;
maintain, expand, and protect our intellectual property portfolio;
hire additional clinical, scientific, and commercial personnel;
add operational, financial, and management personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support operations as a public company; and
acquire or in-license other product candidates or technologies.

Furthermore, our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under “—Risks related to development, clinical testing, manufacturing, and regulatory approval” and “—Risks related to commercialization.” As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we successfully commercialize FX-322 or our other product candidates, we may continue to incur substantial research and development and other expenses to identify and develop other product candidates. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially adversely affected.

We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of FX-322 or our additional product candidates.

We expect to spend substantial amounts to complete the development of, seek regulatory approvals for and, if approved, commercialize FX-322 and our other product candidates. These expenditures include and will include, as the case may be, costs related to the Phase 1b trial of FX-322 for the treatment of severe SNHL (FX-322-113), the Phase 2b trial of FX-322 (FX-322-208), extension trials of FX-322-111 and FX-322-112, and any additional trials we conduct to support the development of FX-322 and our other product candidates. In addition, we are obligated to make milestone and royalty payments in connection with the sale of resulting products and licensing revenues under our license agreements with Massachusetts Institute of Technology, or MIT, Massachusetts Eye and Ear, or MEE, the Scripps Research Institute, or Scripps, and Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge), or Cambridge. We also expect to spend substantial amounts to identify and develop new product candidates based on our PCA platform.

39


 

We will require additional capital to enable us to develop additional product candidates based on our PCA platform, which we may acquire through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our development efforts.

Based upon our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities of $160.5 million will enable us to fund our operating expenses and capital expenditure requirements into late 2023. This estimate and our expectation regarding the sufficiency of our current financial resources to advance the clinical development of FX-322 and our other product candidates are based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, or our clinical trials, including our Phase 1b trial of FX-322 for the treatment of severe SNHL (FX-322-113) and our Phase 2b trial of FX-322 (FX-322-208), or extension trials of FX-322-111 and FX-322-112, and other clinical trials of FX-322 or our other product candidates, may be more expensive, time consuming or difficult to design or implement than we currently anticipate. Changing circumstances, including any unanticipated expenses, could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and scope of activities associated with successful development of FX-322 or any product candidate we may develop is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:

the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including the Phase 1b severe SNHL trial for FX-322 (FX-322-113), the Phase 2b trial of FX-322 (FX-322-208), extension trials of FX-322-111 and FX-322-112, our other planned clinical trials of FX-322, the development of FX-345 and our remyelination program, and the development of any of our other product candidates including any unforeseen costs we may incur as a result of clinical trials due to the COVID-19 global pandemic or other causes;
the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or the FDA, and other comparable foreign regulatory authorities, including any additional clinical trials required by the FDA or other comparable foreign regulatory authorities;
the willingness of the FDA and other comparable foreign regulatory authorities to accept our clinical trial designs, as well as data from our completed and planned clinical trials and preclinical studies, as the basis for review and approval of FX-322 or our other product candidates;
the cost of filing, prosecuting, defending, and enforcing our patent claims and other intellectual property rights;
the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us;
the effect of competing technological and market developments;
the cost and timing of completion of commercial-scale manufacturing activities;
the costs of operating as a public company;
the cost of making royalty, milestone or other payments under current and any future in-license agreements;
the extent to which we in-license or acquire other product candidates or technologies;
the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved;
our ability to maintain our collaboration with Astellas Pharma Inc., or Astellas, including achievement of the development milestones and to establish new collaborations; and
the initiation, progress, and timing of our commercialization of FX-322, if approved, or our other product candidates.

Depending on our business performance, the economic climate and market conditions, we may be unable to raise additional funds through any sources. Market volatility resulting from the COVID-19 global pandemic could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional capital in sufficient amounts or

40


 

on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of FX-322 or our other product candidates, or potentially discontinue operations.

We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.

We were established and began operations in 2014. Our operations to date have been limited to financing and staffing our company, licensing technologies, developing our PCA platform, developing and conducting preclinical and clinical studies of FX-322 for the treatment of SNHL, and developing a pipeline of preclinical and research programs, including FX-345 and our remyelination program. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.

In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Our Phase 2a results (FX-322-202), for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo, which results were unexpected. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.

As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, the results of any quarterly or annual period are not necessarily indicative of future operating performance.

 

Our ability to use our net operating loss carryforwards to offset future taxable income, or tax credit carryforward to offset future income tax liabilities, may be subject to certain limitations.

As of December 31, 2020, we had net operating loss carryforwards, or NOLs, of $67.9 million for federal income tax purposes and $43.4 million for state income tax purposes, which may be available to offset our future taxable income, if any. Our NOLs begin to expire in various amounts in 2037, provided that federal NOLs generated in taxable years beginning after December 31, 2017 will not be subject to expiration. As of December 31, 2020, we also had federal and state research and development and other tax credit carryforwards of approximately $3.0 million and $1.2 million, respectively, available to reduce future tax liabilities. Our tax credit carryforwards expire at various dates through 2040. These NOLs and tax credit carryforwards could expire unused, to the extent subject to expiration, and be unavailable to offset future income tax liabilities. In addition, in general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to use its pre-change NOLs and tax credit carryforwards to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation’s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We believe we have experienced an ownership change in 2017 and 2019 and may experience ownership changes in the future as a result of future transactions in our stock, some of which may be outside our control. If we undergo additional ownership changes, our ability to use our NOLs and tax credit carryforwards could be further limited. As a result of the changes in ownership in 2017 and 2019, $0.01 million and $0.04 million of NOL carryforwards are limited under Section 382. For these reasons, we may not be able to use a material portion of our NOLs or tax credit carryforwards, even if we attain profitability. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future tax benefits of such assets. Furthermore, NOLs generated in periods beginning after December 31, 2017 may be carried forward indefinitely but may only be used to offset 80% of our taxable income in years beginning after December 31, 2020, which may require us to pay federal income taxes in future years despite generating federal NOLs in prior years.

41


 

Risks related to development, clinical testing, manufacturing, and regulatory approval

We are heavily dependent on the success of FX-322, our lead product candidate, which is still under clinical development, and if FX-322 does not receive regulatory approval or is not successfully commercialized, our business will be materially adversely harmed.

To date, we have invested a significant portion of our efforts and financial resources in the development of FX-322 for the treatment of SNHL. Our future success is substantially dependent on our ability to successfully complete clinical development for, obtain regulatory approval for, and successfully commercialize FX-322, which may never occur. We currently have no products that are approved for commercial sale and may never be able to develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will continue to be devoted to FX-322, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval, establishing commercial scale manufacturing, and significant sales, marketing, and distribution efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities or that, even if it receives regulatory approval, FX-322 will be as effective as anticipated at treating SNHL. Our Phase 2a results (FX-322-202), for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo, and our Phase 1b study of FX-322 in presbycusis (FX-322-112) did not show any significant treatment effects compared to placebo.

The research, testing, manufacturing, labeling, approval, sale, packaging, marketing, and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market FX-322 in the United States until we receive approval of a New Drug Application, or NDA, from the FDA, or in any foreign countries until our collaborator, Astellas, receives the requisite approval from such countries. We have not submitted an NDA to the FDA and Astellas has not submitted comparable applications to other regulatory authorities for FX-322. We or Astellas may not be in a position to do so for several years, if ever. If we or Astellas are unable to obtain the necessary regulatory approval for FX-322 in a country, including as a result of the COVID-19 pandemic, we or Astellas will not be able to commercialize FX-322 for the treatment of SNHL in that country. As a result, our financial position will be materially adversely affected, and we may not be able to generate sufficient revenue to continue our business.

We utilize our PCA platform to develop product candidates that are designed to activate progenitor cells, which is a new approach to therapeutic intervention and, as a result, successful development, approval, and commercialization of our product candidates, including FX-322 and FX-345 is uncertain.

We utilize our PCA platform to develop product candidates, including FX-322 and FX-345, for the treatment of SNHL. Our PCA platform is designed to identify pathways to activate progenitor cells already present in the body to treat conditions or diseases through cellular regeneration. We have not, nor to our knowledge has any other company, received regulatory approval utilizing this mechanism of cellular regeneration. Given the novelty of our approach, we could encounter a longer than expected regulatory review process, increased development costs, or unexpected delays in, or even prevention of, the regulatory approval and commercialization of our product candidates, and we cannot be certain that our approach will lead to the development of any approvable or marketable products. For example, the FDA-approved treatment options available for patients with SNHL are hearing aids and cochlear implants. Unlike FX-322, which is a therapeutic that targets the underlying biology of SNHL, these treatment options are medical devices that are designed to target the symptoms of SNHL. As a result, these treatment options are not directly comparable to FX-322, and FDA requirements for marketing authorization of these treatment options may not be relevant for FX-322. While we are developing what we believe are appropriate measurements of efficacy for FX-322, we cannot be certain that the FDA will agree with our measurements or that they will be sufficient for approval. If we were to encounter any of the foregoing, our business and financial prospects could be materially harmed.

Clinical trials are expensive, time consuming, and difficult to design and implement, and involve an uncertain outcome. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and completed clinical trials are not necessarily predictive of future results, and any product candidates we develop may not be further developed or may have additional unfavorable results in later studies or trials. Clinical trial failure may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection, placebo effect, patient enrollment criteria, selection of patients based on patient misrepresentations, and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. Several companies in the pharmaceutical industry have suffered setbacks in the

42


 

advancement of their drug candidates into later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding favorable results in earlier preclinical studies or clinical trials. Our Phase 2a results (FX-322-202), for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Based upon negative or inconclusive results or a need for additional information, we may decide, or regulatory authorities may require us, to conduct additional clinical trials or preclinical studies.

We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether our clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, or at all. For example, a number of clinical trial sites for our completed Phase 2a clinical trial of FX-322 (FX-322-202) temporarily halted patient enrollment during the first and second quarter of 2020 in response to the COVID-19 pandemic. Enrollment in other ongoing or planned clinical trials could be adversely affected by the pandemic. Clinical trials can be delayed for a variety of reasons, including delays related to:

the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;
obtaining regulatory approval to commence a trial;
reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
obtaining Institutional Review Board, or IRB, approval at each site within the United States, or Independent Ethics Committee, or IEC, approval at sites outside the United States;
business interruptions resulting from the COVID-19 pandemic;
recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;
having patients complete a trial or return for post-treatment follow-up;
imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites or investigators to adhere to regulatory requirements or follow trial protocols;
clinical sites deviating from the trial protocol or dropping out of a trial;
addressing patient safety concerns that arise during a trial;
adding a sufficient number of clinical trial sites; or
manufacturing sufficient quantities of a product candidate for use in clinical trials.

We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the FDA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board, or DSMB, for such trial. Such authorities may impose a suspension or termination or recommend an alteration due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial.

Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in the section titled “—Risks related to our dependence on third parties.”

Our lead product candidate, FX-322, is still in development and will require the successful completion of FX-322-208 as well as at least one, and possibly more, Phase 3 trials before we are prepared to submit an NDA for regulatory approval by the FDA. In addition, we have been advised by the FDA that, while the nonclinical studies conducted by us to date suggest a pharmacodynamic interaction between the two active components of FX-322, the FDA has indicated that the results of such nonclinical studies do not preclude the need for a human study and that inclusion of a factorial study in humans in future trials of FX-322 to thoroughly assess the effects attributable to each component drug of FX-322 in the combination so as to satisfy the FDA’s “combination rule”. The design and conduct of a factorial study in humans, including the development of

43


 

each active component to administer in such study, may cause additional delays in the development of FX-322. We cannot predict with any certainty if or when we might complete the development of FX-322 and submit an NDA for regulatory approval by the FDA of FX-322 or whether any such NDA will be approved by the FDA.

If we experience delays in the commencement or completion of any clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of any product candidate we develop could be harmed, and our ability to generate revenues may be delayed. In addition, any delays in our clinical trials could increase our costs, slow the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may materially harm our business, financial condition, and results of operations. In addition, many of the factors that may cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of a clinical trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of a product candidate.

The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time- consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for FX-322, FX-345, or any of our other product candidates, our business will be substantially harmed.

The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate’s clinical development and may vary among jurisdictions. The approval process may also be delayed by changes in government regulation, the impact of the COVID-19 pandemic, future legislation or administrative action. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for any product candidate. We are not permitted to market any of our product candidates in the United States until we receive approval of an NDA from the FDA.

Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. In addition, data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Furthermore, as more competing drug candidates within a class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other comparable regulatory authorities.

The FDA or any foreign regulatory authority can delay, limit, or deny approval of FX-322, FX-345, or any of our other product candidates that we develop or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;
serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing an active ingredient in our product candidates;
negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;

44


 

we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;
the FDA’s or the applicable foreign regulatory authority’s disagreement regarding the formulation, the labeling, and/or the specifications of our product candidates;
the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; and
significant regulatory GxP non-compliance or data integrity findings from FDA Bioresearch Monitoring inspections or pre-approval inspections inclusive of clinical investigator sites, contracted partners and their company’s quality management system and execution thereof.

Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, and prospects.

In addition, the FDA or the applicable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or applicable foreign regulatory authority may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing circumstances could materially harm the commercial prospects for our product candidates and our business.

Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials.

Patient enrollment and retention in clinical trials depends on many factors, including:

the extent of the ongoing COVID-19 pandemic, see —The COVID-19 pandemic could adversely impact our business, including our preclinical studies, clinical trials and operations;
the patient eligibility criteria defined in the protocol, such as the requirement to establish stable hearing loss in our Phase 2b clinical trial;
the size of the patient population required for analysis of the trial’s primary endpoints;
the nature of the trial protocol, trial design, side effects or other results that may arise in development;
the existing body of safety and efficacy data with respect to the product candidate;
the proximity of patients to clinical sites;
our ability to recruit clinical trial investigators with the appropriate competencies, motivation and experience;
clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or medical devices that may be approved for the indications we are investigating;
competing clinical trials being conducted by other companies or institutions;

45


 

our ability to obtain and maintain patient consents; and
the risk that patients enrolled in clinical trials will drop out of the trials before completion.

In addition, our clinical trials will compete with other clinical trials for product candidates and medical devices that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Furthermore, any negative results we may report in clinical trials of any product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs or program delays, which could have a harmful effect on our ability to develop a product candidate or could render further development impossible.

Results of preclinical studies, clinical trials, or analyses may not be indicative of results that may be obtained in later trials.

The results of preclinical studies, clinical trials, or analyses of the results from such trials, including our prospective and post hoc analyses of the data from the Phase 1/2 trial of FX-322 for the treatment of SNHL (FX-322-201), may not be predictive of the results of later clinical trials. Product candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising results. Our Phase 2a results (FX-322-202), for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo; a finding we believe is due to an uncontrolled bias and the limitation to a single baseline measure. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and post hoc analysis of data from our Phase 1/2 clinical trial of FX-322 for the treatment of SNHL (FX-322-201), may be shown to be incorrect in subsequent clinical trials that have pre-specified end points or may not be considered adequate by regulatory authorities. Even if we complete later clinical trials as planned, we cannot be certain that their results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, our clinical development plans may be materially harmed.

Interim and preliminary “top-line” data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.

From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.

46


 

If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

Any of our product candidates or component of a product candidate that we develop or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales.

Serious adverse events or undesirable side effects caused by our product candidates or component of a product candidate we develop could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects. In our clinical studies to date, subjects treated with FX-322 have experienced adverse events that include ear discomfort and ear pain that are considered to be associated with the intratympanic injection procedure.

If unacceptable side effects arise in the development of any product candidate, we, the FDA, or the IRBs or IECs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may have to train medical personnel regarding the proper administration protocol for our product candidates and to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly.

Additionally, if FX-322, FX-345, or any of our other product candidates we develop receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

regulatory authorities may suspend, withdraw, or limit approvals of such product, or seek an injunction against its manufacture or distribution;
regulatory authorities may require us to recall a product or we may decide to initiate a voluntary recall of a product;
regulatory authorities may require additional warnings on the label, such as a “black box” warning or contraindication;
additional restrictions may be imposed on the marketing of the product or the manufacturing processes for the product or any component thereof;
we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;
we may be required to conduct post-market studies or agree to post marketing commitments;
we could be sued and held liable for harm caused to patients;
the product may become less competitive; and
our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations, and prospects.

 

Disruptions at the FDA and other government agencies caused by funding shortages, changes in the federal administration or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.

47


 

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic or issue guidance materially affecting the conduct of clinical trials. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business.

Although we intend to explore additional product candidates based on our PCA platform, we may fail to identify viable new product candidates for clinical development for several reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.

Research programs to develop additional product candidates based on our PCA platform require substantial technical, financial, and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for several reasons, including:

the research methodology used may not be successful in identifying potential indications or product candidates;
potential product candidates may, after further study, be shown to have harmful or unexpected adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or
it may take greater human and financial resources than we possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio.

Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.

Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. For example, we may encounter delays in the process of selecting a product candidate for the treatment of MS and we may not achieve the timeline we currently anticipate for submitting an IND or comparable foreign equivalent. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.

48


 

The market opportunities for FX-322, if approved, may be smaller than we anticipate and, as a result, our commercial opportunity may be limited.

We expect to initially seek approval of FX-322 for the treatment of SNHL. Our projections of the number of eligible patients are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations, and market research, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of eligible patients, and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited. Our Phase 1b study of FX-322 in presbycusis (FX-322-212), for example, did not show any significant treatment effects. Even if we obtain FDA approval for FX-322, it may be approved for a target population that is more limited than what we currently anticipate. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are smaller, we may never achieve profitability without obtaining marketing approval for additional indications.

We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate.

We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our product candidates. We believe our approach of activating progenitor cells to treat conditions or diseases through cellular regeneration is novel and, as a result, the process for, and the outcome of, FDA approval is especially uncertain. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.

Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.

Even if we obtain FDA approval for a product candidate in the United States, we or our collaborators may never obtain approval for or commercialize the product candidate in any other jurisdiction, which would limit our ability to realize its full market potential.

In order to market any product in a particular jurisdiction, we or our collaborators must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy on a country-by-country basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our or our collaborators’ ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.

Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time- consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and we will be unable to realize the full market potential of any product we develop.

Even if we obtain regulatory approval for any product candidate, we will still face extensive and ongoing regulatory requirements and obligations, which may result in significant additional expense, and any product candidates, if approved, may face future development and regulatory difficulties.

Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and

49


 

advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, and requirements for any clinical trials that we conduct post-approval.

Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If a product candidate receives marketing approval, the accompanying label may limit the approved indicated use of the product, which could limit sales of the product. The FDA may also require costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs, may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.

In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:

restrictions on manufacturing such products;
restrictions on the labeling or marketing of products;
restrictions on product distribution or use;
requirements to conduct post-marketing studies or clinical trials;
warning letters or untitled letters;
refusal to approve pending applications or supplements to approved applications that we submit;
recalls or market withdrawals of products;
fines, restitution, or disgorgement of profits or revenues;
suspension or withdrawal of marketing approvals;
refusal to permit the import or export of our products;
product seizure; or
injunctions, consent decrees, or the imposition of civil or criminal penalties.

Further, the FDA’s policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects, and ability to achieve or sustain profitability.

We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The policies of the FDA and of other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition, and results of operations. Furthermore, noncompliance by us or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in significant financial penalties, which would adversely affect our business.

50


 

We received Fast Track designation by the FDA for FX-322 and may seek Fast Track designation by the FDA for any future product candidates, but we might not receive such a designation. However, such designation may not lead to a faster development or regulatory review or approval process.

In October 2019, FX-322 received Fast Track designation by the FDA. If a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, a drug sponsor may qualify for FDA Fast Track designation. Fast Track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical development, in addition to the potential for rolling review and priority review once a marketing application is filed. The FDA has broad discretion whether to grant Fast Track designation, and we may not receive such a designation for all of the product candidates for which we may request it. Moreover, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA’s priority review procedures.

We may seek a Breakthrough Therapy designation for FX-322 and our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.

We may seek a Breakthrough Therapy designation for FX-322 if results from our ongoing clinical trials support such designation and we may seek a Breakthrough Therapy designation for other product candidates we may develop. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA.

Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that a product candidate meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such a designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a Breakthrough Therapy, the FDA may later decide that it no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.

The use of any product candidate we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

impairment of our business reputation and significant negative media attention;
withdrawal of participants from our clinical trials;
significant costs to defend the litigation;
distraction of management’s attention from our primary business;
substantial monetary awards to patients or other claimants;
inability to commercialize a product candidate;
product recalls, withdrawals or labeling, marketing or promotional restrictions;

51


 

decreased market demand for any product; and
loss of revenue.

The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidate, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any product candidates we develop.

 

The COVID-19 pandemic has caused and could continue to cause disruptions to our business, including our preclinical studies, clinical trials and operations and could adversely impact our financial condition and results of operations.

 

In March 2020, the World Health organization designated the outbreak of the novel strain of coronavirus, known as COVID-19, as a global pandemic. This virus and its variants have and continue to spread globally and governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, business closures, quarantines, border closures, significant restrictions on travel, social distancing practices as well as restrictions that prohibit many employees from going to work. Massachusetts, the primary business location of our company, closed all non-essential business for a period of time in response to the pandemic, but has since May 2021, lifted all restrictions related to the pandemic. The pandemic, and government measures taken in response, have had a significant impact, both direct and indirect, on business and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.

In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals has been on fighting the virus and vaccinating the public and we have been required to take steps consistent with the FDA’s updated industry guidance for conducting clinical trials issued on March 18, 2020. The majority of our non-laboratory based employees have continued to work from home two to three days per week, while our laboratory employees have resumed a full in-person schedule in our Lexington, MA facility. We have also taken steps consistent with the FDA’s updated industry guidance for conducting clinical trials.

If COVID-19 or its variants again spread in the United States and worldwide, and measures to mitigate the ongoing effects of the pandemic, such as stay home orders and/or advisories persist or are reintroduced, we may continue to experience disruptions and other effects on our business that could severely impact our business, operations, preclinical studies and clinical trials, including:

 

delays, difficulties or postponement in enrolling and retaining patients in our clinical trials;

 

delays, difficulties or postponement in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;

 

diversion of healthcare resources away from the conduct of clinical trials, including the diversion of ENT practices and academic centers serving as our clinical trial sites and staff supporting the conduct of our clinical trials;

 

interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;

 

interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;

 

interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;

 

interruptions in planned trials due to restricted or limited operations at our laboratory facility;

52


 

 

continual changes to operating requirements and related expenses, limitations in employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people and resulting losses of productivity and employee work culture;

 

risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;

 

refusal of the FDA, or other government agencies, to accept data from clinical trials in these affected geographies;

 

interruption or delayed to our sourced discovery and clinical activities;

 

inability to obtain additional financing or access the financial markets, and

 

if any of the CMOs involved in the manufacture and supply of FX-322 or FX-345 experience a delay or disruption due to COVID-19, we may not have sufficient quantities of our products for our planned activities and may not be able to transition to a new CMO in a timely or cost-effective manner, or at all, which would negatively impact our ability to develop and potentially commercialize FX-322 and FX-345.

 

The global outbreak of COVID-19 continues to rapidly evolve and continues to have indeterminable adverse effects on general commercial activity and the world economy. We previously experienced an impact from COVID-19 in our completed Phase 2a clinical trial, as a number of clinical trial sites temporarily halted enrollment. Due to the uncertain nature of the effects of the outbreak, particularly in the United States, enrollment, participation and retention in our ongoing and planned trials may be reduced, and for a number of the clinical sites, halted for an unknown period of time. Any reduction in enrollment, participation and retention and any halts may delay our ongoing and planned clinical trials and our development plans for FX-322 and our other product candidates, which could have an adverse impact on our business and results of operations.

The extent to which COVID-19 may continue to impact our business, preclinical studies, clinical trials (including the completion and timing of our Phase 1b clinical trial in severe SNHL (FX-322-113), extension trials of FX-322-111 and FX-322-112, and our Phase 2b clinical trial of FX-322 (FX-322-208)) and operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ongoing and ultimate geographic spread of the disease, duration of the outbreak, including future waves of infection, new variant strains of the underlying virus, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, adoption and effectiveness of vaccines and other actions taken in the United States and other countries to contain, treat and mitigate the spread of COVID-19. In addition, if we or any of the third parties with whom we engage were to experience shutdowns or additional business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted, which could have a material adverse effect on our business and our financial results. The COVID-19 pandemic has resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide, resulting in an economic downturn that could continue to significantly impact our business, financial condition and results of operations. To the extent the COVID-19 pandemic adversely affects our business, financial condition and results of operations, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section.

Risks related to commercialization

We face significant competition from biotechnology, pharmaceutical, and medical device companies, and our operating results will suffer if we fail to compete effectively.

The biotechnology, pharmaceutical, and medical device industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If a product candidate we develop is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies, and early-stage companies, particularly if the early-stage company has a collaborative arrangement with a large and established company. We are aware of several companies developing products to treat SNHL through the regeneration of hair cells or through other mechanisms, and we also anticipate that new companies will enter the SNHL market in the future. If we successfully develop and, if approved, commercialize FX-322 or FX-345 for the treatment of SNHL, it may compete, or potentially be used in conjunction, with currently marketed devices, including the

53


 

hearing aids and cochlear implants currently available and the next generation of improved hearing aids and cochlear implants, and any new therapies that may become available in the future. Furthermore, changes in the regulatory landscape may increase competition from hearing aids. The FDA Reauthorization Act of 2017 created a new category of over-the-counter, or OTC, hearing aids which are intended to be available to consumers without first requiring a visit to a medical professional. While the final regulations needed to implement this new category of devices have not yet been issued, if and when they are, obtaining hearing aids may become less expensive and more convenient. We are also aware of several companies developing programs with research and development efforts to treat MS through the regeneration of myelin. If we successfully develop and, if approved, commercialize our remyelination program for the treatment of MS, it may compete, or potentially be used in conjunction with, currently marketed therapeutics and any new therapeutics that may become available in the future.

Competition could render any product candidate we develop obsolete, less competitive, or uneconomical. Our competitors may, among other things:

have significantly greater name recognition and financial, manufacturing, marketing, product development, technical, and human resources than we do, with mergers and acquisitions in the biotechnology, pharmaceutical, and medical device industries resulting in even more resources being concentrated in our competitors;
more effectively recruit and retain qualified scientific and management personnel;
more effectively establish clinical trial sites and patient registration;
develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects;
obtain quicker regulatory approval;
better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary for, our programs;
implement more effective approaches to sales, marketing, pricing, coverage, and reimbursement; or
form more advantageous strategic alliances or collaborations.

If we are not able to effectively compete for any of the foregoing reasons, our business will be materially harmed.

The successful commercialization of any product candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our or our collaborators’ ability to market those products and decrease our or our collaborators’ ability to generate revenue.

The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford prescription medications. Our ability to achieve acceptable levels of coverage and reimbursement for products or procedures using our products by governmental authorities, private health insurers and other organizations will influence our ability to successfully commercialize any product candidates we develop. Obtaining adequate coverage and reimbursement for any product candidate we develop that is administered under the supervision of a physician, which is what we anticipate for FX-322, may be particularly difficult because of the higher prices associated with such products. In addition, we believe that FX-322 and FX-345 are novel approaches to treating hearing loss and, as a result, availability of coverage and reimbursement by payors is highly uncertain, particularly because the cost of existing treatments for SNHL, such as hearing aids, are generally not reimbursed by payors. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming we obtain coverage for our product candidates or procedures using our products by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product we commercialize, and any reimbursement that may become available may be decreased or eliminated in the future.

Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and the current presidential administration and Congress have introduced several proposals related to drug pricing. Many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. Although there are currently no FDA approved drugs for the treatment of

54


 

SNHL, it is possible that a third-party payor may consider FX-322 or FX-345 as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy, pricing of existing drugs and medical devices, such as hearing aids, may limit the amount we will be able to charge for any product we commercialize. Payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize a satisfactory return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates. Additionally, our ability to obtain a satisfactory financial return depends on what, if any, proposals related to drug pricing may be implemented and, if implemented, when they might take effect.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.

No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, and one third-party payor’s decision to cover a product does not ensure that other payors will also provide similar coverage. Additionally, the process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the reimbursement rate that the payor will pay for the product once coverage is approved. As a result, the determination of coverage and reimbursement is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.

Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any product we commercialize. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations, and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.

We or our collaborators may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we or our collaborators are able to charge for products we or our collaborators commercialize. Accordingly, in markets outside the United States, the reimbursement for products we or our collaborators commercialize may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

Even if a product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success.

If a product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If it does not achieve an

55


 

adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on several factors, including, but not limited to:

the efficacy and potential advantages compared to alternative treatments;
effectiveness of sales and marketing efforts;
the cost of treatment in relation to alternative treatments, including any similar generic treatments;
our ability to offer our products for sale at competitive prices;
the convenience and ease of administration compared to alternative treatments;
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the strength of marketing and distribution support;
the availability of third-party coverage and adequate reimbursement;
the prevalence and severity of any side effects; and
any restrictions on the use of our product together with other medications.

Because we expect sales of our product candidates, if approved, to generate substantially all our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.

If we are unable to establish sales and marketing capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidate we develop, if approved.

In order to market and successfully commercialize any product candidate we develop, if approved, we must build our sales and marketing capabilities or enter into collaborations with third parties for these services. We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We intend to directly market and commercialize FX-322 for the treatment of SNHL, if approved, in the United States by developing our own sales and marketing force, targeting ear, nose, and throat doctors and audiologists. There are significant expenses and risks involved with establishing our own sales and marketing capabilities, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales leads and provide our sales and marketing team with adequate access to physicians who may prescribe our product, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. Any failure or delay in the development of a product candidate that affects the expected timing of commercialization of the product candidate or results in the failure of the product candidate to be commercialized could result in us having prematurely or unnecessarily incurred costly commercialization expenses. Our investment would be lost if we are unable to retain or reposition our sales and marketing personnel.

We may also enter into collaborations for the sales and marketing of our product candidates, if approved. To the extent that we depend on collaborators for sales and marketing activities, any revenues we receive will depend upon the success of those collaborators’ sales and marketing teams and the collaborators’ prioritization of our product and compliance with applicable regulatory requirements, and there can be no assurance that the collaborators’ efforts will be successful. For example, under the License and Collaboration Agreement with Astellas, or the Astellas Agreement, we will depend on Astellas to sell and market FX-322 for the treatment of SNHL, if approved, outside of the United States, and we can have no assurance that it will be successful in its efforts or devote sufficient resources to the sale and marketing of FX-322.

If we are unable to build our own sales and marketing team or enter into a collaboration for the commercialization of product candidates we develop, if approved, we may be forced to delay the commercialization of our product candidates or reduce the scope of our sales or marketing activities, which would have an adverse effect on our business, operating results and prospects.

56


 

A variety of risks associated with operating internationally could materially adversely affect our business.

Our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves several risks, including, but not limited to:

multiple, conflicting, and changing laws and regulations, such as data privacy and security laws and regulations, tax laws, export and import restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;
failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;
additional potentially relevant third-party patent rights;
complexities and difficulties in obtaining protection and enforcing our intellectual property;
difficulties in staffing and managing foreign operations;
complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;
limits in our ability to penetrate international markets;
financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;
natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;
certain expenses, including, among others, expenses for travel, translation, and insurance; and
regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and corruption.

Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.

Risks related to our dependence on third parties

The Astellas Agreement is important to our business. If we or Astellas fail to adequately perform under the Astellas Agreement, or if we or Astellas terminate the Astellas Agreement, the development and commercialization of FX-322 for SNHL outside the United States would be materially delayed and our business would be adversely affected.

Under the Astellas Agreement, Astellas is responsible for the development and commercialization of FX-322 outside of the United States and we are responsible for development and commercialization in the United States. We and Astellas are jointly responsible for conducting global clinical studies and coordinating commercial launch activities.

We have received an upfront payment from Astellas of $80.0 million, and we may also receive development milestone payments up to $230.0 million. If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments plus tiered royalties at rates ranging from low- to mid-teen percentages.

Termination of the Astellas Agreement could cause significant delays in our development and commercialization efforts for FX-322 for the treatment of SNHL outside of the United States. If the Astellas Agreement is terminated, we would need to expand our internal capabilities or enter into another agreement to compensate for the loss in funding and clinical development support from Astellas. Any suitable alternative agreement would take considerable time to negotiate and could also be on less favorable terms to us. Whether or not we identify another suitable collaborator, we may need to seek additional financing to continue the development of FX-322, or we may be forced to discontinue development of FX-322, either of which could have a material adverse effect on our business.

57


 

We intend to continue to collaborate with third parties for the development and commercialization of our product candidates. We may not succeed in establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all.

We have entered into the Astellas Agreement for the development and commercialization of FX-322 for the treatment of SNHL outside the United States and may seek collaborations for the development and commercialization of other product candidates. The process of establishing and maintaining collaborative relationships is difficult, time-consuming, and involves significant uncertainty, such as:

a collaborator may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale, or downsizing;
a collaborator may seek to renegotiate or terminate its relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;
a collaborator may cease development in therapeutic areas which are the subject of our collaboration;
a collaborator may not devote sufficient capital or resources towards our product candidates, or may fail to comply with applicable regulatory requirements;
a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such candidate;
a significant delay in initiation of certain development activities by a collaborator will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;
a collaborator could develop a product that competes, either directly or indirectly, with our product candidate;
a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the marketing, distribution, or sale of a product;
a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to meet demand requirements;
a collaborator may terminate a strategic alliance;
a dispute may arise between us and a collaborator concerning the research, development, or commercialization of a product candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management’s attention and resources; and
a collaborator may use our products or technology in such a way as to invite litigation from a third party.

If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense, or find alternative sources of capital, which would have a material adverse impact on our clinical development plans and business.

Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless, or negligent conduct or unauthorized activities that violate applicable laws, rules, and regulations including: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse, and other healthcare laws and regulations; or laws that require the reporting of true, complete, and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide

58


 

range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these or other laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government agency could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us or them and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.

We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of FX-322 and intend to rely on CMOs for the production of commercial supply of FX-322, if approved, and for clinical and commercial supply of our future product candidates, as well as to supply raw materials necessary to produce our product candidates. Our dependence on CMOs may impair the development of our product candidates and may impair their commercialization, which would adversely impact our business and financial position.

We do not own facilities for manufacturing FX-322 or any product candidate. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials of FX-322 and any product candidates we develop and, in future, for commercial quantities. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. If any CMO we engage is unable to provide sufficient supply of any product candidate we develop, we may be unable to arrange for an alternative supply or to do so on commercially reasonable terms or in a timely manner, which could delay any clinical trials, the commercial launch of our product candidates, if approved, or, regarding any commercial supply, result in a shortage in supply that could negatively impact our revenues. For example, we are substantially dependent on the CMO that supplies us with the proprietary glycogen synthase kinase 3, or GSK3, inhibitor that is a key component of FX-322 and the CMO that lyophilizes FX-322 into a powder. While there are other CMOs who are able to supply the GSK3 inhibitor or lyophilize FX-322, manufacture of the GSK3 inhibitor and the lyophilization process require proprietary knowledge or specialized capabilities that only a limited number of CMOs have. As a result, transitioning to a new CMO for either the supply of the GSK3 inhibitor or to conduct the lyophilization process would be particularly time consuming and costly. We have just begun to engage other CMOs as back-up for the manufacture and supply of FX-322. As a result, if any of the CMOs involved in the manufacture and supply of FX-322 experience a delay or disruption, or if we fail to obtain the appropriate approvals to manufacture and supply FX-322 outside the US (e.g., as a result of a failure to obtain a waiver under the Bayh-Dole Act), we may not have sufficient quantities of FX-322 for our planned activities and may not be able to transition to a new CMO in a timely or cost-effective manner, or at all, which would negatively impact our ability to develop and potentially commercialize FX-322.

The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign regulatory authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. While we have engaged independent auditors to assess the compliance with the protocol that we co-developed with our CMOs regarding the manufacturing process for FX-322, in general, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and we were not involved in developing our CMOs’ policies and procedures.

If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with laws, regulations, and standards related to manufacturing could subject us to risks, including the risk that we may have to suspend the manufacture of our product candidates, that obtained approvals

59


 

could be revoked, and that the FDA or another governmental regulatory authority may take enforcement actions, including untitled letters, warning letters, seizures, injunctions, or product recalls. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.

We contract for the supply of the active pharmaceutical ingredient, or API, and other raw material necessary to produce FX-322 and we may contract in the future for the supply of API and other raw material for any of our other product candidates we develop. Supplies of API or other raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. The extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to mitigate the spread of COVID-19 or treat its effects and may cause delays. In addition, a disruption in the supply of API or other raw material could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues. Growth in the costs and expenses of API or other raw material may also impair our ability to cost-effectively manufacture our product candidates. In addition, there may be a limited number of suppliers for API or other raw material that we may use to manufacture our product candidates, and we cannot be certain that we will be able to engage such suppliers in a timely manner or at all. If we are unable to do so, clinical development of our product candidates, commercialization for any approved product, or our business could be adversely affected.

Finding new CMOs or third-party suppliers involves additional cost and requires our management’s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.

As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved.

We intend to rely on third parties to conduct, supervise, and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.

We rely, and will continue to rely, on CROs, CRO-contracted vendors, and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including our Phase 1b clinical trial (FX-322-113), our Phase 2b trial of FX-322 (FX-322-208), extension trials of FX-322-111 and FX-322-112, any future clinical trials of FX-322 for the treatment of SNHL, and any future clinical trials of our other product candidates. Our reliance on CROs for clinical development activities limits our control over these activities and we were not involved in developing our CRO’s policies and procedures, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards.

We and our CROs will be required to comply with the Good Laboratory Practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.

Our CROs are not our employees, and we do not control whether they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position.

60


 

We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.

If our relationship with any CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management’s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. While the COVID-19 pandemic and government measures taken in response have had a significant impact on our CROs and their ability to conduct clinical trials, there is potential they will face disruption in the future, which may affect our ability to initiate and complete our clinical trials. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects.

Risks related to healthcare laws and other legal compliance matters

Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.

In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of health care. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the biotechnology and pharmaceutical industries include the following:

an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents;
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected;
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and
establishment of a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

 

Since its enactment, there have been judicial challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court’s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or other challenges to the ACA, if any, will impact the ACA or our business.

 

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021, unless additional

61


 

Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, including hospitals, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, in March 2021, the American Rescue Plan Act of 2021 was signed into law, which, among other things, eliminated the statutory cap on drug manufacturers’ Medicaid Drug Rebate Program rebate liability, effective January 1, 2024. Under current law enacted as part of the ACA, drug manufacturers’ Medicaid Drug Rebate Program rebate liability is capped at 100% of the average manufacturer price for a covered outpatient drug. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain.

Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been administration efforts, Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be implemented in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing.

In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.

Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties.

Our business operations and current and future arrangements with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws include:

the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand;
the U.S. federal false claims, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or

62


 

entities for knowingly presenting, or causing to be presented, to the U.S. federal government claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes “any request or demand” for money or property presented to the federal government. In addition, pharmaceutical manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims;
the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation:
the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices;
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;
federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products;
the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (as defined by statute) and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives;
analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities;
similar healthcare laws and regulations in the European Union, or EU, and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers; and
laws and regulations prohibiting bribery and corruption such as the FCPA, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof.

Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and

63


 

business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations.

If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to actions including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.

Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.

The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.

As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the California Consumer Privacy Act (“CCPA”) went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, in November 2020, the California Privacy Rights Act (“CPRA”) passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similarly, on March 2, 2021, Virginia enacted the Virginia Consumer Data Protection Act (“CDPA”), a comprehensive privacy statute that shares similarities with the CCPA, CPRA and legislation proposed in other states. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA, the CDPA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.

64


 

Further, the General Data Protection Regulation (“GDPR”) applies to companies established in the EEA, as well as to companies that are not established in the EEA and which collect and use personal data in relation to (i) offering goods or services to, or (ii) monitoring the behavior of, individuals located in the EEA. If we conduct clinical trial programs in the EEA (whether the trials are conducted directly by us or through a clinical vendor or collaborator), or enter into research collaborations involving the monitoring of individuals in the EEA, or market our products to individuals in the EEA, we will be subject to the GDPR. The GDPR puts in place stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data (or reliance on another appropriate legal basis), the provision of robust and detailed disclosures to individuals about how personal data is collected and processed (in a concise, intelligible and easily accessible form), a comprehensive individual data rights regime (including access, erasure, objection, restriction, rectification and portability), maintaining a record of data processing, data export restrictions governing transfers of data from the EEA, short timelines for data breach notifications to be given to data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches, and limitations on retention of information. The GDPR also puts in place increased requirements pertaining to health data and other special categories of personal data, as well as a definition of pseudonymized (i.e., key-coded) data. Further, the GDPR provides that EEA member states may establish their own laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use, and share such data and/or could cause our costs to increase. In addition, there are certain obligations if we contract third-party processors in connection with the processing of personal data. If our or our collaborators’ or service providers’ privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data, or fines of up to 20 million Euros or up to 4% of our total worldwide annual revenue of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, including class-action type litigation, negative publicity, reputational harm and a potential loss of business and goodwill. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure.

Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.

We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.

Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.

As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials.

65


 

Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.

Risks related to our intellectual property

If we are unable to obtain, maintain, enforce and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.

Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed.

The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, defend, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain, enforce, and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents, and applications may not be prepared, filed, prosecuted, maintained, defended, and enforced in a manner consistent with the best interests of our business.

The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our owned and in-licensed patent rights are uncertain. Moreover, our owned and in-licensed pending and future patent applications may not result in patents being issued that protect our technology and product candidates, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend, and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.

Moreover, we or our licensors may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or

66


 

otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.

It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.

If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could significantly harm our business, financial condition, results of operations, and prospects.

Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, or delay or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements.

67


 

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed.

In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions may be available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations, and prospects could be materially harmed.

It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a United States patent covering any of our product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO.

Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate.

Although we or our licensors are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensors’ issued patents or other intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate, or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable.

An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly and could put any of our owned or in-licensed patent applications at risk of not yielding

68


 

an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations, and prospects.

Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs, and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.

The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party’s intellectual property.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may develop may be found to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not

69


 

infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may develop, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party’s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent or other intellectual property right and could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals, and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.

Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms, and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time

70


 

limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations, and prospects.

If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.

We are party to license and funding agreements that impose, and we may enter into additional licensing and funding arrangements with third parties that may impose, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Under our existing licensing and funding agreements, we are obligated to pay royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects.

Disputes may arise regarding intellectual property subject to a licensing agreement, including:

the scope of rights granted under the license agreement and other interpretation related issues;
the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
the sublicensing of patent and other rights under our collaborative development relationships;
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and
the priority of invention of patented technology.

In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents and/or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

71


 

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors’ ownership of our owned or in-licensed patents, trade secrets, or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered and unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trade names or trademarks that incorporate variations of our unregistered trade names or trademarks. Over the long term, if we are unable to successfully register our trade names and trademarks and establish name recognition based on our trade names and trademarks, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trade names and trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;
it is possible that our owned and in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents;

72


 

issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we cannot ensure that any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;
we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;
we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;
we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own, or license expire;
we may not develop additional proprietary technologies that are patentable;
the patents of others may harm our business; and
we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Risks related to our employees, managing our growth and our operations

Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.

We are highly dependent on the expertise of David L. Lucchino, our President and Chief Executive Officer, as well as the other principal members of our management, scientific, and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.

If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.

In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by other companies or organizations and may have commitments that limit their availability. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited.

We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

Notwithstanding COVID-19, we have continued to identify key talent for critical roles, particularly in the areas of clinical development, regulatory affairs, quality and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, as well as the competition within the region, we may not be able to effectively manage the expansion of our operations or recruit and train additional

73


 

qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

We may engage in transactions that could disrupt our business, cause dilution to our shareholders or reduce our financial resources.

In the future, we may enter into transactions to acquire or in-license rights to product candidates, products or technologies, or to acquire other businesses. If we do identify suitable candidates, we may not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions or in-licenses may not strengthen our competitive position, and these transactions may be viewed negatively by analysts, investors, customers, or other third parties with whom we have relationships. We may decide to incur debt in connection with an acquisition, or in-license or issue our common stock or other equity securities as consideration for the acquisition, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely, and nondisruptive manner. Such transactions may also divert management attention from day-to-day responsibilities, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or in-licenses or the effect that any such transactions might have on our operating results.

Our business and operations would suffer in the event of security breaches or system failures.

The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals. In the ordinary course of our business, we and third parties with which we have relationships will continue to collect and store sensitive data, including clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite the implementation of security measures, our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, malfeasance, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication, electrical failures or other disruptions. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. For instance, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with COVID-19 global pandemic. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. A number of proposed and enacted federal, state and international laws and regulations obligate companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors, or other organizations with which we have formed strategic relationships. While we do not believe that our network has experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing, or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we currently rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under data protection laws, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation, and cause a loss of confidence in us and our or such third parties’ ability to conduct clinical trials, which could adversely affect our reputation and delay the clinical development of our product candidates.

74


 

Risks related to our common stock

The market price of our common stock has been volatile and fluctuated and may in future fluctuate substantially, which could result in substantial losses for our stockholders.

The market price of our common stock has been highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this section titled “Risk factors” and elsewhere in this Quarterly Report on Form 10-Q, these factors include:

any delay in the enrollment or ultimate completion of the Phase 2b trial of FX-322 (FX-322-208), extension trials of FX-322-111 and FX-322-112 and any futures clinical trials of FX-322 for the treatment of SNHL as well as any delay in ultimate completion of our Phase 1b clinical study in severe SNHL (FX-322-113);
the results of the Phase 1b clinical study in severe SNHL (FX-322-113), the Phase 2b trial of FX-322 (FX-322-208), extension trials of FX-322-111 and FX-322-112 or any future clinical trials of FX-322 for the treatment of SNHL or clinical trials of our competitors for the same or similar indication. For example, the price of our common stock decreased significantly following the announcement of our Phase 2a (FX-322-202) interim results, showing that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo;
our ability to develop FX-345, our remyelination program, or any additional product candidates based on our PCA platform;
any delay in submitting a regulatory filing and any adverse development or perceived adverse development with respect to the regulatory review of such filing;
failure to successfully develop and commercialize FX-322 or FX-345 for the treatment of SNHL or any future product candidates;
inability to obtain additional funding;
regulatory or legal developments in the United States and other countries applicable to our PCA platform or any product candidate:
adverse regulatory decisions;
changes in the structure of healthcare payment systems;
adverse developments concerning our CMOs or CROs;
inability to obtain adequate product supply for our other product candidates, or the inability to do so at acceptable prices;
introduction of new products, services or technologies by our competitors;
our ability to effectively manage our growth;
failure to meet or exceed financial projections we provide to the public;
failure to meet or exceed the estimates and projections of the investment community;
changes in the market valuations of companies similar to us;
market conditions in the biotechnology and pharmaceutical sectors, and the issuance of new or changed securities analysts’ reports or recommendations;
announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;
the termination of a collaboration agreement, licensing agreement or other strategic arrangement, or the inability to establish additional collaboration arrangements that we need on favorable terms, or at all;
significant lawsuits and their outcomes, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our product candidates and PCA platform;
additions or departures of key scientific or management personnel;
sales of our common stock by us or our shareholders in the future;

75


 

trading volume of our common stock; and
general economic, industry and market conditions.

In addition, the trading prices for common stock of biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. The ongoing COVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.

Our directors, executive officers and shareholders affiliated with our directors and executive officers own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant influence over matters subject to shareholder approval.

Our directors, executive officers, and shareholders affiliated with our directors and executive officers exert significant influence on us. As of November 8, 2021, these holders beneficially owned approximately 16.7% of the voting power of our outstanding common stock. As a result, these holders, acting together, have significant influence over all matters that require approval of our stockholders, including the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transactions. The interests of these holders may not always coincide with our corporate interests or the interests of other shareholders, and they may act in a manner with which our shareholders may not agree or that may not be in the best interests of our other shareholders.

Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, our loan and security agreement with Silicon Valley Bank currently prohibits us from paying dividends on our equity securities, and any future debt agreements may likewise preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain on an investment in our common stock for the foreseeable future.

We will continue to incur increased costs as a result of operating as a public company, and our management will continue to devote substantial time to compliance initiatives and corporate governance practices.

As a public company, and particularly after we no longer qualify as an emerging growth company, we will continue to incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, these rules and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.

Pursuant to Section 404 of SOX, or Section 404, we are required to furnish a report by our senior management on our internal control over financial reporting, and our independent registered public accounting firm is required to provide an attestation report on our internal control over financial reporting. However, while we remain an emerging growth company, our independent registered public accounting firm will not be required to provide the attestation report. To ensure compliance with Section 404, we continue to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction on the price of our common stock in the market due to a loss of

76


 

confidence in the reliability of our financial statements. Furthermore, if we are unable to conclude that our internal control over financial reporting is effective, our investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline.

We are an “emerging growth company” and a “smaller reporting company” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act, and a “smaller reporting company” as defined under the rules promulgated under the Securities Act. As an emerging growth company and a smaller reporting company we may follow reduced disclosure requirements and do not have to make all the disclosures that public companies that are not emerging growth companies or smaller reporting companies do. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (d) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which means the market value of our voting and non-voting common stock that is held by non-affiliates exceeds $700 million as of the last business day of our second fiscal quarter. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:

not being required to comply with the auditor attestation requirements of Section 404;
an exemption from compliance with the requirement of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on the financial statements;
progressively adding to the number of years of audited financial statements required to be included in our periodic reports; and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation, stockholder approval of any golden parachute payments not previously approved and having to disclose the ratio of the compensation of our chief executive officer to the median compensation of our employees.

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section 404, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors.

We may choose to take advantage of some, but not all, of the available exemptions for emerging growth companies and smaller reporting companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our shares price may be more volatile.

77


 

Provisions in our restated certificate of incorporation and our amended and restated bylaws or Delaware law may discourage, delay or prevent a merger, acquisition or other change in control of our company that our shareholders may consider favorable, including transactions in which our shareholders might otherwise receive a premium for their shares.

Our restated certificate of incorporation and our amended and restated bylaws include certain anti-takeover provisions, including those establishing:

a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;
no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;
the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents shareholders from filling vacancies on our board of directors;
the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
the ability of our board of directors to alter our bylaws without obtaining stockholder approval;
the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors:
a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors: and
advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a shareholders’ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us.

These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Our restated certificate of incorporation and amended and restated bylaws designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.

Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation, or our amended and restated bylaws, (4) any action to interpret, apply, enforce, or determine the validity of our restated certificate of incorporation or our amended and restated bylaws, or (5) any action asserting a claim governed by the internal affairs doctrine. Under our restated certificate of incorporation, this exclusive forum provision will not apply to

78


 

claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. In addition, our amended and restated bylaws specifies that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. For example, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.

General Risk Factors

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial revenues, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, our existing stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. In addition, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts.

Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.

Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement, or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution, and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of

79


 

our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.

We may not be able to protect our intellectual property and proprietary rights throughout the world.

Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent or at all, inventions that constitute new methods of treatment.

Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.

We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers, or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.

Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims.

80


 

In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.

We are currently subject to securities class action litigation and could be subject to similar or other litigation in the future.

In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. For example, the price of our common stock decreased significantly following the announcement of our Phase 2a (FX-322-202) interim results, showing that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Following that announcement, on June 3, 2021, and June 22, 2021, purported stockholders of our company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company entitled Evans v. Frequency Therapeutics, Inc. et al. and Hingston v. Frequency Therapeutics, Inc. et al., respectively. The lawsuits allege violations of Section 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended, due to allegedly false and misleading statements and omissions about our Phase 2a clinical trial (FX-322-202) for our product candidate FX-322 in our public disclosures between November 16, 2020 and March 22, 2021. The lawsuits seek, among other things, damages in connection with our allegedly artificially inflated stock price between November 16, 2020, and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys’ fees and costs.

 

Additionally, on June 23, 2021, two purported stockholders of our company filed a lawsuit in the Court of Chancery of the State of Delaware against (i) us, (ii) our Chief Executive Officer, President, and Director, David Lucchino, (iii) Computershare Inc., and (iv) Computershare Trust Company, N.A., entitled The Gregory J. Parseghian Revocable Trust, et al. v. Frequency Therapeutics, Inc., et al. The lawsuit alleges causes of action against us of conversion and unjust enrichment, and against Mr. Lucchino for breach of the fiduciary duty of loyalty, due to allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The lawsuit seeks monetary damages, as well as interest, attorneys’ fees and costs, against all defendants.

 

We can make no assurances as to the time or resources that will need to be devoted to these lawsuits or their final outcomes, or the impact, if any, of these lawsuits or any proceedings on our business, financial condition, results of operations and cash flows. While we are vigorously defending against all claims asserted, these lawsuits could result in substantial costs to us and a diversion of our management’s attention and resources, which could harm our business. In addition, the uncertainty of the pending lawsuits or potential filing of additional lawsuits could lead to more volatility and a reduction in our stock price.

If securities or industry analysts issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.

The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

81


 

Sales of a substantial number of shares of our common stock, or the perception that substantial sales might occur, could cause the price of our common stock to fall.

Sales of a substantial number of shares of our common stock, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. The shares of common stock that were sold in the initial public offering of our common stock are freely transferable without restrictions or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for any shares acquired by our affiliates, as defined in Rule 144 under the Securities Act. The remaining shares of our common stock that are outstanding are either unrestricted or restricted as a result of securities laws. In addition, there are shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity incentive plans and may become eligible for future sale subject to vesting, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In October 2019, we issued and sold 6,000,000 shares of our common stock in our initial public offering, or IPO, at a public offering price of $14.00 per share and on October 31, 2019 we issued and sold an additional 325,000 shares of our common stock pursuant to the exercise in part by the underwriters of their over-allotment option to purchase additional shares at the same public offering price.

The offer and sale of all the shares in the IPO, inclusive of the underwriters’ exercise in part of their over-allotment option, were registered under the Securities Act pursuant to a registration statement on Form S-1 (Reg. No. 333-233652), as amended, which was declared effective by the SEC on October 2, 2019. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. The IPO commenced on September 23, 2019 and terminated upon the closing of the sale of shares to the underwriters pursuant to the underwriters’ exercise in part of their over-allotment option on October 31, 2019. Upon completion of the IPO, inclusive of the underwriters’ exercise in part of their over-allotment option, we received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses payable by us of approximately $9.3 million. No payments for any expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.

There has been no material change in the expected use of the net proceeds from our IPO as described in our final prospectus, dated October 2, 2019, filed with the SEC pursuant to Rule 424(b) relating to our registration statement on Form S-1 on October 4, 2019.

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None

82


 

Item 6. Exhibits.

 

 

 

 

 

Incorporated by Reference

Exhibit

Number

 

Exhibit Description

 

Form

 

File No.

 

Exhibit

 

Filing

Date

 

Filed/

Furnished
Herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Restated Certificate of Incorporation of Frequency Therapeutics, Inc.

 

8-K

 

001-39062

 

3.1

 

10/7/19

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Amended and Restated Bylaws of Frequency Therapeutics, Inc.

 

8-K

 

001-39062

 

3.1

 

9/23/20

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.1

 

Second Amended and Restated Investors’ Rights Agreement, dated as of July 17, 2019

 

S-1

 

333-233652

 

4.2

 

9/6/19

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Rule 13a‑14(a) / 15d‑14(a) Certification of Chief Executive Officer

 

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Rule 13a‑14(a) / 15d‑14(a) Certification of Chief Financial Officer

 

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Section 1350 Certification of Chief Executive Officer

 

 

 

 

 

 

 

 

 

**

 

 

 

 

 

 

 

 

 

 

 

 

 

32.2

 

Section 1350 Certification of Chief Financial Officer

 

 

 

 

 

 

 

 

 

**

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

 

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline XBRL Extension Definition Linkbase Document

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline XBRL Taxonomy Label Linkbase Document

 

 

 

 

 

 

 

 

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

The cover page for the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101.

 

***

 

* Filed herewith

** Furnished herewith

*** Submitted electronically herewith

83


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

FREQUENCY THERAPEUTICS, INC.

 

 

 

 

Date: November 15, 2021

 

By:

/s/ David L. Lucchino

 

 

 

David L. Lucchino

 

 

 

President and Chief Executive Officer

(principal executive officer)

 

 

 

 

Date: November 15, 2021

 

By:

/s/ Peter P. Pfreundschuh

 

 

 

Peter P. Pfreundschuh

 

 

 

Chief Financial Officer

(principal financial officer and principal accounting officer)

 

84


EX-31.1 2 freq-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

CERTIFICATIONS

I, David L. Lucchino, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Frequency Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 15, 2021

 

By:

/s/ David L. Lucchino

 

 

 

David L. Lucchino

 

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 

 


EX-31.2 3 freq-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

CERTIFICATIONS

I, Peter Pfreundschuh, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Frequency Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 15, 2021

 

By:

/s/ Peter Pfreundschuh

 

 

 

Peter Pfreundschuh

 

 

 

Chief Financial Officer

(Principal Financial Officer)

 

 


EX-32.1 4 freq-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Frequency Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David L. Lucchino, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

Date: November 15, 2021

 

By:

/s/ David L. Lucchino

 

 

 

David L. Lucchino

 

 

 

President and Chief Executive Officer

(principal executive officer)

 

 

 


EX-32.2 5 freq-ex32_2.htm EX-32.2 EX-32.2

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Frequency Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Pfreundschuh, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

Date: November 15, 2021

 

By:

/s/ Peter Pfreundschuh

 

 

 

Peter Pfreundschuh

 

 

 

Chief Financial Officer

(principal financial officer and principal accounting officer)

 

 

 


EX-101.CAL 6 freq-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 7 freq-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Consolidated Statements Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100070 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Recently Adopted And Issued Accounting Standards link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Employee Stock Purchase Plan link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Organization and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Recently Adopted and Issued Accounting Standards - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Property and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Stock-based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Collaboration Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - License Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 8 freq-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 9 freq-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 freq-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Common stock, $0.001 par value; 200,000,000 shares authorized, 34,551,875 and 33,964,000 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively Forfeiture of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Security deposit classified as restricted cash Restricted Cash Restricted Cash, Total Shares of common stock reserved for future issuance Total grant date fair value of stock options vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Purchases of property and equipment in accounts payable and accrued expenses Other comprehensive (loss) (in shares) Other comprehensive (loss) (in shares) Other comprehensive (loss) Purchase under Employee Stock Purchase Plan (in shares) Purchase under Employee Stock Purchase Plan Issuance of common stock in Private Placement, net (in shares) Issuance of common stock in Private Placement, net Stock Issued During Period, Shares, Employee Stock Purchase Plans Shares available for future grant under incentive plans Preferred stock, authorized shares Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, issued shares Preferred Stock, Shares Outstanding Preferred stock, outstanding shares Preferred stock, outstanding shares Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, authorized shares Common Stock, Shares, Issued Common stock, issued shares Common Stock, Shares, Outstanding Ending Balance (in shares) Beginning Balance (in shares) Common stock, outstanding shares Statement of Comprehensive Income [Abstract] Revenue from Contract with Customer, Excluding Assessed Tax Revenue Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Investment Income, Interest Interest income Interest Expense Interest (expense) Realized Investment Gains (Losses) Realized (loss) gain on investments Foreign Currency Transaction Gain (Loss), before Tax Foreign exchange (loss) gain Other Nonoperating Expense Other (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Net tax benefit Income taxes Net Income (Loss) Attributable to Parent Net loss Net loss Net Loss Earnings Per Share, Basic and Diluted Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Equipment [Member] Lab Equipment Furniture and Fixtures [Member] Furniture and Office Equipment Software and Software Development Costs [Member] Net loss per share attributable to common stockholders-basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted-average shares of common stock outstanding-basic and diluted Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Other comprehensive (loss) gain: OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total other comprehensive (loss) gain Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components Equity Component [Domain] Equity Component Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional-paid in Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Retained Earnings [Member] Accumulated Deficit Statement [Line Items] Statement [Line Items] APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of options (in shares) Number of shares, Exercised Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) Non cash lease expenses. Non Cash Lease Expenses Non-cash lease expense Increase decrease in lease liabilities. Increase Decrease In Lease Liabilities Lease liabilities Purchases of property and equipment and right of use asset included in accounts payable. Purchases Of Property And Equipment And Right Of Use Asset Included In Accounts Payable Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Share-based Payment Arrangement, Noncash Expense Stock-based compensation Depreciation Depreciation expense Depreciation expense Paid-in-Kind Interest Non-cash interest expense Gain (Loss) on Disposition of Assets Loss on disposal of assets Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Contract with Customer, Liability Deferred revenue Increase (Decrease) in Accrued Liabilities Accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash (used in) operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Marketable Securities Purchase of marketable securities Proceeds from Sale and Maturity of Marketable Securities Redemption of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Stock Options Exercised Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents, and restricted cash at beginning of period Noncash Investing and Financing Items [Abstract] Non-cash items: Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets in exchange for lease liabilities Capital Expenditures Incurred but Not yet Paid Organization, Consolidation and Presentation of Financial Statements [Abstract] Leasehold Improvements [Member] Leasehold Improvements Construction in Progress [Member] Construction in Progress Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Property, Plant and Equipment, Gross Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Accrued third-party research and development expenses current. Accrued Third Party Research And Development Expenses Current Stock Issued During Period, Value, New Issues Proceeds from Issuance of Private Placement Unrealized (loss) on marketable securities Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Period Focus Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Proceeds from issuance of common stock upon exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Entity Address City Or Town Entity Address, Postal Zip Code Entity Address Postal Zip Code Entity Address, State or Province Entity Address State Or Province City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Statement of Financial Position [Abstract] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Debt Securities, Available-for-sale, Current Short-term marketable securities Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Debt Securities, Available-for-sale, Noncurrent Long-term marketable securities Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Right of use assets Restricted Cash, Noncurrent Restricted cash Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Contract with Customer, Liability, Current Deferred revenue Operating Lease, Liability, Current Lease liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Lease liabilities, net of current portion Loans Payable to Bank, Noncurrent Term loan Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders’ equity: Preferred Stock, Value, Issued Common Stock, Value, Issued Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Ending Balance Beginning Balance Total stockholders’ equity Liabilities and Equity Total liabilities and stockholders’ equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, value per share Preferred Stock, Shares Authorized Third-party research and development expenses Accrued income taxes and other accrued liabilities, current. Accrued Income Taxes And Other Accrued Liabilities Current Taxes and other Employee-related Liabilities, Current Payroll and employee related expenses Accrued Professional Fees, Current Professional fees Debt instrument interest only payment maturity date. Debt Instrument Interest Only Payment Maturity Date Monthly interest only payments due Debt instrument floor interest rate percentage. Debt Instrument Floor Interest Rate Percentage Interest rate floor percentage Schedule of Long-term Debt Instruments [Table] Debt Instrument [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Loan and security agreement. Loan And Security Agreement [Member] Loan Agreement Long-term Debt, Type [Axis] Long-term Debt, Type Long-term Debt, Type [Domain] Long-term Debt, Type Term loan. Term Loan [Member] Term Loan Variable Rate [Axis] Variable Rate Variable Rate [Domain] Variable Rate Prime Rate [Member] Prime Rate Debt Instrument [Axis] Debt Instrument Debt Instrument, Name [Domain] Debt Instrument, Name Prepayment Occurs on or Prior to First Anniversary of Closing Date. Prepayment Occurs On Or Prior To First Anniversary Of Closing Date [Member] Prepayment Occurs on or Prior to First Anniversary of Closing Date Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date. Prepayment Occurs After First Anniversary Of Closing Date And On Or Prior To Second Anniversary Of Closing Date [Member] Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date Prepayment Occurs After Second Anniversary of Closing Date. Prepayment Occurs After Second Anniversary Of Closing Date [Member] Prepayment Occurs After Second Anniversary of Closing Date Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Face Amount Principal balance Debt Instrument, Payment Terms Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name Patent license agreement. Patent License Agreement [Member] Patent License Agreement Legal Entity [Axis] Legal Entity Entity [Domain] Entity Massachusetts Institute of Technology. Massachusetts Institute Of Technology [Member] MIT Product and Service [Axis] Product and Service Product and Service [Domain] Product and Service Royalty [Member] Royalty Title of Individual [Axis] Title of Individual Title of Individual [Domain] Title of Individual Director [Member] Dr. Langer Payment terms, description Debt Instrument, Frequency of Periodic Payment Frequency of interest-only payments Debt Instrument, Maturity Date Loan maturity date Debt Instrument, Basis Spread on Variable Rate Debt instrument, Interest rate Interest Expense, Debt Debt instrument interest payment Debt instrument prepayment premium percentage. Debt Instrument Prepayment Premium Percentage Debt instrument prepayment premium percentage Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Debt instrument final payment Net Income (Loss) Attributable to Parent [Abstract] Numerator: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Denominator: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Unvested Restricted Common Stock [Member]. Unvested Restricted Common Stock [Member] Unvested Restricted Common Stock Unvested restricted stock units. Unvested Restricted Stock Units [Member] Unvested Restricted Stock Units Outstanding stock options. Outstanding Stock Options [Member] Outstanding Stock Options Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share Schedule of Stock by Class [Table] Schedule Of Stock By Class [Table] Sale of Stock [Axis] Sale of Stock Sale of Stock [Domain] Sale of Stock Private Placement [Member] Private Placement Class of Stock [Line Items] Class Of Stock [Line Items] Share-based Payment Arrangement, Option [Member] Stock Options Outstanding Share-based Payment Arrangement [Member] Shares Available for Future Grant Under Stock Option Plan Common Stock, Capital Shares Reserved for Future Issuance Stock Issued During Period, Shares, New Issues Common stock shares issued and sold Shares Issued, Price Per Share Share price per share Proceeds from Issuance of Common Stock Plan Name [Axis] Plan Name Plan Name [Domain] Plan Name Two thousand and nineteen incentive award plan. Weighted average exercise price, Beginning balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, Outstanding as of December 31, 2020 Stock Issued During Period, Value, Employee Stock Purchase Plan Weighted average fair value, Unvested, September 30, 2021 Share-based Payment Arrangement [Text Block] Stock-based Compensation Employee stock purchase plan disclosure. Employee Stock Purchase Plan Disclosure [Text Block] Employee Stock Purchase Plan Retirement Benefits [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Collaborative Arrangement Disclosure [Text Block] Collaboration Agreement License agreement. License Agreement [Text Block] License Agreement Research and Development [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Principles of Consolidation Unaudited interim financial information. Unaudited Interim Financial Information Policy [Text Block] Unaudited Interim Financial Information New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of Financial Assets Measured at Fair Value on Recurring Basis Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Weighted average exercise price, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share based compensation arrangement by share based payment award options granted weighted average remaining contractualterm2. Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term2 Weighted average remaining contractual term (in years), Granted Share based compensation arrangement by share based payment award options exercised weighted average remaining contractualterm2. Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractualterm2 Weighted average remaining contractual term (in years), Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term (in years), Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Schedule of Basic and Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Computation of Diluted Net Loss per Share Schedule of common stock shares reserved for future issuance. Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block] Schedule of Common Stock Shares Reserved for Future Issuance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Award Type [Axis] Award Type Award Type [Domain] Award Type Restricted Stock [Member] Restricted Common Stock Restricted Stock Units (RSUs) [Member] Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Summary of Status of Restricted Common Stock and Restricted Stock Units Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of Recognized Stock-based Compensation Entity Incorporation, Date of Incorporation Date of incorporation Accounting Standards Update and Change in Accounting Principle [Table] New Accounting Pronouncements Or Change In Accounting Principle [Table] Accounting Standards Update [Axis] Accounting Standards Update Accounting Standards Update [Domain] Accounting Standards Update Accounting Standards Update 2019-12 [Member] Accounting Standards Update 2019-12 Accounting Standards Update 2018-15 [Member] Accounting Standards Update 2018-15 New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements Or Change In Accounting Principle [Line Items] Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change in accounting principle, accounting standards update, adopted Change in Accounting Principle, Accounting Standards Update, Adoption Date Change in accounting principle, accounting standards update, adoption date Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Change in accounting principle, accounting standards update, immaterial effect Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Investment Type [Axis] Investment Type Investments [Domain] Investments Money Market Funds [Member] Money Market Funds Short-term marketable securities. Short Term Marketable Securities [Member] Short-term Marketable Securities Long term marketable securities. Long Term Marketable Securities [Member] Long-term Marketable Securities Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Measurement Frequency [Axis] Measurement Frequency Measurement Frequency [Domain] Measurement Frequency Fair Value, Recurring [Member] Fair Value, Recurring Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Debt Securities, Available-for-sale, Amortized Cost Amortization Cost Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Loss Debt Securities, Available-for-sale Fair Market Value Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset [Axis] Software Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate intrinsic value, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value of stock options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Total grant date fair value of stock options vested Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Options vesting period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares, Unvested as of December 31, 2020 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares, Awarded Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Number of shares, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of shares, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average fair value, Unvested as of December 31, 2020 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value, Awarded Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted average fair value, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted average fair value, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total value of restricted stock awards, vested based on estimated fair value of stock Share-based compensation arrangement by share-based payment award, award vesting description. Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Description Vesting description Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Income Statement Location Research and Development Expense [Member] Research and Development General and Administrative Expense [Member] General and Administrative Share-based Payment Arrangement, Expense Stock-based compensation Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Total unrecognized stock-based compensation expense relating to unvested stock options, restricted stock awards and restricted stock units Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized unvested stock options, restricted stock awards and restricted stock units, weighted-average period Percentage of eligible employee compensation. Percentage Of Eligible Employee Compensation Percentage of eligible employee compensation Period for automatic increase in common stock available for future issuance. Income Tax Expense (Benefit), Total Gain (Loss) on Disposition of Assets, Total Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-based Payment Arrangement, Noncash Expense, Total Other Comprehensive Income (Loss), Net of Tax, Total Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Period For Automatic Increase In Common Stock Available For Future Issuance Period for automatic increase in common available for future issuance Employee Stock [Member] 2019 Employee Stock Purchase Plan Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Percentage of shares issued from outstanding number of shares Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Shares issued Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Statutory rate Deferred Federal, State and Local, Tax Expense (Benefit) Federal and state deferred tax benefits Contract with customer liability revenue recognized from commercialization milestones. Contract With Customer Liability Revenue Recognized From Commercialization Milestones Revenue recognized commercialization milestone payments to receive Revenue recognition potential commercial milestone payments eligible upon successful commercialization. Revenue Recognition Potential Commercial Milestone Payments Eligible Upon Successful Commercialization Potential commercial milestone payments eligible to receive upon successful commercialization Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] License and collaboration agreement. License And Collaboration Agreement [Member] License and Collaboration Agreement Statistical Measurement [Axis] Statistical Measurement Statistical Measurement [Domain] Statistical Measurement Minimum [Member] Minimum Maximum [Member] Maximum Counterparty Name [Axis] Counterparty Name Counterparty Name [Domain] Counterparty Name Astellas pharma limited liability company. Astellas Pharma Limited Liability Company [Member] Astellas Pharma LLC Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Phase 2b clinical trial. Number of shares, Unvested as of September 30, 2021 Weighted average exercise price, Options unvested as of September 30, 2021 Number of shares, Options exercisable as of September 30, 2021 Number of shares, Options unvested as of September 30, 2021 Weighted average exercise price, Options exercisable as of September 30, 2021 Aggregate intrinsic value, Outstanding as of September 30, 2021 Aggregate intrinsic value, Options exercisable as of September 30, 2021 Aggregate intrinsic value, Options unvested as of September 30, 2021 Weighted average remaining contractual term (in years), Options exercisable as of September 30, 2021 Weighted average remaining contractual term (in years), Options unvested as of September 30, 2021 Purchases of property and equipment in accounts payable and accrued expenses Proceeds from Employee Stock Purchase Plan Proceeds from Stock Plans Proceeds from Private Placement, net of issuance costs Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2021 and December 31, 2020, respectively Entity Central Index Key Entity Central Index Key Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Basis of Presentation Accounting Policies [Abstract] Accounting Standards Update and Change in Accounting Principle [Text Block] Recently Adopted and Issued Accounting Standards Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Payables and Accruals [Abstract] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Earnings Per Share [Abstract] Earnings Per Share [Text Block] Net Loss Per Share Equity [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Share-based Payment Arrangement [Abstract] Two Thousand And Nineteen Incentive Award Plan [Member] 2019 Plan Two thousand and fourteen stock incentive plan. Two Thousand And Fourteen Stock Incentive Plan [Member] Two Thousand And Fourteen Stock Incentive Plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of shares, Ending balance Number of shares, Beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of shares, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of shares, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price, Ending balance Debt Securities, Available-for-sale, Total Revenue from Contract with Customer, Excluding Assessed Tax, Total Depreciation, Total Additional Paid in Capital, Total Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Increase (Decrease) in Prepaid Expense and Other Assets, Total Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Research and Development Expense, Total Common Stock, Shares, Issued, Total General and Administrative Expense, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accounts Payable, Current, Total Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Realized Investment Gains (Losses), Total Foreign Currency Transaction Gain (Loss), before Tax, Total Loss Contingency Accrual, Beginning Balance Loss Contingency Accrual, Ending Balance Preferred Stock, Shares Issued, Total Phase2b Clinical Trial [Member] Phase 2b Clinical Trial Phase 3 clinical trail. Phase3 Clinical Trail [Member] Phase 3 Clinical Trial Geographical [Axis] Geographical Geographical [Domain] Geographical Europe [Member] Europe Asia [Member] Asia Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Proceeds from Collaborators Payments received under collaboration agreement Contract with Customer, Liability, Revenue Recognized Revenue recognized potential development milestone payments to receive Agreement termination notice period. Agreement Termination Notice Period Agreement termination notice period Right to terminate agreement if breach remains uncured. Right To Terminate Agreement If Breach Remains Uncured Right to terminate agreement if breach remains uncured Right to terminate agreement incase of nonpayment. Right To Terminate Agreement Incase Of Nonpayment Right to terminate agreement incase of nonpayment Revenue recognition transaction price. Revenue Recognition Transaction Price Transaction price allocated to single combined performance obligation Upfront fee recognized as revenue. Upfront Fee Recognized As Revenue Upfront fee recognized as revenue Accrued Royalties, Current Accrued upfront payment related to sub License revenue Royalty Expense Royalty License agreement entered date. License Agreement Entered Date License agreement entered date Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Finite-Lived Intangible Assets by Major Class [Axis] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] Description of future development obligations. Description Of Future Development Obligations Description of future development obligations License fee payment. License Fee Payment License fee payment Percentage of shares of common stock issued. Percentage Of Shares Of Common Stock Issued Percentage of shares of common stock issued Milestone payments. Milestone Payments Milestone payments Right to terminate agreement upon prior written notice. Right To Terminate Agreement Upon Prior Written Notice Right to terminate agreement upon prior written notice Description of conditions to terminate license agreement. Description Of Conditions To Terminate License Agreement Description of conditions to terminate license agreement Payment for Management Fee Payment to director Lessee, Lease, Description [Table] Lessee Lease Description [Table] Lexington Massachusetts facility. Lexington Massachusetts Facility [Member] Lexington Massachusetts Facility Lessee, Lease, Description [Line Items] Lessee Lease Description [Line Items] Long-term Purchase Commitment, Amount Commitment payments related to research Lessee, Operating Lease, Term of Contract Operating lease term Loss Contingency, Loss in Period Losses related to indemnification obligations Loss Contingency Accrual Legal contingencies, accruals recorded Loss Contingency, Damages Sought, Value Loss Contingency Damages Sought Value Proceeds from Sale and Maturity of Marketable Securities, Total Deferred Federal, State and Local, Tax Expense (Benefit), Total Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Interest Expense, Debt, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Employee-related Liabilities, Current, Total Increase (Decrease) in Accrued Liabilities, Total Payments to Acquire Marketable Securities, Total Earnings Per Share, Basic and Diluted, Total APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Debt Securities, Available-for-sale, Current, Total Payments to Acquire Property, Plant, and Equipment, Total Other Nonoperating Expense, Total Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Interest Expense, Total Other Liabilities, Noncurrent, Total Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Increase (Decrease) in Accounts Payable, Total Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance XML 11 freq-20210930_htm.xml IDEA: XBRL DOCUMENT 0001703647 2019-12-31 0001703647 freq:UnvestedRestrictedStockUnitsMember 2021-07-01 2021-09-30 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember freq:LicenseAndCollaborationAgreementMember 2019-07-01 2019-07-31 0001703647 us-gaap:EquipmentMember 2021-09-30 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember us-gaap:RoyaltyMember freq:MassachusettsInstituteOfTechnologyMember 2016-12-01 2016-12-31 0001703647 2021-11-08 0001703647 us-gaap:RestrictedStockMember 2021-09-30 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001703647 us-gaap:RestrictedStockMember 2020-12-31 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember freq:LicenseAndCollaborationAgreementMember 2021-01-01 2021-09-30 0001703647 freq:LoanAndSecurityAgreementMember 2020-12-11 0001703647 us-gaap:CommonStockMember 2021-06-30 0001703647 freq:TermLoanMember 2021-01-01 2021-09-30 0001703647 us-gaap:EmployeeStockMember 2021-01-01 2021-06-30 0001703647 freq:LexingtonMassachusettsFacilityMember 2021-09-30 0001703647 2021-07-01 2021-09-30 0001703647 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001703647 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001703647 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001703647 freq:OutstandingStockOptionsMember 2021-07-01 2021-09-30 0001703647 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001703647 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember freq:LicenseAndCollaborationAgreementMember 2019-07-01 2019-09-30 0001703647 us-gaap:RetainedEarningsMember 2021-06-30 0001703647 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001703647 freq:UnvestedRestrictedCommonStockMember 2020-07-01 2020-09-30 0001703647 srt:MaximumMember freq:MassachusettsInstituteOfTechnologyMember 2016-12-01 2016-12-31 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember srt:EuropeMember freq:Phase3ClinicalTrailMember freq:LicenseAndCollaborationAgreementMember 2019-07-01 2019-07-31 0001703647 freq:PatentLicenseAgreementMember freq:MassachusettsInstituteOfTechnologyMember 2016-12-01 2016-12-31 0001703647 srt:DirectorMember freq:MassachusettsInstituteOfTechnologyMember 2020-01-01 2020-12-31 0001703647 freq:OutstandingStockOptionsMember 2020-07-01 2020-09-30 0001703647 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001703647 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001703647 2014-01-01 2021-09-30 0001703647 us-gaap:FurnitureAndFixturesMember 2021-09-30 0001703647 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001703647 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001703647 us-gaap:EmployeeStockOptionMember 2020-12-31 0001703647 2021-01-01 2021-09-30 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2021-01-01 2021-09-30 0001703647 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember freq:LongTermMarketableSecuritiesMember 2021-09-30 0001703647 2020-01-01 2020-12-31 0001703647 us-gaap:ConstructionInProgressMember 2020-12-31 0001703647 freq:TermLoanMember freq:LoanAndSecurityAgreementMember 2020-12-11 2020-12-11 0001703647 freq:TermLoanMember freq:LoanAndSecurityAgreementMember 2020-12-11 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember srt:AsiaMember freq:Phase2bClinicalTrialMember freq:LicenseAndCollaborationAgreementMember 2019-07-01 2019-07-31 0001703647 us-gaap:CommonStockMember 2021-09-30 0001703647 freq:OutstandingStockOptionsMember 2020-01-01 2020-09-30 0001703647 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001703647 2020-12-31 0001703647 freq:MassachusettsInstituteOfTechnologyMember 2016-12-01 2016-12-31 0001703647 freq:OutstandingStockOptionsMember 2021-01-01 2021-09-30 0001703647 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001703647 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001703647 us-gaap:CommonStockMember 2020-06-30 0001703647 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001703647 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001703647 us-gaap:CommonStockMember 2019-12-31 0001703647 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001703647 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-07-20 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2021-01-01 2021-09-30 0001703647 2021-09-30 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001703647 us-gaap:RetainedEarningsMember 2021-09-30 0001703647 us-gaap:CommonStockMember 2020-12-31 0001703647 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001703647 us-gaap:EmployeeStockMember 2019-09-19 2019-09-20 0001703647 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember freq:ShortTermMarketableSecuritiesMember 2021-09-30 0001703647 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2021-09-30 0001703647 srt:DirectorMember freq:MassachusettsInstituteOfTechnologyMember 2021-07-01 2021-09-30 0001703647 us-gaap:StockCompensationPlanMember 2020-12-31 0001703647 us-gaap:StockCompensationPlanMember 2021-09-30 0001703647 freq:MassachusettsInstituteOfTechnologyMember 2021-01-01 2021-09-30 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember srt:AsiaMember freq:Phase3ClinicalTrailMember freq:LicenseAndCollaborationAgreementMember 2019-07-01 2019-07-31 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember freq:LicenseAndCollaborationAgreementMember 2021-09-30 0001703647 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001703647 us-gaap:AccountingStandardsUpdate201912Member 2021-09-30 0001703647 freq:PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember freq:TermLoanMember freq:LoanAndSecurityAgreementMember 2020-12-11 2020-12-11 0001703647 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0001703647 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001703647 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember freq:LicenseAndCollaborationAgreementMember 2019-07-01 2021-06-30 0001703647 2021-06-30 0001703647 us-gaap:RestrictedStockMember 2021-07-01 2021-09-30 0001703647 us-gaap:RetainedEarningsMember 2020-12-31 0001703647 freq:UnvestedRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001703647 us-gaap:CommonStockMember 2020-09-30 0001703647 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001703647 us-gaap:EmployeeStockMember 2021-09-30 0001703647 freq:PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember freq:TermLoanMember freq:LoanAndSecurityAgreementMember 2020-12-11 2020-12-11 0001703647 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-09-30 0001703647 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001703647 2020-01-01 2020-09-30 0001703647 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-09-30 0001703647 freq:TermLoanMember freq:LoanAndSecurityAgreementMember us-gaap:PrimeRateMember 2020-12-11 2020-12-11 0001703647 us-gaap:RetainedEarningsMember 2020-09-30 0001703647 us-gaap:RetainedEarningsMember 2019-12-31 0001703647 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001703647 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001703647 freq:UnvestedRestrictedCommonStockMember 2020-01-01 2020-09-30 0001703647 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2020-12-31 0001703647 us-gaap:AccountingStandardsUpdate201815Member 2021-09-30 0001703647 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001703647 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001703647 us-gaap:EquipmentMember 2020-12-31 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember srt:EuropeMember freq:Phase2bClinicalTrialMember freq:LicenseAndCollaborationAgreementMember 2019-07-01 2019-07-31 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2020-01-01 2020-12-31 0001703647 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001703647 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember srt:MaximumMember freq:LicenseAndCollaborationAgreementMember 2019-07-01 2019-07-31 0001703647 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001703647 2020-06-30 0001703647 us-gaap:ConstructionInProgressMember 2021-09-30 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2020-12-31 0001703647 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001703647 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001703647 srt:DirectorMember freq:MassachusettsInstituteOfTechnologyMember 2021-01-01 2021-09-30 0001703647 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001703647 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001703647 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001703647 freq:MassachusettsInstituteOfTechnologyMember 2016-12-31 0001703647 us-gaap:EmployeeStockOptionMember 2021-09-30 0001703647 freq:PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember freq:TermLoanMember freq:LoanAndSecurityAgreementMember 2020-12-11 2020-12-11 0001703647 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001703647 freq:AstellasPharmaLimitedLiabilityCompanyMember freq:LicenseAndCollaborationAgreementMember 2021-07-01 2021-09-30 0001703647 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-07-20 2020-07-20 0001703647 2020-07-01 2020-09-30 0001703647 2020-09-30 0001703647 freq:TermLoanMember 2021-07-01 2021-09-30 0001703647 us-gaap:RetainedEarningsMember 2020-06-30 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2021-09-30 pure iso4217:USD shares shares iso4217:USD true false true 2014-11-30 Q3 0001703647 true --12-31 true 10-Q true 2021-09-30 2021 false 001-39062 FREQUENCY THERAPEUTICS, INC. DE 47-2324450 75 Hayden Avenue Suite 300 Lexington MA 02421 781 315-4600 Common Stock, $0.001 par value per share FREQ NASDAQ Yes Yes Non-accelerated Filer true true false false 34602285 112034000 220341000 36040000 1835000 4723000 149909000 225064000 12397000 6232000 7287000 31921000 30551000 1726000 1820000 202185000 264722000 3607000 5506000 5197000 6663000 14068000 1681000 397000 10485000 26634000 29306000 30597000 15000000 15000000 278000 55069000 72231000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 200000000 200000000 34551875 34551875 33964000 33964000 35000 34000 305663000 287829000 3000 27000 -158585000 -95399000 147116000 192491000 202185000 264722000 11247000 14068000 27034000 15662000 10153000 48169000 25587000 9328000 6512000 28571000 18720000 24990000 16665000 76740000 44307000 -24990000 -5418000 -62672000 -17273000 172000 74000 315000 962000 182000 582000 -9000 -23000 65000 -4000 18000 16000 27000 139000 227000 -25152000 -5326000 -63173000 -16219000 3000 15000 13000 60000 -25155000 -5341000 -63186000 -16279000 -0.73 -0.16 -1.84 -0.51 34448746 33073889 34268736 31729702 -25155000 -5341000 -63186000 -16279000 -4000 -16000 -24000 -10000 -4000 -16000 -24000 -10000 -25159000 -5357000 -63210000 -16289000 30844507 31000 236161000 54000 -68888000 167358000 7218000 7218000 537675 1000 1161000 1162000 2350108 2000 40141000 40143000 -10000 -10000 -16279000 -16279000 33732290 34000 284681000 44000 -85167000 199592000 33964000 34000 287829000 27000 -95399000 192491000 16586000 16586000 7064 1000 60000 61000 582976 1188000 1188000 2165 -24000 -24000 -63186000 -63186000 34551875 35000 305663000 3000 -158585000 147116000 31249499 31000 241436000 60000 -79826000 161701000 2643000 2643000 132683 1000 461000 462000 2350108 2000 40141000 40143000 -16000 -16000 -5341000 -5341000 33732290 34000 284681000 44000 -85167000 199592000 34385916 34000 299429000 7000 -133430000 166040000 5886000 5886000 7064 1000 60000 61000 161060 288000 288000 2165 -4000 -4000 -25155000 -25155000 34551875 35000 305663000 3000 -158585000 147116000 -63186000 -16279000 16586000 7218000 2038000 760000 495000 256000 179000 -16000 -2888000 -985000 -1910000 2870000 -14068000 -27034000 -7000 -1202000 869000 -58171000 -30355000 2853000 2253000 66226000 17600000 17090000 -51479000 14837000 1188000 1162000 61000 40143000 1249000 41305000 -108401000 25787000 222161000 200259000 113760000 226046000 2163000 34000 24000 <p id="n1_organization_basis_presentation" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, and Frequency Therapeutics Securities Corporation, (the Company), headquartered in Lexington, Massachusetts, was incorporated in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_38bfb0ac-8eef-43ab-8ceb-0831564c0069;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 2014</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as a Delaware corporation. The Company is a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting Standards</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Codification (ASC).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements on Form 10-Q are consistent with those discussed in Note 2, “</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary of significant accounting policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,” in the Company’s Form 10-K.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unaudited interim financial information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated balance sheet as of September 30, 2021 and the consolidated statements of operations, the consolidated statements of comprehensive loss and the consolidated statements of stockholders’ equity (deficit) for the three and nine months ended September 30, 2021 and 2020, and the consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2021, the results of its operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2020 are also unaudited. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. The consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date. These unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Form 10-K.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting Standards</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Codification (ASC).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements on Form 10-Q are consistent with those discussed in Note 2, “</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary of significant accounting policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,” in the Company’s Form 10-K.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unaudited interim financial information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated balance sheet as of September 30, 2021 and the consolidated statements of operations, the consolidated statements of comprehensive loss and the consolidated statements of stockholders’ equity (deficit) for the three and nine months ended September 30, 2021 and 2020, and the consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2021, the results of its operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2020 are also unaudited. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. The consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date. These unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Form 10-K.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Recently adopted and issued accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently adopted accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0d3fabd-4b5c-42cc-94bc-b599797c4249;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the standard on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and it did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_284e49fe-62b0-496e-b45d-a81598009bcc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have a significant impact on its consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently issued accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments - Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.</span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This new guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. ASU 2018-15 generally aligns the guidance on recognizing implementation costs incurred to develop or obtain internal use software, which includes hosting arrangements that include an internal-use software license. This standard will become </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1233df5-3c9c-406e-993b-ae5899790706;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effective</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the Company for the 2021 annual financial statements. The Company is still evaluating the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_15ea78b3-db07-48d6-8830-f772b82e700e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impact</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this standard on its consolidated financial statements. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently adopted accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0d3fabd-4b5c-42cc-94bc-b599797c4249;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the standard on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and it did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_284e49fe-62b0-496e-b45d-a81598009bcc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have a significant impact on its consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently issued accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments - Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.</span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This new guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. ASU 2018-15 generally aligns the guidance on recognizing implementation costs incurred to develop or obtain internal use software, which includes hosting arrangements that include an internal-use software license. This standard will become </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1233df5-3c9c-406e-993b-ae5899790706;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effective</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the Company for the 2021 annual financial statements. The Company is still evaluating the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_15ea78b3-db07-48d6-8830-f772b82e700e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impact</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this standard on its consolidated financial statements. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 2021-01-01 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Fair value measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:-10.154%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 Quoted prices in active markets for identical assets or liabilities.</span></p><p style="margin-left:4.533%;text-indent:-10.154%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></p><p style="margin-left:4.533%;text-indent:-10.154%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 and December 31, 2020 are summarized as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.692%;"/> <td style="width:1.212%;"/> <td style="width:12.87%;"/> <td style="width:1.212%;"/> <td style="width:1.63%;"/> <td style="width:10.932%;"/> <td style="width:0.944%;"/> <td style="width:1.212%;"/> <td style="width:1.62%;"/> <td style="width:10.912%;"/> <td style="width:0.994%;"/> <td style="width:1.212%;"/> <td style="width:1.62%;"/> <td style="width:10.972%;"/> <td style="width:0.964%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortization</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Hierarchy</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,060</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,040</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,401</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,397</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,400</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,376</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.595%;"/> <td style="width:1.312%;"/> <td style="width:12.826%;"/> <td style="width:1.312%;"/> <td style="width:1.76%;"/> <td style="width:10.986%;"/> <td style="width:1.054%;"/> <td style="width:1.312%;"/> <td style="width:1.75%;"/> <td style="width:10.907%;"/> <td style="width:1.074%;"/> <td style="width:1.312%;"/> <td style="width:1.75%;"/> <td style="width:10.976%;"/> <td style="width:1.074%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="10" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortization</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Hierarchy</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gain</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214,522</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214,549</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214,522</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214,549</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values.</span></p> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 and December 31, 2020 are summarized as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.692%;"/> <td style="width:1.212%;"/> <td style="width:12.87%;"/> <td style="width:1.212%;"/> <td style="width:1.63%;"/> <td style="width:10.932%;"/> <td style="width:0.944%;"/> <td style="width:1.212%;"/> <td style="width:1.62%;"/> <td style="width:10.912%;"/> <td style="width:0.994%;"/> <td style="width:1.212%;"/> <td style="width:1.62%;"/> <td style="width:10.972%;"/> <td style="width:0.964%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortization</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Hierarchy</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,939</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,060</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,040</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,401</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,397</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,400</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,376</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.595%;"/> <td style="width:1.312%;"/> <td style="width:12.826%;"/> <td style="width:1.312%;"/> <td style="width:1.76%;"/> <td style="width:10.986%;"/> <td style="width:1.054%;"/> <td style="width:1.312%;"/> <td style="width:1.75%;"/> <td style="width:10.907%;"/> <td style="width:1.074%;"/> <td style="width:1.312%;"/> <td style="width:1.75%;"/> <td style="width:10.976%;"/> <td style="width:1.074%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="10" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortization</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Hierarchy</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gain</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214,522</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214,549</span></p></td> <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214,522</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214,549</span></p></td> <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span> </p></td> </tr> </table> 65939000 65939000 36060000 20000 36040000 12401000 4000 12397000 114400000 24000 114376000 214522000 27000 214549000 214522000 27000 214549000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Property and equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.372%;"/> <td style="width:1.402%;"/> <td style="width:1.63%;"/> <td style="width:12.793%;"/> <td style="width:0.994%;"/> <td style="width:1.402%;"/> <td style="width:1.63%;"/> <td style="width:12.783%;"/> <td style="width:0.994%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,107</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,166</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,220</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">283</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">291</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">291</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,419</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,340</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,679</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,499</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,447</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,212</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,232</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,287</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">735</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,038</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">301</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">760</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of depreciation expense for the three and nine months ended September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.372%;"/> <td style="width:1.402%;"/> <td style="width:1.63%;"/> <td style="width:12.793%;"/> <td style="width:0.994%;"/> <td style="width:1.402%;"/> <td style="width:1.63%;"/> <td style="width:12.783%;"/> <td style="width:0.994%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,107</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,166</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,220</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">283</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">291</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">291</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,419</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,340</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,679</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,499</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated depreciation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,447</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,212</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,232</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,287</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 6107000 4166000 3220000 283000 291000 291000 1419000 61000 4340000 9679000 10499000 3447000 3212000 6232000 7287000 735000 2038000 301000 760000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Accrued expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.67%;"/> <td style="width:1.382%;"/> <td style="width:1.63%;"/> <td style="width:12.684%;"/> <td style="width:0.954%;"/> <td style="width:1.402%;"/> <td style="width:1.63%;"/> <td style="width:12.694%;"/> <td style="width:0.954%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and employee related expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,522</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,062</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">666</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">647</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">766</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">874</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Taxes and other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">243</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,197</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,663</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.67%;"/> <td style="width:1.382%;"/> <td style="width:1.63%;"/> <td style="width:12.684%;"/> <td style="width:0.954%;"/> <td style="width:1.402%;"/> <td style="width:1.63%;"/> <td style="width:12.694%;"/> <td style="width:0.954%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and employee related expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,522</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,062</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">666</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">647</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">766</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">874</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Taxes and other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">243</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,197</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,663</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 3522000 5062000 666000 647000 766000 874000 243000 80000 5197000 6663000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Debt</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 11, 2020 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with a commercial bank for a term loan with a principal balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will make </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">monthly</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> interest only payments through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 30, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 1, 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the “Loan Maturity Date”)</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% plus the Prime Rate (as reported in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> The Wall Street Journal</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, subject to an interest rate floor of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) or (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. The interest rate at September 30, 2021 was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, resulting in interest expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">182</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">582</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the three and nine months ended September 30, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the borrowings under the Loan Agreement are refinanced by the bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will pay a final payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which will occur on the earliest of: (i) the Loan Maturity Date; (ii) the date that the Company prepays all of the outstanding principal in full; (iii) the date the loan payments are accelerated due to an event of default; or (iv) the termination of the Loan Agreement. The Company is accruing the final payment as interest expense over the term of the loan. The term loan is secured by substantially all of the Company’s assets, excluding intellectual property.</span></p> 15000000 The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”) monthly 2022-11-30 2024-05-01 0.0150 0 0.0475 0.0475 182000 582000 0.020 0.010 0.000 150000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Net loss per share</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the three and nine months ended September 30, 2021 and 2020 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.946%;"/> <td style="width:0.933%;"/> <td style="width:1.673%;"/> <td style="width:9.35%;"/> <td style="width:1.024%;"/> <td style="width:0.933%;"/> <td style="width:1.673%;"/> <td style="width:9.37%;"/> <td style="width:1.024%;"/> <td style="width:0.933%;"/> <td style="width:1.673%;"/> <td style="width:9.37%;"/> <td style="width:1.024%;"/> <td style="width:0.974%;"/> <td style="width:1.673%;"/> <td style="width:9.401%;"/> <td style="width:1.024%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended <br/>September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended <br/>September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net Loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,155</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,186</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,279</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares of common stock outstanding-<br/>   basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,448,746</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,073,889</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,268,736</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,729,702</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders-<br/>   basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.73</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.84</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.51</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.806%;"/> <td style="width:1.362%;"/> <td style="width:1.004%;"/> <td style="width:13.218%;"/> <td style="width:1.004%;"/> <td style="width:1.362%;"/> <td style="width:1.004%;"/> <td style="width:13.238%;"/> <td style="width:1.004%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three and Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,557</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">698,300</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding stock options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,279,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,753,568</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,977,699</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,757,125</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div> <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period</span><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.946%;"/> <td style="width:0.933%;"/> <td style="width:1.673%;"/> <td style="width:9.35%;"/> <td style="width:1.024%;"/> <td style="width:0.933%;"/> <td style="width:1.673%;"/> <td style="width:9.37%;"/> <td style="width:1.024%;"/> <td style="width:0.933%;"/> <td style="width:1.673%;"/> <td style="width:9.37%;"/> <td style="width:1.024%;"/> <td style="width:0.974%;"/> <td style="width:1.673%;"/> <td style="width:9.401%;"/> <td style="width:1.024%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended <br/>September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended <br/>September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net Loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,155</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,341</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,186</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,279</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares of common stock outstanding-<br/>   basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,448,746</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,073,889</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,268,736</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,729,702</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders-<br/>   basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.73</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.84</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.51</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> -25155000 -5341000 -63186000 -16279000 34448746 33073889 34268736 31729702 -0.73 -0.16 -1.84 -0.51 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.806%;"/> <td style="width:1.362%;"/> <td style="width:1.004%;"/> <td style="width:13.218%;"/> <td style="width:1.004%;"/> <td style="width:1.362%;"/> <td style="width:1.004%;"/> <td style="width:13.238%;"/> <td style="width:1.004%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three and Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,557</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">698,300</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding stock options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,279,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,753,568</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,977,699</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,757,125</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 3557 3557 698300 698300 7279399 7279399 6753568 6753568 7977699 7977699 6757125 6757125 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Stockholders’ equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Capital stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has authorized </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> par value preferred stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> par value common stock. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,551,875</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,964,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 and December 31, 2020, respectively. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has reserved the following shares of common stock for future issuance as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 and December 31, 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.164%;"/> <td style="width:1.481%;"/> <td style="width:1.004%;"/> <td style="width:12.93%;"/> <td style="width:1.004%;"/> <td style="width:1.481%;"/> <td style="width:1.004%;"/> <td style="width:12.93%;"/> <td style="width:1.004%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,279,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,816,798</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future grant under incentive plans</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,090,606</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,475,923</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,370,005</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,292,721</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Private placement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 20, 2020, the Company issued and sold an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,350,108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share (the “Shares”), at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share to new and existing investors in a private placement for net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after deducting placement agent fees and offering expenses (the “Private Placement”). In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within 60 days after the closing of the Private Placement (the “Initial Filing Date”) for purposes of registering the resale of the Shares. The Company filed a registration statement (the “Registration Statement”) to register the Shares, which was declared effective by the SEC on September 3, 2020.</span></p> 10000000 0.001 200000000 0.001 0 34551875 34551875 33964000 33964000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has reserved the following shares of common stock for future issuance as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 and December 31, 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.164%;"/> <td style="width:1.481%;"/> <td style="width:1.004%;"/> <td style="width:12.93%;"/> <td style="width:1.004%;"/> <td style="width:1.481%;"/> <td style="width:1.004%;"/> <td style="width:12.93%;"/> <td style="width:1.004%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,279,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,816,798</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future grant under incentive plans</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,090,606</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,475,923</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,370,005</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,292,721</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 7279399 6816798 1090606 1475923 8370005 8292721 2350108 0.001 18.00 40100000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The below summary includes stock option activity within the Company’s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the nine months ended September 30, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.583%;"/> <td style="width:1.322%;"/> <td style="width:0.964%;"/> <td style="width:9.304%;"/> <td style="width:0.994%;"/> <td style="width:1.322%;"/> <td style="width:1.63%;"/> <td style="width:9.254%;"/> <td style="width:0.964%;"/> <td style="width:1.322%;"/> <td style="width:0.974%;"/> <td style="width:13.211%;"/> <td style="width:0.964%;"/> <td style="width:1.322%;"/> <td style="width:1.63%;"/> <td style="width:9.274%;"/> <td style="width:0.964%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>average<br/>exercise</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted average<br/>remaining contractual<br/>term</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>intrinsic</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">in Plans</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,816,798</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.45</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,415</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,343,376</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.04</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.65</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">582,976</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.04</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,369</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">297,799</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.85</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,279,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.55</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.71</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,138</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of September 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,702,862</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.13</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.36</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,197</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options unvested as of September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,576,537</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.07</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,942</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock option valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employees and directors were as follows, presented on a weighted average basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:75.778%;"/> <td style="width:1.663%;"/> <td style="width:1.336%;"/> <td style="width:17.2%;"/> <td style="width:4.023%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.8</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value of options granted during the three and nine months ended September 30, 2021 and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.64</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.57</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total grant date fair value of options vested during the three and nine months ended September 30, 2021 and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,418</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,231</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,406</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,751</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted common stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company issued common stock to founders, employees and advisors which was subject to vesting over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the status of restricted common stock as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 is presented below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.769%;"/> <td style="width:1.431%;"/> <td style="width:0.984%;"/> <td style="width:12.873%;"/> <td style="width:1.004%;"/> <td style="width:1.431%;"/> <td style="width:1.64%;"/> <td style="width:12.873%;"/> <td style="width:0.994%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>average fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested, December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.75</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awarded</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">928</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.75</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,165</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.75</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total value of restricted stock awards that vested during the three and nine months ended September 30, 2021 and 2020, based on estimated fair values of the stock underlying the restricted stock awards was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted stock units</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, the Company issued restricted stock units to employees which will </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">vest in equal installments in the first quarter of 2022 and the third quarter of 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the status of restricted stock units as of September 30, 2021 is presented below:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.809%;"/> <td style="width:1.431%;"/> <td style="width:0.974%;"/> <td style="width:12.873%;"/> <td style="width:1.004%;"/> <td style="width:1.431%;"/> <td style="width:1.63%;"/> <td style="width:12.853%;"/> <td style="width:0.994%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>average fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested, December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awarded</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">800,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.54</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101,700</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.54</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">698,300</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.54</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.215%;"/> <td style="width:1.034%;"/> <td style="width:1.62%;"/> <td style="width:9.026%;"/> <td style="width:0.934%;"/> <td style="width:1.034%;"/> <td style="width:1.62%;"/> <td style="width:9.056%;"/> <td style="width:0.934%;"/> <td style="width:1.153%;"/> <td style="width:1.62%;"/> <td style="width:9.056%;"/> <td style="width:0.934%;"/> <td style="width:1.153%;"/> <td style="width:1.62%;"/> <td style="width:9.056%;"/> <td style="width:0.934%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended <br/>September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended <br/>September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,774</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,036</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,393</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,039</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,112</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,607</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,193</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,179</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,886</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,643</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,218</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, total unrecognized stock-based compensation expense relating to unvested stock options, restricted stock awards, and restricted stock units was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,901</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This amount is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.64</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The below summary includes stock option activity within the Company’s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the nine months ended September 30, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.583%;"/> <td style="width:1.322%;"/> <td style="width:0.964%;"/> <td style="width:9.304%;"/> <td style="width:0.994%;"/> <td style="width:1.322%;"/> <td style="width:1.63%;"/> <td style="width:9.254%;"/> <td style="width:0.964%;"/> <td style="width:1.322%;"/> <td style="width:0.974%;"/> <td style="width:13.211%;"/> <td style="width:0.964%;"/> <td style="width:1.322%;"/> <td style="width:1.63%;"/> <td style="width:9.274%;"/> <td style="width:0.964%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>average<br/>exercise</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted average<br/>remaining contractual<br/>term</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>intrinsic</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">in Plans</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,816,798</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.45</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,415</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,343,376</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.04</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.65</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">582,976</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.04</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,369</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">297,799</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.85</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,279,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.55</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.71</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,138</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of September 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,702,862</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.13</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.36</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,197</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options unvested as of September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,576,537</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.07</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,942</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 6816798 10.11 P8Y5M12D 171415000 1343376 33.04 P8Y7M24D 582976 2.04 11369000 297799 20.85 7279399 14.55 P7Y8M15D 13138000 3702862 9.13 P7Y4M9D 10197000 3576537 20.16 P8Y25D 2942000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employees and directors were as follows, presented on a weighted average basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:75.778%;"/> <td style="width:1.663%;"/> <td style="width:1.336%;"/> <td style="width:17.2%;"/> <td style="width:4.023%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.8</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table> 0.005 P6Y 0.798 0.000 5.64 22.57 14.02 15.73 3418000 12231000 2406000 5751000 P4Y <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the status of restricted common stock as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 is presented below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.769%;"/> <td style="width:1.431%;"/> <td style="width:0.984%;"/> <td style="width:12.873%;"/> <td style="width:1.004%;"/> <td style="width:1.431%;"/> <td style="width:1.64%;"/> <td style="width:12.873%;"/> <td style="width:0.994%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>average fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested, December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.75</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awarded</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">928</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.75</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,165</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.75</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 3093 1.75 928 1.75 2165 1.75 0 0 0 2000 1000 19000 vest in equal installments in the first quarter of 2022 and the third quarter of 2022 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the status of restricted stock units as of September 30, 2021 is presented below:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.809%;"/> <td style="width:1.431%;"/> <td style="width:0.974%;"/> <td style="width:12.873%;"/> <td style="width:1.004%;"/> <td style="width:1.431%;"/> <td style="width:1.63%;"/> <td style="width:12.853%;"/> <td style="width:0.994%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>average fair<br/>value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested, December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awarded</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">800,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.54</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101,700</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.54</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">698,300</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.54</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 0 0 800000 9.54 101700 9.54 698300 9.54 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.215%;"/> <td style="width:1.034%;"/> <td style="width:1.62%;"/> <td style="width:9.026%;"/> <td style="width:0.934%;"/> <td style="width:1.034%;"/> <td style="width:1.62%;"/> <td style="width:9.056%;"/> <td style="width:0.934%;"/> <td style="width:1.153%;"/> <td style="width:1.62%;"/> <td style="width:9.056%;"/> <td style="width:0.934%;"/> <td style="width:1.153%;"/> <td style="width:1.62%;"/> <td style="width:9.056%;"/> <td style="width:0.934%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended <br/>September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended <br/>September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,774</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,036</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,393</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,039</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,112</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,607</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,193</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,179</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,886</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,643</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,586</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,218</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 2774000 1036000 7393000 3039000 3112000 1607000 9193000 4179000 5886000 2643000 16586000 7218000 46901000 P2Y7M20D <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Employee stock purchase plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 20, 2019, the Company’s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the “ESPP”) which became effective on the date of the Company’s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible compensation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of the Company’s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. The Company’s first offering period of 2021 concluded on June 30, 2021 with the purchase of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,064</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares in July 2021 related to this offering period. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">956,021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remain for future offering periods.</span> 0.15 P10Y 0.01 7064 956021 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s total provision is based on the United States statutory rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, increased by state taxes and reduced by a full valuation allowance on the Company’s deferred tax assets. The income tax expense </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the three and nine months ended September 30, 2021 and 2020 represents state taxes on interest income earned by the Company’s subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at September 30, 2021 and December 31, 2020 because the Company’s management has determined that it is more likely than not that the Company will </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> net tax benefit has been recorded due to uncertainty around utilizing these tax attributes within the respective carryforward periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 0.21 0.21 0 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Collaboration agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the “Astellas Agreement”), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the “Astellas Licensed Products”), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3108333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These parties have agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The collaboration is governed by a joint steering committee (“JSC”) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party’s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in July 2019 and has agreed to pay potential development milestone payments up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">230,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and commercialization milestones of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">315,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Specifically, the Company would receive development milestone payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">315,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days’ written notice. Each party has the right to terminate the Astellas Agreement due to the other party’s material breach if such breach remains uncured for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days in the case of nonpayment) or if the other party becomes bankrupt.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The Company determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and continued until the completion of the Phase 2a clinical trial of FX-322 (FX-322-202). The transaction price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was allocated to the single combined performance obligation and recognized over such period. At commencement and throughout the trial, management analyzed the progress of the Phase 2a clinical trial (FX-322-202) and estimated the completion date of such trial and the total research and development costs it expects to incur in performing the trial to be June 30, 2021. As such, the Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> upfront fee as revenue over the period from July 2019 until June 30, 2021, the completion date of the Phase 2a clinical trial (FX-322-202), using the input method. The Company was required to pay MIT a royalty of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on the $80,000 of sublicense revenues. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> royalty was expensed in the third quarter of 2019. For a description of the MIT License Agreement, refer to Note 13.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and was recognized as revenue according to the policy described above. As of June 30, 2021, the Company completed its performance obligation with respect to the upfront payment and, accordingly, recognized all remaining revenue related to the Astellas Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee’s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statements of operations during the development period. In the three and nine months ended September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company invoiced Astellas $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">229</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">741</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for joint costs.</span></p> 80000000 230000000 315000000 65000000 25000000 100000000 40000000 315000000 P60D P90D P45D 80000000 80000000 16000000 16000000 80000000 229000 741000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Massachusetts Institute of Technology</span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 2016</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company entered into an exclusive patent license agreement (MIT License Agreement) with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement.</span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">research </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s future development obligations are: (i) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product, (ii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii) to make a first commercial sale of such Product within 11 years of the IND filing for such Product.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company also has certain development obligations for a second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fails to cure such breach within ninety (90) days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations.</span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon entering into the MIT License Agreement, the Company paid a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> license fee payment and issued to MIT shares of our common stock equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,900</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related to the upfront payment received from Astellas, see Note 12.</span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents, including filed patent applications licensed thereunder, unless terminated earlier. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the right to terminate for any reason upon a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) days (or thirty (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.</span></span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Pursuant to MIT’s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,980</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from MIT under the MIT Policy during the year ended December 31, 2020.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Dr. Langer received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from MIT under the MIT Policy during the three and nine months ended September 30, 2021.</span></p> 2016-12 The Company’s future development obligations are: (i) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product, (ii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii) to make a first commercial sale of such Product within 11 years of the IND filing for such Product. 50000 0.05 2900000 16000000 The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. P3M P90D P30D 1980000 6000 6000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Commitments and contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contract commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> through December 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also enters into contracts in the normal course of business with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Guarantees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Guarantees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases office space in Lexington, Massachusetts under a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> noncancelable operating lease. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,726</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> security deposit for this lease is classified as restricted cash as of September 30, 2021. The Company exited its Woburn, Massachusetts facility in the second quarter of 2021. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company’s accrued liabilities would be recorded in the period in which such determination is made.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 3, 2021 and June 22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company entitled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Evans v. Frequency Therapeutics, Inc. et al.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Hingston v. Frequency Therapeutics, Inc. et al.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">respectively. The lawsuits allege violations of Section 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended, due to allegedly false and misleading statements and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">omissions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">about the Company’s Phase 2a clinical trial (FX-322-202) for its product candidate FX-322 in the Company’s public disclosures between November 16, 2020 and March 22, 2021. The lawsuits seek, among other things, damages in connection with the Company’s allegedly artificially inflated stock price between November 16, 2020 and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys’ fees and costs. These matters are at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company is vigorously defending against all claims asserted in both lawsuits. The Company has not yet filed a responsive pleading. Since an estimate of the possible loss or range of loss cannot be made at this time, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accruals have been recorded as of September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 23, 2021, two purported stockholders of the Company filed a lawsuit in the Court of Chancery of the State of Delaware against (i) the Company, (ii) the Company’s Chief Executive Officer, President, and Director, David Lucchino, (iii) Computershare Inc., and (iv) Computershare Trust Company, N.A., entitled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The Gregory J. Parseghian Revocable Trust</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">et al.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> v. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Frequency Therapeutics, Inc., et al. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The lawsuit alleges causes of action against the Company of conversion and unjust enrichment, and against Mr. Lucchino for breach of the fiduciary duty of loyalty, due to allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The lawsuit seeks monetary damages, as well as interest, attorneys’ fees and costs, against all defendants. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. We are vigorously defending against all claims asserted and have filed a motion to dismiss the complaint. Since an estimate of the possible loss or range of loss cannot be made at this time, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accruals have been recorded as of September 30, 2021.</span></p> 600000 P10Y 1726000 0 0 0 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2021
Nov. 08, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001703647  
Entity File Number 001-39062  
Entity Registrant Name FREQUENCY THERAPEUTICS, INC.  
Entity Incorporation State Country Code DE  
Entity Tax Identification Number 47-2324450  
Entity Address Address Line 75 Hayden Avenue  
Entity Address, Address Line Two Suite 300  
Entity Address City Or Town Lexington  
Entity Address Postal Zip Code 02421  
Entity Address State Or Province MA  
City Area Code 781  
Local Phone Number 315-4600  
Title of 12(b) Security Common Stock, $0.001 par value per share  
Trading Symbol FREQ  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   34,602,285
Document Quarterly Report true  
Document Transition Report false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 112,034 $ 220,341
Short-term marketable securities 36,040  
Prepaid expenses and other current assets 1,835 4,723
Total current assets 149,909 225,064
Long-term marketable securities 12,397  
Property and equipment, net 6,232 7,287
Right of use assets 31,921 30,551
Restricted cash 1,726 1,820
Total assets 202,185 264,722
Current liabilities:    
Accounts payable 3,607 5,506
Accrued expenses 5,197 6,663
Deferred revenue   14,068
Lease liabilities 1,681 397
Total current liabilities 10,485 26,634
Lease liabilities, net of current portion 29,306 30,597
Term loan 15,000 15,000
Other long-term liabilities 278  
Total liabilities 55,069 72,231
Stockholders’ equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2021 and December 31, 2020, respectively
Common stock, $0.001 par value; 200,000,000 shares authorized, 34,551,875 and 33,964,000 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively 35 34
Additional paid-in capital 305,663 287,829
Accumulated other comprehensive income 3 27
Accumulated deficit (158,585) (95,399)
Total stockholders’ equity 147,116 192,491
Total liabilities and stockholders’ equity $ 202,185 $ 264,722
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, authorized shares 10,000,000 10,000,000
Preferred stock, issued shares 0 0
Preferred stock, outstanding shares 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, authorized shares 200,000,000 200,000,000
Common stock, issued shares 34,551,875 33,964,000
Common stock, outstanding shares 34,551,875 33,964,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Revenue   $ 11,247,000 $ 14,068,000 $ 27,034,000
Operating expenses:        
Research and development $ 15,662,000 10,153,000 48,169,000 25,587,000
General and administrative 9,328,000 6,512,000 28,571,000 18,720,000
Total operating expenses 24,990,000 16,665,000 76,740,000 44,307,000
Loss from operations (24,990,000) (5,418,000) (62,672,000) (17,273,000)
Interest income 172,000 74,000 315,000 962,000
Interest (expense) (182,000)   (582,000)  
Realized (loss) gain on investments (9,000)   (23,000) 65,000
Foreign exchange (loss) gain (4,000) 18,000 16,000 27,000
Other (expense), net (139,000)   (227,000)  
Loss before income taxes (25,152,000) (5,326,000) (63,173,000) (16,219,000)
Income taxes (3,000) (15,000) (13,000) (60,000)
Net loss $ (25,155,000) $ (5,341,000) $ (63,186,000) $ (16,279,000)
Net loss per share attributable to common stockholders-basic and diluted $ (0.73) $ (0.16) $ (1.84) $ (0.51)
Weighted-average shares of common stock outstanding-basic and diluted 34,448,746 33,073,889 34,268,736 31,729,702
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net loss $ (25,155) $ (5,341) $ (63,186) $ (16,279)
Other comprehensive (loss) gain:        
Unrealized (loss) on marketable securities (4) (16) (24) (10)
Total other comprehensive (loss) gain (4) (16) (24) (10)
Comprehensive loss $ (25,159) $ (5,357) $ (63,210) $ (16,289)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional-paid in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Beginning Balance at Dec. 31, 2019 $ 167,358 $ 31 $ 236,161 $ 54 $ (68,888)
Beginning Balance (in shares) at Dec. 31, 2019   30,844,507      
Stock-based compensation expense 7,218   7,218    
Issuance of common stock upon exercise of stock options 1,162 $ 1 1,161    
Issuance of common stock upon exercise of options (in shares)   537,675      
Issuance of common stock in Private Placement, net 40,143 $ 2 40,141    
Issuance of common stock in Private Placement, net (in shares)   2,350,108      
Other comprehensive (loss) (10)     (10)  
Net loss (16,279)       (16,279)
Ending Balance at Sep. 30, 2020 199,592 $ 34 284,681 44 (85,167)
Ending Balance (in shares) at Sep. 30, 2020   33,732,290      
Beginning Balance at Jun. 30, 2020 161,701 $ 31 241,436 60 (79,826)
Beginning Balance (in shares) at Jun. 30, 2020   31,249,499      
Stock-based compensation expense 2,643   2,643    
Issuance of common stock upon exercise of stock options 462 $ 1 461    
Issuance of common stock upon exercise of options (in shares)   132,683      
Issuance of common stock in Private Placement, net 40,143 $ 2 40,141    
Issuance of common stock in Private Placement, net (in shares)   2,350,108      
Other comprehensive (loss) (16)     (16)  
Net loss (5,341)       (5,341)
Ending Balance at Sep. 30, 2020 199,592 $ 34 284,681 44 (85,167)
Ending Balance (in shares) at Sep. 30, 2020   33,732,290      
Beginning Balance at Dec. 31, 2020 $ 192,491 $ 34 287,829 27 (95,399)
Beginning Balance (in shares) at Dec. 31, 2020 33,964,000 33,964,000      
Stock-based compensation expense $ 16,586   16,586    
Purchase under Employee Stock Purchase Plan 61 $ 1 60    
Purchase under Employee Stock Purchase Plan (in shares)   7,064      
Issuance of common stock upon exercise of stock options 1,188   1,188    
Issuance of common stock upon exercise of options (in shares)   582,976      
Forfeiture of restricted stock (in shares)   (2,165)      
Other comprehensive (loss) (24)     (24)  
Net loss (63,186)       (63,186)
Ending Balance at Sep. 30, 2021 $ 147,116 $ 35 305,663 3 (158,585)
Ending Balance (in shares) at Sep. 30, 2021 34,551,875 34,551,875      
Beginning Balance at Jun. 30, 2021 $ 166,040 $ 34 299,429 7 (133,430)
Beginning Balance (in shares) at Jun. 30, 2021   34,385,916      
Stock-based compensation expense 5,886   5,886    
Purchase under Employee Stock Purchase Plan 61 $ 1 60    
Purchase under Employee Stock Purchase Plan (in shares)   7,064      
Issuance of common stock upon exercise of stock options 288   288    
Issuance of common stock upon exercise of options (in shares)   161,060      
Forfeiture of restricted stock (in shares)   (2,165)      
Other comprehensive (loss) (4)     (4)  
Net loss (25,155)       (25,155)
Ending Balance at Sep. 30, 2021 $ 147,116 $ 35 $ 305,663 $ 3 $ (158,585)
Ending Balance (in shares) at Sep. 30, 2021 34,551,875 34,551,875      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (63,186) $ (16,279)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Stock-based compensation 16,586 7,218
Depreciation expense 2,038 760
Non-cash lease expense 495 256
Non-cash interest expense 179  
Loss on disposal of assets 16  
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 2,888 985
Accounts payable (1,910) 2,870
Deferred revenue (14,068) (27,034)
Lease liabilities (7)  
Accrued expenses (1,202) 869
Net cash (used in) operating activities (58,171) (30,355)
Cash flows from investing activities:    
Purchases of property and equipment (2,853) (2,253)
Purchase of marketable securities (66,226)  
Redemption of marketable securities 17,600 17,090
Net cash (used in) provided by investing activities (51,479) 14,837
Cash flows from financing activities:    
Proceeds from issuance of common stock upon exercise of stock options 1,188 1,162
Proceeds from Employee Stock Purchase Plan 61  
Proceeds from Private Placement, net of issuance costs   40,143
Net cash provided by financing activities 1,249 41,305
Net (decrease) increase in cash, cash equivalents and restricted cash (108,401) 25,787
Cash, cash equivalents, and restricted cash at beginning of period 222,161 200,259
Cash, cash equivalents, and restricted cash at end of period 113,760 226,046
Non-cash items:    
Right-of-use assets in exchange for lease liabilities   2,163
Purchases of property and equipment in accounts payable and accrued expenses $ 34 $ 24
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Basis of Presentation
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Basis of Presentation

1. Organization and basis of presentation

 

Organization

Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, and Frequency Therapeutics Securities Corporation, (the Company), headquartered in Lexington, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function.

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC).

Principles of consolidation

The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements on Form 10-Q are consistent with those discussed in Note 2, “Summary of significant accounting policies,” in the Company’s Form 10-K.

Unaudited interim financial information

The accompanying consolidated balance sheet as of September 30, 2021 and the consolidated statements of operations, the consolidated statements of comprehensive loss and the consolidated statements of stockholders’ equity (deficit) for the three and nine months ended September 30, 2021 and 2020, and the consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2021, the results of its operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2020 are also unaudited. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. The consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date. These unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Form 10-K. 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Recently Adopted And Issued Accounting Standards
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Recently Adopted and Issued Accounting Standards

2. Recently adopted and issued accounting standards

 

Recently adopted accounting standards

In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. The Company adopted the standard on January 1, 2021 and it did not have a significant impact on its consolidated financial statements.

Recently issued accounting standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This new guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. ASU 2018-15 generally aligns the guidance on recognizing implementation costs incurred to develop or obtain internal use software, which includes hosting arrangements that include an internal-use software license. This standard will become effective for the Company for the 2021 annual financial statements. The Company is still evaluating the impact of this standard on its consolidated financial statements.  

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

3. Fair value measurements

Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:

Level 1 Quoted prices in active markets for identical assets or liabilities.

Level 2 Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3 Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy at September 30, 2021 and December 31, 2020 are summarized as follows:

 

 

 

 

 

September 30, 2021

 

 

 

Fair Value

 

Amortization

 

 

Unrealized

 

 

Fair Market

 

 

 

Hierarchy

 

Cost

 

 

Loss

 

 

Value

 

Money market funds

 

Level 1

 

 

65,939

 

 

 

 

 

 

65,939

 

Short-term marketable securities

 

Level 2

 

 

36,060

 

 

 

(20

)

 

 

36,040

 

Long-term marketable securities

 

Level 2

 

 

12,401

 

 

 

(4

)

 

 

12,397

 

 

 

 

 

$

114,400

 

 

$

(24

)

 

$

114,376

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2020

 

 

 

Fair Value

 

Amortization

 

 

Unrealized

 

 

Fair Market

 

 

 

Hierarchy

 

Cost

 

 

Gain

 

 

Value

 

Money market funds

 

Level 1

 

 

214,522

 

 

 

27

 

 

 

214,549

 

 

 

 

 

$

214,522

 

 

$

27

 

 

$

214,549

 

 

The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable, accrued expenses, other liabilities, and term loan are shown at their historical values which approximate their fair values.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment

4. Property and equipment

Property and equipment include the following:

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Lab equipment

 

$

6,107

 

 

$

4,166

 

Furniture and office equipment

 

 

3,220

 

 

 

283

 

Software

 

 

291

 

 

 

291

 

Leasehold improvements

 

 

 

 

 

1,419

 

Construction in progress

 

 

61

 

 

 

4,340

 

Total

 

 

9,679

 

 

 

10,499

 

Accumulated depreciation

 

 

(3,447

)

 

 

(3,212

)

Property and equipment, net

 

$

6,232

 

 

$

7,287

 

 

The Company recognized $735 and $2,038, and $301 and $760 of depreciation expense for the three and nine months ended September 30, 2021 and 2020, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses
9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
Accrued Expenses

5. Accrued expenses

Accrued expenses consist of the following:

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Payroll and employee related expenses

 

$

3,522

 

 

$

5,062

 

Professional fees

 

 

666

 

 

 

647

 

Third-party research and development expenses

 

 

766

 

 

 

874

 

Taxes and other

 

 

243

 

 

 

80

 

Total

 

$

5,197

 

 

$

6,663

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Debt
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Debt

6. Debt

On December 11, 2020 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with a commercial bank for a term loan with a principal balance of $15,000. The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”). Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in The Wall Street Journal, subject to an interest rate floor of zero) or (ii) 4.75%. The interest rate at September 30, 2021 was 4.75%, resulting in interest expense of $182 and $582 for the three and nine months ended September 30, 2021.

The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the borrowings under the Loan Agreement are refinanced by the bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date.

The Company will pay a final payment of $150, which will occur on the earliest of: (i) the Loan Maturity Date; (ii) the date that the Company prepays all of the outstanding principal in full; (iii) the date the loan payments are accelerated due to an event of default; or (iv) the termination of the Loan Agreement. The Company is accruing the final payment as interest expense over the term of the loan. The term loan is secured by substantially all of the Company’s assets, excluding intellectual property.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share

7. Net loss per share

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the three and nine months ended September 30, 2021 and 2020 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods.

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$

(25,155

)

 

$

(5,341

)

 

$

(63,186

)

 

$

(16,279

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares of common stock outstanding-
   basic and diluted

 

 

34,448,746

 

 

 

33,073,889

 

 

 

34,268,736

 

 

 

31,729,702

 

Net loss per share attributable to common stockholders-
   basic and diluted

 

$

(0.73

)

 

$

(0.16

)

 

$

(1.84

)

 

$

(0.51

)

 

The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.

 

 

 

Three and Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

Unvested restricted common stock

 

 

-

 

 

 

3,557

 

Unvested restricted stock units

 

 

698,300

 

 

 

-

 

Outstanding stock options

 

 

7,279,399

 

 

 

6,753,568

 

Total

 

 

7,977,699

 

 

 

6,757,125

 

 

 

 

 

 

 

 

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Stockholders' Equity

8. Stockholders’ equity

Capital stock

The Company has authorized 10,000,000 shares of $0.001 par value preferred stock and 200,000,000 shares of $0.001 par value common stock. There were no shares of preferred stock outstanding as of September 30, 2021. There were 34,551,875 and 33,964,000 shares of common stock issued and outstanding as of September 30, 2021 and December 31, 2020, respectively. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.

The Company has reserved the following shares of common stock for future issuance as of September 30, 2021 and December 31, 2020:

 

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Stock options outstanding

 

 

7,279,399

 

 

 

6,816,798

 

Shares available for future grant under incentive plans

 

 

1,090,606

 

 

 

1,475,923

 

 

 

 

8,370,005

 

 

 

8,292,721

 

 

Private placement

On July 20, 2020, the Company issued and sold an aggregate of 2,350,108 shares of its common stock, par value $0.001 per share (the “Shares”), at a purchase price of $18.00 per share to new and existing investors in a private placement for net proceeds of $40,100 after deducting placement agent fees and offering expenses (the “Private Placement”). In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within 60 days after the closing of the Private Placement (the “Initial Filing Date”) for purposes of registering the resale of the Shares. The Company filed a registration statement (the “Registration Statement”) to register the Shares, which was declared effective by the SEC on September 3, 2020.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based Compensation
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation

9. Stock-based compensation

Stock options

The below summary includes stock option activity within the Company’s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the nine months ended September 30, 2021:

 

 

Number of
shares

 

 

Weighted
average
exercise

 

 

Weighted average
remaining contractual
term

 

 

Aggregate
intrinsic

 

 

 

in Plans

 

 

price

 

 

(in years)

 

 

value

 

Outstanding as of December 31, 2020

 

 

6,816,798

 

 

$

10.11

 

 

 

8.45

 

 

$

171,415

 

Granted

 

 

1,343,376

 

 

 

33.04

 

 

 

8.65

 

 

 

 

Exercised

 

 

(582,976

)

 

 

2.04

 

 

 

 

 

$

11,369

 

Forfeited

 

 

(297,799

)

 

 

20.85

 

 

 

 

 

 

 

Outstanding as of September 30, 2021

 

 

7,279,399

 

 

$

14.55

 

 

 

7.71

 

 

$

13,138

 

Options exercisable as of September 30, 2021

 

 

3,702,862

 

 

$

9.13

 

 

 

7.36

 

 

$

10,197

 

Options unvested as of September 30, 2021

 

 

3,576,537

 

 

$

20.16

 

 

 

8.07

 

 

$

2,942

 

 

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock.

Stock option valuation

The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:

 

 

September 30,

 

 

 

2021

 

Risk-free interest rate

 

 

0.5

%

Expected term (in years)

 

 

6.0

 

Expected volatility

 

 

79.8

%

Expected dividend yield

 

 

0.0

%

 

The weighted-average grant date fair value of options granted during the three and nine months ended September 30, 2021 and 2020 was $5.64 and $22.57, and $14.02 and $15.73, respectively.

The total grant date fair value of options vested during the three and nine months ended September 30, 2021 and 2020 was $3,418 and $12,231, and $2,406 and $5,751, respectively.

Restricted common stock

The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder.

A summary of the status of restricted common stock as of September 30, 2021 is presented below:

 

 

 

Number of
shares

 

 

Weighted
average fair
value

 

Unvested, December 31, 2020

 

 

3,093

 

 

$

1.75

 

Awarded

 

 

 

 

 

 

Vested

 

 

(928

)

 

 

1.75

 

Forfeited

 

 

(2,165

)

 

 

1.75

 

Unvested as of September 30, 2021

 

 

 

 

$

-

 

 

 

 

 

 

 

 

 

The total value of restricted stock awards that vested during the three and nine months ended September 30, 2021 and 2020, based on estimated fair values of the stock underlying the restricted stock awards was $0 and $2, and $1 and $19, respectively.

Restricted stock units

In April 2021, the Company issued restricted stock units to employees which will vest in equal installments in the first quarter of 2022 and the third quarter of 2022.

 

A summary of the status of restricted stock units as of September 30, 2021 is presented below:

 

 

Number of
shares

 

 

Weighted
average fair
value

 

Unvested, December 31, 2020

 

 

 

 

$

-

 

Awarded

 

 

800,000

 

 

 

9.54

 

Vested

 

 

 

 

 

 

Forfeited

 

 

(101,700

)

 

 

9.54

 

Unvested as of September 30, 2021

 

 

698,300

 

 

$

9.54

 

 

Stock-based compensation

The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows:

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

2,774

 

 

$

1,036

 

 

$

7,393

 

 

$

3,039

 

General and administrative

 

 

3,112

 

 

 

1,607

 

 

 

9,193

 

 

 

4,179

 

Total

 

$

5,886

 

 

$

2,643

 

 

$

16,586

 

 

$

7,218

 

 

As of September 30, 2021, total unrecognized stock-based compensation expense relating to unvested stock options, restricted stock awards, and restricted stock units was $46,901. This amount is expected to be recognized over a weighted-average period of 2.64 years.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Employee Stock Purchase Plan
9 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Employee Stock Purchase Plan

10. Employee stock purchase plan

On September 20, 2019, the Company’s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the “ESPP”) which became effective on the date of the Company’s initial public offering of shares of its common stock. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company’s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. The Company’s first offering period of 2021 concluded on June 30, 2021 with the purchase of 7,064 shares in July 2021 related to this offering period. A total of 956,021 shares remain for future offering periods.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

11. Income taxes

The Company’s total provision is based on the United States statutory rate of 21%, increased by state taxes and reduced by a full valuation allowance on the Company’s deferred tax assets. The income tax expense for the three and nine months ended September 30, 2021 and 2020 represents state taxes on interest income earned by the Company’s subsidiary, Frequency Therapeutics Securities Corporation, a Massachusetts Securities Corporation.

ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at September 30, 2021 and December 31, 2020 because the Company’s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position.

Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which no net tax benefit has been recorded due to uncertainty around utilizing these tax attributes within the respective carryforward periods.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreement
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaboration Agreement

12. Collaboration agreement

In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the “Astellas Agreement”), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the “Astellas Licensed Products”), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States.

These parties have agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries.

The collaboration is governed by a joint steering committee (“JSC”) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party’s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC.

As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80,000 in July 2019 and has agreed to pay potential development milestone payments up to $230,000 and commercialization milestones of up to $315,000. Specifically, the Company would receive development milestone payments of $65,000 and $25,000 upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100,000 and $40,000 upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315,000 in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan.

The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days’ written notice. Each party has the right to terminate the Astellas Agreement due to the other party’s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt.

The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808.

The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation.

Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The Company determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and continued until the completion of the Phase 2a clinical trial of FX-322 (FX-322-202). The transaction price of $80,000 was allocated to the single combined performance obligation and recognized over such period. At commencement and throughout the trial, management analyzed the progress of the Phase 2a clinical trial (FX-322-202) and estimated the completion date of such trial and the total research and development costs it expects to incur in performing the trial to be June 30, 2021. As such, the Company recognized the $80,000 upfront fee as revenue over the period from July 2019 until June 30, 2021, the completion date of the Phase 2a clinical trial (FX-322-202), using the input method. The Company was required to pay MIT a royalty of $16,000 on the $80,000 of sublicense revenues. The $16,000 royalty was expensed in the third quarter of 2019. For a description of the MIT License Agreement, refer to Note 13.

The $80,000 upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and was recognized as revenue according to the policy described above. As of June 30, 2021, the Company completed its performance obligation with respect to the upfront payment and, accordingly, recognized all remaining revenue related to the Astellas Agreement.

The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee’s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statements of operations during the development period. In the three and nine months ended September 30, 2021, the Company invoiced Astellas $229 and $741 for joint costs.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
License Agreement
9 Months Ended
Sep. 30, 2021
Research and Development [Abstract]  
License Agreement

13. License Agreement

 

Massachusetts Institute of Technology

In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement) with the Massachusetts Institute of Technology (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement.

The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on

research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company’s future development obligations are: (i) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product, (ii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii) to make a first commercial sale of such Product within 11 years of the IND filing for such Product. The Company also has certain development obligations for a second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fails to cure such breach within ninety (90) days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations.

Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 12.

The MIT License Agreement will remain in effect until the expiration or abandonment of all issued patents, including filed patent applications licensed thereunder, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.

In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product.

 

The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Pursuant to MIT’s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer received $1,980 from MIT under the MIT Policy during the year ended December 31, 2020. Dr. Langer received $6 from MIT under the MIT Policy during the three and nine months ended September 30, 2021.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

14. Commitments and contingencies

Contract commitments

The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $600 through December 2021.

The Company also enters into contracts in the normal course of business with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run.

Guarantees

The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees.

As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid.

The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.

The Company leases office space in Lexington, Massachusetts under a ten-year noncancelable operating lease. The $1,726 security deposit for this lease is classified as restricted cash as of September 30, 2021. The Company exited its Woburn, Massachusetts facility in the second quarter of 2021. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease.

As of September 30, 2021, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established.

 

Legal Contingencies

 

The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company’s accrued liabilities would be recorded in the period in which such determination is made.

 

In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred.

 

On June 3, 2021 and June 22, 2021, purported stockholders of the Company filed putative class action lawsuits in the U.S. District Court for the District of Massachusetts against the Company entitled Evans v. Frequency Therapeutics, Inc. et al. and Hingston v. Frequency Therapeutics, Inc. et al., respectively. The lawsuits allege violations of Section 10(b), 20(a) and Rule 10b5 of the Securities Exchange Act of 1934, as amended, due to allegedly false and misleading statements and

omissions about the Company’s Phase 2a clinical trial (FX-322-202) for its product candidate FX-322 in the Company’s public disclosures between November 16, 2020 and March 22, 2021. The lawsuits seek, among other things, damages in connection with the Company’s allegedly artificially inflated stock price between November 16, 2020 and March 22, 2021 as a result of those allegedly false and misleading statements and omissions, as well as interest, attorneys’ fees and costs. These matters are at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. The Company is vigorously defending against all claims asserted in both lawsuits. The Company has not yet filed a responsive pleading. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of September 30, 2021.

 

On June 23, 2021, two purported stockholders of the Company filed a lawsuit in the Court of Chancery of the State of Delaware against (i) the Company, (ii) the Company’s Chief Executive Officer, President, and Director, David Lucchino, (iii) Computershare Inc., and (iv) Computershare Trust Company, N.A., entitled The Gregory J. Parseghian Revocable Trust, et al. v. Frequency Therapeutics, Inc., et al. The lawsuit alleges causes of action against the Company of conversion and unjust enrichment, and against Mr. Lucchino for breach of the fiduciary duty of loyalty, due to allegations that actions were taken to prevent the purported stockholders from selling their shares in the Company. The lawsuit seeks monetary damages, as well as interest, attorneys’ fees and costs, against all defendants. This matter is at the very early stages of the legal process, and as a result, the Company is not able to estimate a range of possible loss. We are vigorously defending against all claims asserted and have filed a motion to dismiss the complaint. Since an estimate of the possible loss or range of loss cannot be made at this time, no accruals have been recorded as of September 30, 2021.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Basis of Presentation (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC).

Principles of Consolidation

Principles of consolidation

The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation and Frequency Therapeutics PTY, LTD. All intercompany transactions and balances have been eliminated. The significant accounting policies used in preparation of these interim financial statements on Form 10-Q are consistent with those discussed in Note 2, “Summary of significant accounting policies,” in the Company’s Form 10-K.

Unaudited Interim Financial Information

Unaudited interim financial information

The accompanying consolidated balance sheet as of September 30, 2021 and the consolidated statements of operations, the consolidated statements of comprehensive loss and the consolidated statements of stockholders’ equity (deficit) for the three and nine months ended September 30, 2021 and 2020, and the consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2021, the results of its operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2020 are also unaudited. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. The consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date. These unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Form 10-K. 

Recently Adopted Accounting Pronouncements

Recently adopted accounting standards

In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. The Company adopted the standard on January 1, 2021 and it did not have a significant impact on its consolidated financial statements.

Recently issued accounting standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This new guidance requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. ASU 2018-15 generally aligns the guidance on recognizing implementation costs incurred to develop or obtain internal use software, which includes hosting arrangements that include an internal-use software license. This standard will become effective for the Company for the 2021 annual financial statements. The Company is still evaluating the impact of this standard on its consolidated financial statements.  

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Measured at Fair Value on Recurring Basis

The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy at September 30, 2021 and December 31, 2020 are summarized as follows:

 

 

 

 

 

September 30, 2021

 

 

 

Fair Value

 

Amortization

 

 

Unrealized

 

 

Fair Market

 

 

 

Hierarchy

 

Cost

 

 

Loss

 

 

Value

 

Money market funds

 

Level 1

 

 

65,939

 

 

 

 

 

 

65,939

 

Short-term marketable securities

 

Level 2

 

 

36,060

 

 

 

(20

)

 

 

36,040

 

Long-term marketable securities

 

Level 2

 

 

12,401

 

 

 

(4

)

 

 

12,397

 

 

 

 

 

$

114,400

 

 

$

(24

)

 

$

114,376

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2020

 

 

 

Fair Value

 

Amortization

 

 

Unrealized

 

 

Fair Market

 

 

 

Hierarchy

 

Cost

 

 

Gain

 

 

Value

 

Money market funds

 

Level 1

 

 

214,522

 

 

 

27

 

 

 

214,549

 

 

 

 

 

$

214,522

 

 

$

27

 

 

$

214,549

 

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment (Tables)
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment include the following:

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Lab equipment

 

$

6,107

 

 

$

4,166

 

Furniture and office equipment

 

 

3,220

 

 

 

283

 

Software

 

 

291

 

 

 

291

 

Leasehold improvements

 

 

 

 

 

1,419

 

Construction in progress

 

 

61

 

 

 

4,340

 

Total

 

 

9,679

 

 

 

10,499

 

Accumulated depreciation

 

 

(3,447

)

 

 

(3,212

)

Property and equipment, net

 

$

6,232

 

 

$

7,287

 

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consist of the following:

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Payroll and employee related expenses

 

$

3,522

 

 

$

5,062

 

Professional fees

 

 

666

 

 

 

647

 

Third-party research and development expenses

 

 

766

 

 

 

874

 

Taxes and other

 

 

243

 

 

 

80

 

Total

 

$

5,197

 

 

$

6,663

 

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss per Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$

(25,155

)

 

$

(5,341

)

 

$

(63,186

)

 

$

(16,279

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares of common stock outstanding-
   basic and diluted

 

 

34,448,746

 

 

 

33,073,889

 

 

 

34,268,736

 

 

 

31,729,702

 

Net loss per share attributable to common stockholders-
   basic and diluted

 

$

(0.73

)

 

$

(0.16

)

 

$

(1.84

)

 

$

(0.51

)

Computation of Diluted Net Loss per Share

The Company excluded the following potential shares of common stock from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.

 

 

 

Three and Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

Unvested restricted common stock

 

 

-

 

 

 

3,557

 

Unvested restricted stock units

 

 

698,300

 

 

 

-

 

Outstanding stock options

 

 

7,279,399

 

 

 

6,753,568

 

Total

 

 

7,977,699

 

 

 

6,757,125

 

 

 

 

 

 

 

 

 

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of Common Stock Shares Reserved for Future Issuance

The Company has reserved the following shares of common stock for future issuance as of September 30, 2021 and December 31, 2020:

 

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Stock options outstanding

 

 

7,279,399

 

 

 

6,816,798

 

Shares available for future grant under incentive plans

 

 

1,090,606

 

 

 

1,475,923

 

 

 

 

8,370,005

 

 

 

8,292,721

 

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based Compensation (Tables)
9 Months Ended
Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan

The below summary includes stock option activity within the Company’s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the nine months ended September 30, 2021:

 

 

Number of
shares

 

 

Weighted
average
exercise

 

 

Weighted average
remaining contractual
term

 

 

Aggregate
intrinsic

 

 

 

in Plans

 

 

price

 

 

(in years)

 

 

value

 

Outstanding as of December 31, 2020

 

 

6,816,798

 

 

$

10.11

 

 

 

8.45

 

 

$

171,415

 

Granted

 

 

1,343,376

 

 

 

33.04

 

 

 

8.65

 

 

 

 

Exercised

 

 

(582,976

)

 

 

2.04

 

 

 

 

 

$

11,369

 

Forfeited

 

 

(297,799

)

 

 

20.85

 

 

 

 

 

 

 

Outstanding as of September 30, 2021

 

 

7,279,399

 

 

$

14.55

 

 

 

7.71

 

 

$

13,138

 

Options exercisable as of September 30, 2021

 

 

3,702,862

 

 

$

9.13

 

 

 

7.36

 

 

$

10,197

 

Options unvested as of September 30, 2021

 

 

3,576,537

 

 

$

20.16

 

 

 

8.07

 

 

$

2,942

 

Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis

The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:

 

 

September 30,

 

 

 

2021

 

Risk-free interest rate

 

 

0.5

%

Expected term (in years)

 

 

6.0

 

Expected volatility

 

 

79.8

%

Expected dividend yield

 

 

0.0

%

Summary of Recognized Stock-based Compensation

The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows:

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

2,774

 

 

$

1,036

 

 

$

7,393

 

 

$

3,039

 

General and administrative

 

 

3,112

 

 

 

1,607

 

 

 

9,193

 

 

 

4,179

 

Total

 

$

5,886

 

 

$

2,643

 

 

$

16,586

 

 

$

7,218

 

Restricted Common Stock  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Status of Restricted Common Stock and Restricted Stock Units

A summary of the status of restricted common stock as of September 30, 2021 is presented below:

 

 

 

Number of
shares

 

 

Weighted
average fair
value

 

Unvested, December 31, 2020

 

 

3,093

 

 

$

1.75

 

Awarded

 

 

 

 

 

 

Vested

 

 

(928

)

 

 

1.75

 

Forfeited

 

 

(2,165

)

 

 

1.75

 

Unvested as of September 30, 2021

 

 

 

 

$

-

 

 

 

 

 

 

 

 

Restricted Stock Units  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Status of Restricted Common Stock and Restricted Stock Units

A summary of the status of restricted stock units as of September 30, 2021 is presented below:

 

 

Number of
shares

 

 

Weighted
average fair
value

 

Unvested, December 31, 2020

 

 

 

 

$

-

 

Awarded

 

 

800,000

 

 

 

9.54

 

Vested

 

 

 

 

 

 

Forfeited

 

 

(101,700

)

 

 

9.54

 

Unvested as of September 30, 2021

 

 

698,300

 

 

$

9.54

 

 

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Basis of Presentation - Additional Information (Details)
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Date of incorporation Nov. 30, 2014
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Recently Adopted and Issued Accounting Standards - Additional Information (Details)
Sep. 30, 2021
Accounting Standards Update 2019-12  
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]  
Change in accounting principle, accounting standards update, adopted true
Change in accounting principle, accounting standards update, adoption date Jan. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect true
Accounting Standards Update 2018-15  
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]  
Change in accounting principle, accounting standards update, adopted true
Change in accounting principle, accounting standards update, immaterial effect true
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortization Cost $ 114,400 $ 214,522
Unrealized Gain   27
Unrealized Loss (24)  
Fair Market Value 114,376 214,549
Money Market Funds | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortization Cost 65,939 214,522
Unrealized Gain   27
Fair Market Value 65,939 $ 214,549
Short-term Marketable Securities | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortization Cost 36,060  
Unrealized Loss (20)  
Fair Market Value 36,040  
Long-term Marketable Securities | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortization Cost 12,401  
Unrealized Loss (4)  
Fair Market Value $ 12,397  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Total $ 9,679 $ 10,499
Accumulated depreciation (3,447) (3,212)
Property and equipment, net 6,232 7,287
Lab Equipment    
Property Plant And Equipment [Line Items]    
Total 6,107 4,166
Furniture and Office Equipment    
Property Plant And Equipment [Line Items]    
Total 3,220 283
Software    
Property Plant And Equipment [Line Items]    
Total 291 291
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Total   1,419
Construction in Progress    
Property Plant And Equipment [Line Items]    
Total $ 61 $ 4,340
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 735 $ 301 $ 2,038 $ 760
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Payroll and employee related expenses $ 3,522 $ 5,062
Professional fees 666 647
Third-party research and development expenses 766 874
Taxes and other 243 80
Total $ 5,197 $ 6,663
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 11, 2020
Sep. 30, 2021
Sep. 30, 2021
Debt Instrument [Line Items]      
Debt instrument, Interest rate     4.75%
Term Loan      
Debt Instrument [Line Items]      
Debt instrument interest payment   $ 182 $ 582
Loan Agreement      
Debt Instrument [Line Items]      
Debt instrument final payment $ 150    
Loan Agreement | Term Loan      
Debt Instrument [Line Items]      
Principal balance $ 15,000    
Payment terms, description The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”)    
Frequency of interest-only payments monthly    
Monthly interest only payments due Nov. 30, 2022    
Loan maturity date May 01, 2024    
Debt instrument, Interest rate 4.75%    
Interest rate floor percentage 0.00%    
Loan Agreement | Term Loan | Prepayment Occurs on or Prior to First Anniversary of Closing Date      
Debt Instrument [Line Items]      
Debt instrument prepayment premium percentage 2.00%    
Loan Agreement | Term Loan | Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date      
Debt Instrument [Line Items]      
Debt instrument prepayment premium percentage 1.00%    
Loan Agreement | Term Loan | Prepayment Occurs After Second Anniversary of Closing Date      
Debt Instrument [Line Items]      
Debt instrument prepayment premium percentage 0.00%    
Loan Agreement | Term Loan | Prime Rate      
Debt Instrument [Line Items]      
Debt instrument, Interest rate 1.50%    
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Numerator:        
Net Loss $ (25,155) $ (5,341) $ (63,186) $ (16,279)
Denominator:        
Weighted-average shares of common stock outstanding-basic and diluted 34,448,746 33,073,889 34,268,736 31,729,702
Net loss per share attributable to common stockholders-basic and diluted $ (0.73) $ (0.16) $ (1.84) $ (0.51)
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share 7,977,699 6,757,125 7,977,699 6,757,125
Unvested Restricted Common Stock        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share   3,557   3,557
Unvested Restricted Stock Units        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share 698,300   698,300  
Outstanding Stock Options        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share 7,279,399 6,753,568 7,279,399 6,753,568
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Jul. 20, 2020
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2021
Jun. 30, 2021
Dec. 31, 2020
Jun. 30, 2020
Dec. 31, 2019
Class Of Stock [Line Items]                
Preferred stock, shares authorized       10,000,000   10,000,000    
Preferred Stock, value per share       $ 0.001   $ 0.001    
Common stock, authorized shares       200,000,000   200,000,000    
Common stock, par value       $ 0.001   $ 0.001    
Preferred stock, outstanding shares       0   0    
Common stock, issued shares       34,551,875   33,964,000    
Common stock, outstanding shares       34,551,875   33,964,000    
Common Stock                
Class Of Stock [Line Items]                
Common stock, outstanding shares   33,732,290 33,732,290 34,551,875 34,385,916 33,964,000 31,249,499 30,844,507
Common stock shares issued and sold   2,350,108 2,350,108          
Common Stock | Private Placement                
Class Of Stock [Line Items]                
Common stock, par value $ 0.001              
Common stock shares issued and sold 2,350,108              
Share price per share $ 18.00              
Proceeds from Issuance of Common Stock $ 40,100              
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) - shares
Sep. 30, 2021
Dec. 31, 2020
Class Of Stock [Line Items]    
Shares of common stock reserved for future issuance 8,370,005 8,292,721
Stock Options Outstanding    
Class Of Stock [Line Items]    
Shares of common stock reserved for future issuance 7,279,399 6,816,798
Shares Available for Future Grant Under Stock Option Plan    
Class Of Stock [Line Items]    
Shares of common stock reserved for future issuance 1,090,606 1,475,923
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
2019 Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Number of shares, Beginning balance | shares 6,816,798  
Number of shares, Granted | shares 1,343,376  
Number of shares, Exercised | shares (582,976)  
Number of shares, Forfeited | shares (297,799)  
Number of shares, Ending balance | shares 7,279,399 6,816,798
Number of shares, Options exercisable as of September 30, 2021 | shares 3,702,862  
Number of shares, Options unvested as of September 30, 2021 | shares 3,576,537  
Weighted average exercise price, Beginning balance | $ / shares $ 10.11  
Weighted average exercise price, Granted | $ / shares 33.04  
Weighted average exercise price, Exercised | $ / shares 2.04  
Weighted average exercise price, Forfeited | $ / shares 20.85  
Weighted average exercise price, Ending balance | $ / shares 14.55 $ 10.11
Weighted average exercise price, Options exercisable as of September 30, 2021 | $ / shares 9.13  
Weighted average exercise price, Options unvested as of September 30, 2021 | $ / shares $ 20.16  
Weighted average remaining contractual term (in years), Outstanding 7 years 8 months 15 days 8 years 5 months 12 days
Weighted average remaining contractual term (in years), Granted 8 years 7 months 24 days  
Weighted average remaining contractual term (in years), Options exercisable as of September 30, 2021 7 years 4 months 9 days  
Weighted average remaining contractual term (in years), Options unvested as of September 30, 2021 8 years 25 days  
Two Thousand And Fourteen Stock Incentive Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Aggregate intrinsic value, Outstanding as of December 31, 2020 | $ $ 171,415  
Aggregate intrinsic value, Exercised | $ 11,369  
Aggregate intrinsic value, Outstanding as of September 30, 2021 | $ 13,138 $ 171,415
Aggregate intrinsic value, Options exercisable as of September 30, 2021 | $ 10,197  
Aggregate intrinsic value, Options unvested as of September 30, 2021 | $ $ 2,942  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Risk-free interest rate 0.50%
Expected term (in years) 6 years
Expected volatility 79.80%
Expected dividend yield 0.00%
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Weighted-average grant date fair value of stock options granted $ 5.64 $ 14.02 $ 22.57 $ 15.73
Total grant date fair value of stock options vested $ 3,418 $ 2,406 $ 12,231 $ 5,751
Total unrecognized stock-based compensation expense relating to unvested stock options, restricted stock awards and restricted stock units 46,901   $ 46,901  
Unrecognized unvested stock options, restricted stock awards and restricted stock units, weighted-average period     2 years 7 months 20 days  
Restricted Common Stock        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Options vesting period     4 years  
Total value of restricted stock awards, vested based on estimated fair value of stock $ 0 $ 1 $ 2 $ 19
Restricted Stock Units        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Vesting description     vest in equal installments in the first quarter of 2022 and the third quarter of 2022  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details)
9 Months Ended
Sep. 30, 2021
$ / shares
shares
Restricted Common Stock  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of shares, Unvested as of December 31, 2020 | shares 3,093
Number of shares, Vested | shares (928)
Number of shares, Forfeited | shares (2,165)
Number of shares, Unvested as of September 30, 2021 | shares 0
Weighted average fair value, Unvested as of December 31, 2020 | $ / shares $ 1.75
Weighted average fair value, Vested | $ / shares 1.75
Weighted average fair value, Forfeited | $ / shares 1.75
Weighted average fair value, Unvested, September 30, 2021 | $ / shares $ 0
Restricted Stock Units  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of shares, Unvested as of December 31, 2020 | shares 0
Number of shares, Awarded | shares 800,000
Number of shares, Forfeited | shares (101,700)
Number of shares, Unvested as of September 30, 2021 | shares 698,300
Weighted average fair value, Unvested as of December 31, 2020 | $ / shares $ 0
Weighted average fair value, Awarded | $ / shares 9.54
Weighted average fair value, Forfeited | $ / shares 9.54
Weighted average fair value, Unvested, September 30, 2021 | $ / shares $ 9.54
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock-based compensation $ 5,886 $ 2,643 $ 16,586 $ 7,218
Research and Development        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock-based compensation 2,774 1,036 7,393 3,039
General and Administrative        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Stock-based compensation $ 3,112 $ 1,607 $ 9,193 $ 4,179
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Employee Stock Purchase Plan - Additional Information (Details) - shares
6 Months Ended
Sep. 20, 2019
Jun. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Shares available for future grant under incentive plans     8,370,005 8,292,721
2019 Employee Stock Purchase Plan        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Percentage of eligible employee compensation 15.00%      
Period for automatic increase in common available for future issuance 10 years      
Percentage of shares issued from outstanding number of shares 1.00%      
Shares issued   7,064    
Shares available for future grant under incentive plans     956,021  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended 93 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Sep. 30, 2021
Income Tax Disclosure [Abstract]            
Statutory rate 21.00%   21.00%      
Federal and state deferred tax benefits     $ 0   $ 0  
Net tax benefit $ 3,000 $ 15,000 $ 13,000 $ 60,000   $ 0
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreement - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 24 Months Ended
Jul. 31, 2019
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue     $ 11,247   $ 14,068 $ 27,034  
Research and development   $ 15,662 $ 10,153   48,169 $ 25,587  
License and Collaboration Agreement | Astellas Pharma LLC              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Payments received under collaboration agreement $ 80,000            
Agreement termination notice period 60 days            
Right to terminate agreement if breach remains uncured 90 days            
Right to terminate agreement incase of nonpayment 45 days            
Transaction price allocated to single combined performance obligation         80,000    
Accrued upfront payment related to sub License revenue   16,000     16,000    
Royalty       $ 16,000      
Upfront fee recognized as revenue         80,000   $ 80,000
Research and development   $ 229     $ 741    
License and Collaboration Agreement | Astellas Pharma LLC | Phase 2b Clinical Trial | Europe              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized potential development milestone payments to receive $ 65,000            
License and Collaboration Agreement | Astellas Pharma LLC | Phase 2b Clinical Trial | Asia              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized potential development milestone payments to receive 25,000            
License and Collaboration Agreement | Astellas Pharma LLC | Phase 3 Clinical Trial | Europe              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized potential development milestone payments to receive 100,000            
License and Collaboration Agreement | Astellas Pharma LLC | Phase 3 Clinical Trial | Asia              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized potential development milestone payments to receive 40,000            
License and Collaboration Agreement | Maximum | Astellas Pharma LLC              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized potential development milestone payments to receive 230,000            
Revenue recognized commercialization milestone payments to receive 315,000            
Potential commercial milestone payments eligible to receive upon successful commercialization $ 315,000            
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
License Agreement - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Research And Development Arrangement Contract To Perform For Others [Line Items]            
Revenue     $ 11,247 $ 14,068 $ 27,034  
MIT            
Research And Development Arrangement Contract To Perform For Others [Line Items]            
Description of future development obligations       The Company’s future development obligations are: (i) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product, (ii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii) to make a first commercial sale of such Product within 11 years of the IND filing for such Product.    
License fee payment $ 50          
Percentage of shares of common stock issued 5.00%          
Description of conditions to terminate license agreement       The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.    
Right to terminate agreement upon prior written notice 3 months          
Right to terminate agreement if breach remains uncured 90 days          
Right to terminate agreement incase of nonpayment 30 days          
MIT | Dr. Langer            
Research And Development Arrangement Contract To Perform For Others [Line Items]            
Payment to director   $ 6   $ 6   $ 1,980
MIT | Astellas Pharma LLC | Royalty            
Research And Development Arrangement Contract To Perform For Others [Line Items]            
Revenue $ 16,000          
MIT | Maximum            
Research And Development Arrangement Contract To Perform For Others [Line Items]            
Milestone payments $ 2,900          
Patent License Agreement | MIT            
Research And Development Arrangement Contract To Perform For Others [Line Items]            
License agreement entered date 2016-12          
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Additional Information (Details)
9 Months Ended
Sep. 30, 2021
USD ($)
Lessee Lease Description [Line Items]  
Commitment payments related to research $ 600,000
Losses related to indemnification obligations 0
Legal contingencies, accruals recorded $ 0
Lexington Massachusetts Facility  
Lessee Lease Description [Line Items]  
Operating lease term 10 years
Security deposit classified as restricted cash $ 1,726,000
EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 141 305 1 false 48 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements Stockholders' Equity (Deficit) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit Consolidated Statements Stockholders' Equity (Deficit) Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Cash Flows Sheet http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Organization and Basis of Presentation Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Recently Adopted And Issued Accounting Standards Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandards Recently Adopted And Issued Accounting Standards Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Property and Equipment Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 100110 - Disclosure - Accrued Expenses Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 100120 - Disclosure - Debt Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebt Debt Notes 13 false false R14.htm 100130 - Disclosure - Net Loss Per Share Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShare Net Loss Per Share Notes 14 false false R15.htm 100140 - Disclosure - Stockholders' Equity Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 100150 - Disclosure - Stock-based Compensation Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-based Compensation Notes 16 false false R17.htm 100160 - Disclosure - Employee Stock Purchase Plan Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlan Employee Stock Purchase Plan Notes 17 false false R18.htm 100170 - Disclosure - Income Taxes Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 100180 - Disclosure - Collaboration Agreement Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreement Collaboration Agreement Notes 19 false false R20.htm 100190 - Disclosure - License Agreement Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreement License Agreement Notes 20 false false R21.htm 100200 - Disclosure - Commitments and Contingencies Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 100210 - Disclosure - Organization and Basis of Presentation (Policies) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationPolicies Organization and Basis of Presentation (Policies) Policies http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandards 22 false false R23.htm 100220 - Disclosure - Fair Value Measurements (Tables) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements 23 false false R24.htm 100230 - Disclosure - Property and Equipment (Tables) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipment 24 false false R25.htm 100240 - Disclosure - Accrued Expenses (Tables) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpenses 25 false false R26.htm 100250 - Disclosure - Net Loss Per Share (Tables) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShare 26 false false R27.htm 100260 - Disclosure - Stockholders' Equity (Tables) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquity 27 false false R28.htm 100270 - Disclosure - Stock-based Compensation (Tables) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensation 28 false false R29.htm 100280 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails Organization and Basis of Presentation - Additional Information (Details) Details 29 false false R30.htm 100290 - Disclosure - Recently Adopted and Issued Accounting Standards - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails Recently Adopted and Issued Accounting Standards - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) Details 31 false false R32.htm 100310 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 32 false false R33.htm 100320 - Disclosure - Property and Equipment - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails Property and Equipment - Additional Information (Details) Details 33 false false R34.htm 100330 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 34 false false R35.htm 100340 - Disclosure - Debt - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails Debt - Additional Information (Details) Details 35 false false R36.htm 100350 - Disclosure - Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 36 false false R37.htm 100360 - Disclosure - Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 37 false false R38.htm 100370 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 38 false false R39.htm 100380 - Disclosure - Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) Details 39 false false R40.htm 100390 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details) Details 40 false false R41.htm 100400 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details) Details 41 false false R42.htm 100410 - Disclosure - Stock-based Compensation - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails Stock-based Compensation - Additional Information (Details) Details 42 false false R43.htm 100420 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details) Details 43 false false R44.htm 100430 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details) Details 44 false false R45.htm 100440 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails Employee Stock Purchase Plan - Additional Information (Details) Details 45 false false R46.htm 100450 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 46 false false R47.htm 100460 - Disclosure - Collaboration Agreement - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails Collaboration Agreement - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - License Agreement - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails License Agreement - Additional Information (Details) Details 48 false false R49.htm 100480 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 49 false false All Reports Book All Reports freq-20210930.htm freq-20210930.xsd freq-20210930_cal.xml freq-20210930_def.xml freq-20210930_lab.xml freq-20210930_pre.xml freq-ex31_1.htm freq-ex31_2.htm freq-ex32_1.htm freq-ex32_2.htm http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "freq-20210930.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 141, "dts": { "calculationLink": { "local": [ "freq-20210930_cal.xml" ] }, "definitionLink": { "local": [ "freq-20210930_def.xml" ] }, "inline": { "local": [ "freq-20210930.htm" ] }, "labelLink": { "local": [ "freq-20210930_lab.xml" ] }, "presentationLink": { "local": [ "freq-20210930_pre.xml" ] }, "schema": { "local": [ "freq-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 395, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 6, "http://xbrl.sec.gov/dei/2021": 5, "total": 11 }, "keyCustom": 29, "keyStandard": 276, "memberCustom": 19, "memberStandard": 29, "nsprefix": "freq", "nsuri": "http://frequencytx.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Fair Value Measurements", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Property and Equipment", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Accrued Expenses", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Debt", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Net Loss Per Share", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Stockholders' Equity", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stock-based Compensation", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "freq:EmployeeStockPurchasePlanDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Employee Stock Purchase Plan", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlan", "shortName": "Employee Stock Purchase Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "freq:EmployeeStockPurchasePlanDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Income Taxes", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Collaboration Agreement", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreement", "shortName": "Collaboration Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "freq:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - License Agreement", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreement", "shortName": "License Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "freq:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Commitments and Contingencies", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Organization and Basis of Presentation (Policies)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationPolicies", "shortName": "Organization and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Fair Value Measurements (Tables)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Property and Equipment (Tables)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Accrued Expenses (Tables)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Net Loss Per Share (Tables)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Stockholders' Equity (Tables)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Stock-based Compensation (Tables)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails", "shortName": "Organization and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_a937c3c5-4842-4b6d-95bb-61acc1a95edf", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Recently Adopted and Issued Accounting Standards - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails", "shortName": "Recently Adopted and Issued Accounting Standards - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_a937c3c5-4842-4b6d-95bb-61acc1a95edf", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_fe31c372-747a-4246-b48a-be932af71e65", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_fe31c372-747a-4246-b48a-be932af71e65", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Property and Equipment - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails", "shortName": "Property and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Debt - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "shortName": "Debt - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "shortName": "Net Loss Per Share - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "shortName": "Net Loss Per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_514c5683-c785-40ce-b924-3f4e7e2fa109", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails", "shortName": "Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_54c5ebb0-26b0-4f60-9e3c-bdea7108c156", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_e61bb2be-7026-4766-904b-1762f1a710fd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations (Unaudited)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "-3", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_6c63d29e-ebd3-4470-85c9-9cd5f7190a77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails", "shortName": "Stock-based Compensation - Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_548dab18-ebfb-469c-89c4-0b7cf3ea30cc", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails", "shortName": "Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Stock-based Compensation - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_fe9e69ec-8dd6-46d7-b7e2-f6223ee95c2a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails", "shortName": "Stock-based Compensation - Summary of Status of Restricted Common Stock and Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_fe9e69ec-8dd6-46d7-b7e2-f6223ee95c2a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails", "shortName": "Stock-based Compensation - Summary of Recognized Stock-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_059a3e9b-9d6f-45af-bb21-5102a0c51b06", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails", "shortName": "Employee Stock Purchase Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_3c70fcb0-7f4b-45a3-834a-6ecf0b0ccf74", "decimals": "2", "lang": null, "name": "freq:PercentageOfEligibleEmployeeCompensation", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_e61bb2be-7026-4766-904b-1762f1a710fd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Collaboration Agreement - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "shortName": "Collaboration Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_b4091be1-45fb-4922-b41c-6a129f57c141", "decimals": "-3", "lang": null, "name": "us-gaap:ProceedsFromCollaborators", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_e61bb2be-7026-4766-904b-1762f1a710fd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - License Agreement - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails", "shortName": "License Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "freq:LicenseAgreementTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_19de1594-1c67-46fd-8780-e6405eb41934", "decimals": null, "lang": "en-US", "name": "freq:DescriptionOfFutureDevelopmentObligations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited", "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_7ea9659d-7ce3-4e34-ac46-1def80a752ad", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_0b323d56-3112-4f71-b310-c64886a123ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements Stockholders' Equity (Deficit)", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit", "shortName": "Consolidated Statements Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_0b323d56-3112-4f71-b310-c64886a123ad", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Cash Flows", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Organization and Basis of Presentation", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Recently Adopted And Issued Accounting Standards", "role": "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandards", "shortName": "Recently Adopted And Issued Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "freq-20210930.htm", "contextRef": "C_809f5399-7193-4e2b-a8e2-a787b5a987d4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address Address Line" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Date of incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued income taxes and other accrued liabilities, current.", "label": "Accrued Income Taxes And Other Accrued Liabilities Current", "terseLabel": "Taxes and other" } } }, "localname": "AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued third-party research and development expenses current.", "label": "Accrued Third Party Research And Development Expenses Current", "terseLabel": "Third-party research and development expenses" } } }, "localname": "AccruedThirdPartyResearchAndDevelopmentExpensesCurrent", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "freq_AgreementTerminationNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement termination notice period.", "label": "Agreement Termination Notice Period", "terseLabel": "Agreement termination notice period" } } }, "localname": "AgreementTerminationNoticePeriod", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "freq_AstellasPharmaLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Astellas pharma limited liability company.", "label": "Astellas Pharma Limited Liability Company [Member]", "terseLabel": "Astellas Pharma LLC" } } }, "localname": "AstellasPharmaLimitedLiabilityCompanyMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with customer liability revenue recognized from commercialization milestones.", "label": "Contract With Customer Liability Revenue Recognized From Commercialization Milestones", "terseLabel": "Revenue recognized commercialization milestone payments to receive" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "freq_DebtInstrumentFloorInterestRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument floor interest rate percentage.", "label": "Debt Instrument Floor Interest Rate Percentage", "terseLabel": "Interest rate floor percentage" } } }, "localname": "DebtInstrumentFloorInterestRatePercentage", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "freq_DebtInstrumentInterestOnlyPaymentMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest only payment maturity date.", "label": "Debt Instrument Interest Only Payment Maturity Date", "terseLabel": "Monthly interest only payments due" } } }, "localname": "DebtInstrumentInterestOnlyPaymentMaturityDate", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "freq_DebtInstrumentPrepaymentPremiumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument prepayment premium percentage.", "label": "Debt Instrument Prepayment Premium Percentage", "terseLabel": "Debt instrument prepayment premium percentage" } } }, "localname": "DebtInstrumentPrepaymentPremiumPercentage", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "freq_DescriptionOfConditionsToTerminateLicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of conditions to terminate license agreement.", "label": "Description Of Conditions To Terminate License Agreement", "terseLabel": "Description of conditions to terminate license agreement" } } }, "localname": "DescriptionOfConditionsToTerminateLicenseAgreement", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "freq_DescriptionOfFutureDevelopmentObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of future development obligations.", "label": "Description Of Future Development Obligations", "terseLabel": "Description of future development obligations" } } }, "localname": "DescriptionOfFutureDevelopmentObligations", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "freq_EmployeeStockPurchasePlanDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan disclosure.", "label": "Employee Stock Purchase Plan Disclosure [Text Block]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlanDisclosureTextBlock", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlan" ], "xbrltype": "textBlockItemType" }, "freq_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in lease liabilities.", "label": "Increase Decrease In Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "freq_LexingtonMassachusettsFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lexington Massachusetts facility.", "label": "Lexington Massachusetts Facility [Member]", "terseLabel": "Lexington Massachusetts Facility" } } }, "localname": "LexingtonMassachusettsFacilityMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_LicenseAgreementEnteredDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement entered date.", "label": "License Agreement Entered Date", "terseLabel": "License agreement entered date" } } }, "localname": "LicenseAgreementEnteredDate", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "freq_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Text Block]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreement" ], "xbrltype": "textBlockItemType" }, "freq_LicenseAndCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreement.", "label": "License And Collaboration Agreement [Member]", "terseLabel": "License and Collaboration Agreement" } } }, "localname": "LicenseAndCollaborationAgreementMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_LicenseFeePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License fee payment.", "label": "License Fee Payment", "terseLabel": "License fee payment" } } }, "localname": "LicenseFeePayment", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "freq_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]", "terseLabel": "Loan Agreement" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_LongTermMarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term marketable securities.", "label": "Long Term Marketable Securities [Member]", "terseLabel": "Long-term Marketable Securities" } } }, "localname": "LongTermMarketableSecuritiesMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "freq_MassachusettsInstituteOfTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Massachusetts Institute of Technology.", "label": "Massachusetts Institute Of Technology [Member]", "terseLabel": "MIT" } } }, "localname": "MassachusettsInstituteOfTechnologyMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_MilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "MilestonePayments", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "freq_NonCashLeaseExpenses": { "auth_ref": [], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash lease expenses.", "label": "Non Cash Lease Expenses", "terseLabel": "Non-cash lease expense" } } }, "localname": "NonCashLeaseExpenses", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "freq_OtherComprehensiveLossInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other comprehensive (loss) (in shares)", "label": "Other comprehensive (loss) (in shares)" } } }, "localname": "OtherComprehensiveLossInShares", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "freq_OutstandingStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding stock options.", "label": "Outstanding Stock Options [Member]", "terseLabel": "Outstanding Stock Options" } } }, "localname": "OutstandingStockOptionsMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "freq_PatentLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent license agreement.", "label": "Patent License Agreement [Member]", "terseLabel": "Patent License Agreement" } } }, "localname": "PatentLicenseAgreementMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_PercentageOfEligibleEmployeeCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of eligible employee compensation.", "label": "Percentage Of Eligible Employee Compensation", "terseLabel": "Percentage of eligible employee compensation" } } }, "localname": "PercentageOfEligibleEmployeeCompensation", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "freq_PercentageOfSharesOfCommonStockIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares of common stock issued.", "label": "Percentage Of Shares Of Common Stock Issued", "terseLabel": "Percentage of shares of common stock issued" } } }, "localname": "PercentageOfSharesOfCommonStockIssued", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for automatic increase in common stock available for future issuance.", "label": "Period For Automatic Increase In Common Stock Available For Future Issuance", "verboseLabel": "Period for automatic increase in common available for future issuance" } } }, "localname": "PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "freq_Phase2bClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phase 2b clinical trial.", "label": "Phase2b Clinical Trial [Member]", "terseLabel": "Phase 2b Clinical Trial" } } }, "localname": "Phase2bClinicalTrialMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_Phase3ClinicalTrailMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phase 3 clinical trail.", "label": "Phase3 Clinical Trail [Member]", "terseLabel": "Phase 3 Clinical Trial" } } }, "localname": "Phase3ClinicalTrailMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date.", "label": "Prepayment Occurs After First Anniversary Of Closing Date And On Or Prior To Second Anniversary Of Closing Date [Member]", "terseLabel": "Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date" } } }, "localname": "PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Occurs After Second Anniversary of Closing Date.", "label": "Prepayment Occurs After Second Anniversary Of Closing Date [Member]", "terseLabel": "Prepayment Occurs After Second Anniversary of Closing Date" } } }, "localname": "PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment Occurs on or Prior to First Anniversary of Closing Date.", "label": "Prepayment Occurs On Or Prior To First Anniversary Of Closing Date [Member]", "terseLabel": "Prepayment Occurs on or Prior to First Anniversary of Closing Date" } } }, "localname": "PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_PurchasesOfPropertyAndEquipmentAndRightOfUseAssetIncludedInAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchases of property and equipment and right of use asset included in accounts payable.", "label": "Purchases Of Property And Equipment And Right Of Use Asset Included In Accounts Payable", "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses" } } }, "localname": "PurchasesOfPropertyAndEquipmentAndRightOfUseAssetIncludedInAccountsPayable", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue recognition potential commercial milestone payments eligible upon successful commercialization.", "label": "Revenue Recognition Potential Commercial Milestone Payments Eligible Upon Successful Commercialization", "terseLabel": "Potential commercial milestone payments eligible to receive upon successful commercialization" } } }, "localname": "RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "freq_RevenueRecognitionTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue recognition transaction price.", "label": "Revenue Recognition Transaction Price", "terseLabel": "Transaction price allocated to single combined performance obligation" } } }, "localname": "RevenueRecognitionTransactionPrice", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "freq_RightToTerminateAgreementIfBreachRemainsUncured": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to terminate agreement if breach remains uncured.", "label": "Right To Terminate Agreement If Breach Remains Uncured", "terseLabel": "Right to terminate agreement if breach remains uncured" } } }, "localname": "RightToTerminateAgreementIfBreachRemainsUncured", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "freq_RightToTerminateAgreementIncaseOfNonpayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to terminate agreement incase of nonpayment.", "label": "Right To Terminate Agreement Incase Of Nonpayment", "terseLabel": "Right to terminate agreement incase of nonpayment" } } }, "localname": "RightToTerminateAgreementIncaseOfNonpayment", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "freq_RightToTerminateAgreementUponPriorWrittenNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to terminate agreement upon prior written notice.", "label": "Right To Terminate Agreement Upon Prior Written Notice", "terseLabel": "Right to terminate agreement upon prior written notice" } } }, "localname": "RightToTerminateAgreementUponPriorWrittenNotice", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock shares reserved for future issuance.", "label": "Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Common Stock Shares Reserved for Future Issuance" } } }, "localname": "ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, award vesting description.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Description", "terseLabel": "Vesting description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDescription", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualterm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options exercised weighted average remaining contractualterm2.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractualterm2", "terseLabel": "Weighted average remaining contractual term (in years), Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualterm2", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "durationItemType" }, "freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractualterm2.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted average remaining contractual term (in years), Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "durationItemType" }, "freq_ShortTermMarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term marketable securities.", "label": "Short Term Marketable Securities [Member]", "terseLabel": "Short-term Marketable Securities" } } }, "localname": "ShortTermMarketableSecuritiesMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "freq_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "freq_TwoThousandAndFourteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and fourteen stock incentive plan.", "label": "Two Thousand And Fourteen Stock Incentive Plan [Member]", "terseLabel": "Two Thousand And Fourteen Stock Incentive Plan" } } }, "localname": "TwoThousandAndFourteenStockIncentivePlanMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "domainItemType" }, "freq_TwoThousandAndNineteenIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and nineteen incentive award plan.", "label": "Two Thousand And Nineteen Incentive Award Plan [Member]", "terseLabel": "2019 Plan" } } }, "localname": "TwoThousandAndNineteenIncentiveAwardPlanMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "domainItemType" }, "freq_UnauditedInterimFinancialInformationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unaudited interim financial information.", "label": "Unaudited Interim Financial Information Policy [Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "localname": "UnauditedInterimFinancialInformationPolicyTextBlock", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "freq_UnvestedRestrictedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Restricted Common Stock [Member].", "label": "Unvested Restricted Common Stock [Member]", "terseLabel": "Unvested Restricted Common Stock" } } }, "localname": "UnvestedRestrictedCommonStockMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "freq_UnvestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock units.", "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested Restricted Stock Units" } } }, "localname": "UnvestedRestrictedStockUnitsMember", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "freq_UpfrontFeeRecognizedAsRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront fee recognized as revenue.", "label": "Upfront Fee Recognized As Revenue", "terseLabel": "Upfront fee recognized as revenue" } } }, "localname": "UpfrontFeeRecognizedAsRevenue", "nsuri": "http://frequencytx.com/20210930", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia [Member]", "terseLabel": "Asia" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r43", "r45", "r95", "r96", "r215", "r251" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Dr. Langer" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r214", "r250", "r294", "r295", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r505", "r508", "r551", "r552" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r214", "r250", "r294", "r295", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r505", "r508", "r551", "r552" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r148", "r276", "r279", "r465", "r504", "r506" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r148", "r276", "r279", "r465", "r504", "r506" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r214", "r250", "r285", "r294", "r295", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r505", "r508", "r551", "r552" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r214", "r250", "r285", "r294", "r295", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r505", "r508", "r551", "r552" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r44", "r45", "r95", "r96", "r215", "r251" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r149", "r150", "r276", "r280", "r507", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r149", "r150", "r276", "r280", "r507", "r536", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r152", "r449" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201815Member": { "auth_ref": [ "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).", "label": "Accounting Standards Update 2018-15 [Member]", "terseLabel": "Accounting Standards Update 2018-15" } } }, "localname": "AccountingStandardsUpdate201815Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201912Member": { "auth_ref": [ "r351", "r352", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.", "label": "Accounting Standards Update 2019-12 [Member]", "terseLabel": "Accounting Standards Update 2019-12" } } }, "localname": "AccountingStandardsUpdate201912Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r31", "r452" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r12", "r13", "r33" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r12", "r13", "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued upfront payment related to sub License revenue" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r30", "r186" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r48", "r49", "r50", "r494", "r516", "r520" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r47", "r50", "r57", "r58", "r59", "r98", "r99", "r100", "r380", "r511", "r512", "r565" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r337", "r452" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r98", "r99", "r100", "r333", "r334", "r335", "r397" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional-paid in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r104", "r105", "r106", "r108", "r118", "r153", "r154", "r168", "r169", "r170", "r171", "r174", "r175", "r199", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r351", "r352", "r353", "r354", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r409", "r410", "r412", "r413", "r414", "r415", "r419", "r420", "r446", "r467", "r468", "r469", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r296", "r298", "r340", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r298", "r325", "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r92", "r137", "r140", "r146", "r164", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r374", "r381", "r408", "r450", "r452", "r476", "r491" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r10", "r42", "r92", "r164", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r374", "r381", "r408", "r450", "r452" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r162" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r163" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r160", "r176" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortization Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r157", "r161", "r176", "r480" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Market Value", "totalLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r159", "r176" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Short-term marketable securities", "totalLabel": "Debt Securities, Available-for-sale, Current, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r159", "r176" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Long-term marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r299", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r83", "r84", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r28", "r82" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r76", "r82", "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r76", "r425" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r98", "r99", "r102", "r153", "r154", "r165", "r166", "r167", "r168", "r169", "r199", "r329", "r330", "r331", "r351", "r387", "r388", "r389", "r409", "r411", "r412", "r413", "r419", "r420", "r439", "r446", "r467", "r468", "r509", "r510", "r561" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r98", "r99", "r112", "r153", "r154", "r165", "r166", "r167", "r168", "r169", "r199", "r329", "r330", "r331", "r351", "r387", "r388", "r389", "r390", "r393", "r409", "r411", "r412", "r413", "r419", "r420", "r439", "r446", "r467", "r468", "r509", "r510", "r561" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r104", "r117", "r155", "r172", "r337", "r357" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r366", "r367", "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration Agreement" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r191", "r192", "r193", "r197", "r538" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares available for future grant under incentive plans", "verboseLabel": "Shares of common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r98", "r99", "r397" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued shares", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, outstanding shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r452" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized, 34,551,875 and 33,964,000 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r53", "r55", "r56", "r65", "r484", "r500" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) gain:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r87", "r376" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r273", "r274", "r277" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized potential development milestone payments to receive" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r88", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r228", "r235", "r236", "r238", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r91", "r97", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r240", "r241", "r242", "r243", "r437", "r477", "r478", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, Interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r211", "r240", "r241", "r435", "r437", "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal balance" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r37", "r488" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Frequency of interest-only payments" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r35", "r214", "r404" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Loan maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r37", "r91", "r97", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r240", "r241", "r242", "r243", "r437" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r36", "r488" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Payment terms, description" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "terseLabel": "Debt instrument final payment" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r37", "r91", "r97", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r237", "r240", "r241", "r242", "r243", "r265", "r268", "r269", "r270", "r434", "r435", "r437", "r438", "r489" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal, State and Local, Tax Expense (Benefit)", "terseLabel": "Federal and state deferred tax benefits", "totalLabel": "Deferred Federal, State and Local, Tax Expense (Benefit), Total" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r80", "r184" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r299", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of Recognized Stock-based Compensation" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders-basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r124", "r125", "r126", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r93", "r347", "r360" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and employee related expenses", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized stock-based compensation expense relating to unvested stock options, restricted stock awards and restricted stock units", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized unvested stock options, restricted stock awards and restricted stock units, weighted-average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "2019 Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options Outstanding" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Lab Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r57", "r58", "r59", "r98", "r99", "r100", "r105", "r114", "r116", "r129", "r171", "r264", "r271", "r333", "r334", "r335", "r353", "r354", "r397", "r426", "r427", "r428", "r429", "r430", "r432", "r511", "r512", "r513", "r565" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r400", "r401", "r402", "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r226", "r240", "r241", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r401", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r400", "r401", "r403", "r404", "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r226", "r286", "r287", "r292", "r293", "r401", "r453" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r226", "r240", "r241", "r286", "r287", "r292", "r293", "r401", "r454" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r226", "r240", "r241", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r405", "r407" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r177", "r178", "r180", "r181", "r466", "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r177", "r179" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r421", "r422", "r423", "r424" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign exchange (loss) gain", "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Office Equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r80" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on disposal of assets", "totalLabel": "Gain (Loss) on Disposition of Assets, Total" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r62", "r137", "r139", "r142", "r145", "r147", "r474", "r481", "r486", "r501" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r188", "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r93", "r348", "r349", "r350", "r358", "r361", "r363", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r115", "r116", "r136", "r346", "r359", "r362", "r502" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income taxes", "terseLabel": "Net tax benefit", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r79" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r79" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r79", "r463" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r79" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r61", "r135", "r433", "r436", "r485" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest (expense)", "totalLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r70", "r232", "r239", "r242", "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Debt instrument interest payment", "totalLabel": "Interest Expense, Debt, Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r69", "r134" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r32", "r92", "r141", "r164", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r375", "r381", "r382", "r408", "r450", "r451" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r92", "r164", "r408", "r452", "r479", "r496" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r34", "r92", "r164", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r375", "r381", "r382", "r408", "r450", "r451", "r452" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermLoansFromBank": { "auth_ref": [ "r19", "r478", "r492" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.", "label": "Loans Payable to Bank, Noncurrent", "terseLabel": "Term loan" } } }, "localname": "LongTermLoansFromBank", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Commitment payments related to research" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r37", "r198" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "periodEndLabel": "Loss Contingency Accrual, Ending Balance", "periodStartLabel": "Loss Contingency Accrual, Beginning Balance", "terseLabel": "Legal contingencies, accruals recorded" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r194", "r195", "r196" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss Contingency Damages Sought Value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyLossInPeriod": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.", "label": "Loss Contingency, Loss in Period", "terseLabel": "Losses related to indemnification obligations" } } }, "localname": "LossContingencyLossInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r76" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r76" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r76", "r78", "r81" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r51", "r54", "r59", "r63", "r81", "r92", "r104", "r110", "r111", "r112", "r113", "r115", "r116", "r121", "r137", "r139", "r142", "r145", "r147", "r164", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r399", "r408", "r482", "r498" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r5", "r102", "r103", "r106", "r107", "r118", "r119", "r120", "r155", "r156", "r172", "r173", "r281", "r282", "r283", "r284", "r336", "r355", "r356", "r357", "r395", "r416", "r417", "r418", "r447", "r470", "r471", "r472", "r515", "r516", "r517", "r518", "r520", "r566" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recently Adopted and Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r101", "r104", "r105", "r106", "r108", "r109", "r112", "r118", "r127", "r153", "r154", "r168", "r169", "r170", "r171", "r174", "r175", "r199", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r351", "r352", "r353", "r354", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r409", "r410", "r412", "r413", "r414", "r415", "r419", "r420", "r446", "r467", "r468", "r469", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash items:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r137", "r139", "r142", "r145", "r147" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r441" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r441" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r440" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r7", "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r52", "r55", "r57", "r58", "r60", "r64", "r264", "r426", "r431", "r432", "r483", "r499" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total", "verboseLabel": "Other comprehensive (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r52", "r55", "r372", "r373", "r379" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive (loss) gain" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r46", "r48" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized (loss) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r71" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other (expense), net", "totalLabel": "Other Nonoperating Expense, Total" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r80" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentForManagementFee": { "auth_ref": [ "r74", "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).", "label": "Payment for Management Fee", "terseLabel": "Payment to director" } } }, "localname": "PaymentForManagementFee", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r158" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities", "totalLabel": "Payments to Acquire Marketable Securities, Total" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r72" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r299", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r20", "r248" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "verboseLabel": "Preferred Stock, value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized shares", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20", "r248" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued shares", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, outstanding shares", "verboseLabel": "Preferred stock, outstanding shares" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r20", "r452" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2021 and December 31, 2020, respectively", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r9", "r26", "r27" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromCollaborators": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from collaborators during the current period.", "label": "Proceeds from Collaborators", "terseLabel": "Payments received under collaboration agreement" } } }, "localname": "ProceedsFromCollaborators", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r73" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "verboseLabel": "Proceeds from Private Placement, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Redemption of marketable securities", "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r73", "r328" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r73" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "verboseLabel": "Proceeds from Employee Stock Purchase Plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r51", "r54", "r59", "r75", "r92", "r104", "r115", "r116", "r137", "r139", "r142", "r145", "r147", "r164", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r372", "r377", "r378", "r384", "r385", "r399", "r408", "r486" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r30", "r187" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r189", "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r29", "r185" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Total", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r187", "r452", "r487", "r497" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r185" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r503" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "terseLabel": "Realized (loss) gain on investments", "totalLabel": "Realized Investment Gains (Losses), Total" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r343", "r464", "r553" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r86", "r475", "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Security deposit classified as restricted cash", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r11", "r16", "r86", "r537" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Common Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r271", "r337", "r452", "r495", "r515", "r520" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r98", "r99", "r100", "r105", "r114", "r116", "r171", "r333", "r334", "r335", "r353", "r354", "r397", "r511", "r513" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r132", "r133", "r138", "r143", "r144", "r148", "r149", "r151", "r275", "r276", "r465" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r444", "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Computation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r30", "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r299", "r327" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r303", "r313", "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity with in 2014 Stock Incentive Plan and 2019 Incentive Award Plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Status of Restricted Common Stock and Restricted Stock Units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r39", "r89", "r130", "r131", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r257", "r262", "r265", "r266", "r267", "r268", "r269", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r79" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of shares, Awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value, Awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of shares, Unvested as of September 30, 2021", "periodStartLabel": "Number of shares, Unvested as of December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average fair value, Unvested, September 30, 2021", "periodStartLabel": "Weighted average fair value, Unvested as of December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total value of restricted stock awards, vested based on estimated fair value of stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of shares, Options exercisable as of September 30, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Options exercisable as of September 30, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value, Outstanding as of September 30, 2021", "periodStartLabel": "Aggregate intrinsic value, Outstanding as of December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r305", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares, Ending balance", "periodStartLabel": "Number of shares, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, Ending balance", "periodStartLabel": "Weighted average exercise price, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Options unvested as of September 30, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of shares, Options unvested as of September 30, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Options unvested as of September 30, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of shares issued from outstanding number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Shares issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r297", "r301" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockAndRestrictedStockUnitsDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r320", "r338" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Options exercisable as of September 30, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years), Options exercisable as of September 30, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years), Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years), Options unvested as of September 30, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total grant date fair value of stock options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Total grant date fair value of stock options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Share price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r41", "r57", "r58", "r59", "r98", "r99", "r100", "r105", "r114", "r116", "r129", "r171", "r264", "r271", "r333", "r334", "r335", "r353", "r354", "r397", "r426", "r427", "r428", "r429", "r430", "r432", "r511", "r512", "r513", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r98", "r99", "r100", "r129", "r465" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Shares Available for Future Grant Under Stock Option Plan" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r20", "r21", "r264", "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Purchase under Employee Stock Purchase Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r264", "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in Private Placement, net (in shares)", "verboseLabel": "Common stock shares issued and sold" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r20", "r21", "r264", "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedLabel": "Forfeiture of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r264", "r271", "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of shares, Exercised", "terseLabel": "Issuance of common stock upon exercise of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityWithIn2014StockIncentivePlanAnd2019IncentiveAwardPlanDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r20", "r21", "r264", "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Purchase under Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r264", "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in Private Placement, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r41", "r264", "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r58", "r92", "r98", "r99", "r100", "r105", "r114", "r164", "r171", "r271", "r333", "r334", "r335", "r353", "r354", "r370", "r371", "r383", "r397", "r408", "r426", "r427", "r432", "r512", "r513", "r565" ], "calculation": { "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r90", "r249", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r104", "r105", "r106", "r108", "r118", "r153", "r154", "r168", "r169", "r170", "r171", "r174", "r175", "r199", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r351", "r352", "r353", "r354", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r409", "r410", "r412", "r413", "r414", "r415", "r419", "r420", "r446", "r467", "r468", "r469", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureRecentlyAdoptedAndIssuedAccountingStandardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted-average shares of common stock outstanding-basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://frequencytx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://frequencytx.com/20210930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r554": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r555": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r556": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r557": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r558": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r559": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r560": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" } }, "version": "2.1" } ZIP 68 0000950170-21-004466-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-21-004466-xbrl.zip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

S5C&Y"$46*"+2C[ O!$[K%"9ORZY$&, MQ+(QE'U(&VBD ,U\4:*-DY)!;ZOO(L$1W@X=8FY6@^PHRL+E=] EBAE_DZZS MJ%3+]%2U,!&*2XN"_U5?$/RC;X\$,@KO5'_7/TE4%.N_[96L+S @#BDF8=7? M]TK:99@$>"_'QDB\(T$5QGI2F_6[M&"3ITONF;Y.%#4A2ZZO,E&?13' @AH] MK!QL>]S!-:E\

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

&UL4$L! A0#% M @ 1SUO4ZS \H)9" 3D( \ ( !@.(# &9R97$M97@S M,5\Q+FAT;5!+ 0(4 Q0 ( $<];U/::.=D3 @ $-" / M " 0;K P!F#,R7S$N:'1M4$L! A0# M% @ 1SUO4[LS%I[^! !BH \ ( !J/@# &9R97$M @97@S,E\R+FAT;5!+!08 "@ * 'X" #3_0, ! end

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